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CHAPTER I.
GENERAL INTRODUCTION
Historically, terrestrial plants and, to a lesser degree, animals have provided many
of the drugs and other products used to treat human disease. In 1815 C.A. Seydler, a
medical student in Germany, coined the term "pharmacognosy" from the Greek words
pharmakon (drug) and gnosis (knowledge) to describe the comprehensive study of natural
drugs! In the United States the term "natural products" is perhaps more commonly used
to describe the study of naturally derived chemical substances and includes the study of
natural drugs as well as non-medicinal agents. Pharmacognosy has traditionally focused
upon the study of terrestrial plants and has evolved, with the discovery of antibiotic
producing bacteria and fungi, to include the study of microbial metabolites.1 Within the
last thirty years the search for new natural products from the marine environment has
experienced an explosive growth. Two series of reviews have provided comprehensive
coverage of the advancement of marine naturalproducts.2-14 Marine natural products may
now be considered a scientific discipline, independent of, yet inherently based uponthe
traditional practice of pharmacognosy.
Both marine and terrestrial natural products research have undergone an evolution
over the past three decades. Recent advances in spectroscopic technologies have spurred a
revolution in natural products research. The structures of trace metabolites with exquisitely
potent activities may now be deduced, efforts inconceivable only a few years ago. In the
1980's high-field Fourier-transformed (FT) pulsed instrumentation first allowed
researchers to determine the structures of new compounds available only in multimilligram2
quantities. The introduction of proton-detected 2- and 3-D NMR techniques, especially
HMQC and HMBC, has facilitated complete structural assignment of submilligram to
milligram quantities of complex natural products.15'16 These inverse-detected NMR
techniques also dramatically reduce the instrument time required to determine long-range
heteronuclear-coupling information which is routinely required to establish molecular
connectivity. Currently, extremely high-field (500 to 800 MHz) and microprobe NMR
technologies provide a means to investigate the structure of trace quantities of natural
products.17
During the 1980s several marine natural product research groups began extensive
microorganism culture efforts. Several recent reviews illustrate how marine bacteria,18
dinoflaggelates,19 diatoms,19 and blue-green algae19-21 which were impossible to evaluate
from individual field collections are now producing exciting new leads in culture.
Marine Ethnomedicine and Natural Products
One approach to the study of the marine natural products is that of a classical
ethnomedicinal investigation! Traditional medical practices and folkloric toxicological
information are utilized as a guide for the chemical investigation of marine organisms.
Whereas the ethnobotanical method of terrestrial natural products research has directed the
discovery of many effective therapeutic agents, the inaccessibility of the oceanic
environment may have acted as a limiting influence on the folkloric utilization of marine
organisms. The organisms which seem to have provided the greatest utility have been
those limited to intertidal and shallow water environments, those species most accessible to
indigenous peoples. Although the number of ethnomedical leads in marine science have
been relatively small, several notable exceptions have provided exciting natural products
research projects.
For centuries the people of China and Japan have prepared an extract from the3
boiled fresh blades of the red alga Digenea simplex to use as a remedy for intestinal parasite
infections of small children.22 Following isolation, the structure of the anthelmintic
constituent of D. simplex was determined to be that of an unusual amino acid, a-kainic acid
1 (Figure I.1).23 Since its discovery, 1 has proven to be an extremely important
neuropharmacological probe.24As a structural analog of proline and the excitatory amino
acids aspartic and glutamic acid (2), 1 has defined the kainate receptor, a specific subtype
of excitatory amino acid receptors, and is now an essential tool in neuroscience.
Two distinctly different types of Japanese marine organisms, which have long been
observed to rapidly kill flies that land upon them, have provided valuable folkloric leads to
important natural product discoveries. Aside from its beach fly insecticidal activity, the
tropical red alga Chondria annata has, like D. simplex, represented a traditional
anthelmintic remedy.
25Subsequent research has shown C. annata to contain palytoxin
analogs, domoic acid (3), and seven domoic acid derivatives 26 The marine annelid
Lumbriconereis heteropoda has long been used as fish bait in Tokyo Bay. Flies die when
they contact these worms and fishermen which handle them have complained of respiratory
problems, headaches, and vomiting.27 An unusual toxic sulfur containing amine,
nereistoxin (4), was later isolated from extracts of the annelid and served as a lead
compound for the synthesis of a new insecticide, PADEN (5).
Aqueous extracts of the brown alga Laminaria japonica have been used in traditional
oriental medicine for the treatment of hypertension.28 The hypotensive effects of the alga
have been attributed to an unusual ganglionic-blocking amino acid, laminine (6), present in
numerous members of theLaminariaceae.28
Marine Toxins
Terrestrial plant pharmacognosy has as a primary focus the search for new
medicinal agents, a theme which has traditionally predominated as the most important4
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Figure I.1 Structures of Compounds Discovered From Marine Ethnopharmacological
Leads and Related Structures.5
direction of study. In contrast, a crucial force in marine natural products has been the
exploration of marine toxins.29'30 Some of the first scientists involved in the study of
marine chemistry searched for the agents responsible for seafood intoxications.27 Marine
toxin research has since become an integral component of the field. Animal poisonings and
human intoxications have been reported, or recounted in folkloric tales, to be caused by
species representing members from a majority of all known phyla (or divisions) of marine
organisms.27'29-30 Marine toxins, because of their unique structures and pharmacological
properties, have proved invaluable as research tools for biochemical, medical, and
ecological studies.29 '3°
The potent water-soluble sodium channel blocker tetrodotoxin (7, Figure 1.2) was
first isolated from pufferfishes,31 which are eaten in Japan, despite the fact they have been
known for centuries to have toxic entrails.27 Together with saxitoxin (8) and other
paralytic shellfish toxins produced by dinoflagellates associated with red tides (Gonyaulax
spp.), these toxins have allowed pharmacologists to study the location, shape, and function
of sodium channels.32 Brevitoxins A (9) and B (1 0), lipid-soluble toxins first isolated
from Caribbean Gonyaulax spp., have also proved to be valuable tools as activators of
sodium channels.33
The study of toxins still remains a major theme in marine chemistry. The
introduction of modern high-field multi-dimensional NMR methods have recently facilitated
the structure elucidation of maitotoxin (1 1, Figure 1.3), a causative agent of ciguatera fish
poisoning.' 6 Ciguatera seafood poisoning is a form of neurological intoxication which is
associated with the ingestion of carnivorous fishes which have
concentrated levels of dinoflagellate (Gambierdiscus toxicus) toxins in theirtissues.34
Maitotoxin (1 1) acts as an extremely potent calcium channel activating toxin (LD50 in mice
is ca. 50 ng/kg, ip) and is the largest natural product, other than a biopolymer,known.34'35
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the soft coral metabolite palytoxin (1 2, Figure 1.4) in toxicological potency and to exceed
its molecular size. More recently, the toxin polycavernoside A (1 3) has been isolated from
the red alga Polycaverrtosa tsudai (formerly Gracilaria edulis), following an intoxication of
thirteen people, and the subsequent death of three in Guam.36
The search for ecologically significant chemistry represents another approach to
marine natural products discovery. While still in its relative infancy, this field has
contributed much to our understanding of the complex biochemical interactions which
exemplify the marine environment. Marine chemical ecology involves, but is in no way
limited to, chemical defence from herbivory or predation, chemical communication between
organisms, and pheromonal chemical signals needed for reproduction. The ecological
significance of only a fraction of the toxic or biologically active metabolites isolated have
been described.37'"
Pharmacology and Natural Products Discovery
Perhaps the major approach to marine natural products research has remained, like
its terrestrial equivalent, the pursuit of new pharmaceutical leads. Spurred by discovery of
the antimetabolites spongothymidine (1 4) and spongouridine (1 5) (from the marine sponge
Cryptotethia crypta) which led to the synthesis of the anticancer drug Ara-C (1 6) and the
antiviral agent Ara-A (17), the marine environment rapidly became a viable alternative
source of new leads for medical research (FigureL5).23'39 However, few truly promising
leads emerged over the next twenty years. Only within the last few years have marine-
derived natural products again come to the forefront of medical research. Potential drug
candidates from marine animals, algae, and bacteria have begun to reach either clinical or
preclinical evaluation. Just a few recent examples of marine-derived antineoplastic leads
would include the bryostatins (bryostatin 1: 18), dolastatin 10 (1 9), cephalostatin 1 (2 0),H2N
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CH3
CH3
OH
"011
9OH
14
CH3
CH3
OH
15
OH
16
,H
H3C0 0 H3C H3C0
18
bryostatin 1
CH3
NH2
N
HOH2C
OH
0
19
dolastatin 10
Figure 1.5 Structures of Compounds From Marine Pharmacological Leads.
17
1011
didemnin B (21), and halomone (2 2) a polyhalogenated monoterpene from the red alga
Portieria homemannii (Figure I.6).4°-43
Oxylipins
It has been a relatively recent development in the study of natural products to
recognize that marine organisms are a rich source of eicosanoids and related fatty acid
derivatives, collectively known as oxylipins.44'45 "Oxylipin" is defined as an
encompassing term for oxidized compounds which are formed from fatty acids by
reaction(s) involving at least one step of mono- or dioxygenase-dependentoxidation.45
Thus, this term includes eicosanoids, C-20 metabolites of arachidonic acid (AA, 2 3) and
eicosapentaenoic acid (EPA, 2 4), as well as biosynthetically related compounds of longer
and shorter chain length (Figure 1.7). In mammalian systems, prostaglandins (PGs) and
thromboxanes (TXAs) are formed from AA via fatty acid cyclooxygenase;
hydroperoxyeicosanoids (HPETEs), leukotrienes (LTs), and lipoxins (LXs) are produced
by the action of lipoxygenase enzymes; and some hydroxyeicosanoids (HETEs) are
produced by the action of several different cytochrome P450 monooxygenases (Figure
I.8).46 PGs, LTs, HETEs, and other metabolites of this class have been recognized to
play a crucial role in both mammalian physiology and disease. Eicosanoids have been
shown to participate in the regulation of a wide range of biological and physiological
processes, including ion flux, vascular constriction, and the chemotactic movementof
white blood cells.46 These functions have been demonstrated to result from the
intracellular second messenger activity of eicosanoids in signal transductionpathways.46
Because of these findings, the interest in the structural chemistry, biosynthesis, and
pharmacological activities of these marine products has recently become intense.
Marine oxylipin research traces its origins to the pioneering discovery of
prostaglandin A2 esters from the Caribbean gorgonian, Plexaurahomomalla.47 It is nowH3C,,
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established that oxylipins are produced in a broad spectrum of life forms that inhabit the
sea, including algae, bacteria,48 invertebrates,45 and fishes.49'5° It is the marine algae
which have predominated in the scientific efforts of our group for the past five years and
has been the subject of several reviews.51-55 Our research has evolved from an early
discovery of the occurrence of mammalian immunoregulatory eicosanoids in red algae to
the development of a vastly more complex appreciation of the structural diversity and
novelty of marine carbocyclic oxylipin chemistry. Due to the wealth of new oxylipin
structures encountered in marine organisms, the uniqueness of the biosynthetic pathways
which lead to their formation, and the potency of their biological effects,56 much is to be
learned from study of this metabolism in the marine environment.57
Little is known concerning the biochemical, ecological, or physiological
significance of oxylipin metabolism in marine organisms. However, several interesting
correlations have emerged. Over 80 years ago Wilson demonstrated that when a living
sponge was strained through a gauze cloth the dissociated sponge cells would move with
amoeboid motion and form new sponge colonies.58-6° When two distinct sponge species
were similarly dissociated and mixed they reformed as homogeneous single sponges.61'62
Inclusion of rabbit antiserum specific to only one sponge inhibited the aggregation of only
that sponge species, similar to an antigen-antibody type reaction.63 It was reported that the
aggregation of dissociated marine sponge cells is a calcium-dependent process resembling
the immunological response of human neutrophils and platelets.64'65 The 5-LPO product
leukotriene B4 (LTB4) (2 5), a known calcium ionophore,66 was shown to cause sponge
cell aggregation in Microciona prolifera.67 Hence, it has been suggested that an
endogenous LTB4 analog may be involved in sponge cell aggregation phenomena.67
The relatively simple nervous system of the marine mollusc Aplysia califomica has
proven to be an invaluable model for neurochemical investigation. The large and readily
isolated neurons of Aplysia have provided a wealth of biochemical information concerning16
the function of oxylipins, especially AA metabolites, in neurochemical signal transduction.
The role of AA metabolism in molluscan signal transduction has been the subject of several
reviews.68-70 Both active lipoxygenase and cyclooxygenase systems appear to be present
in Aplysia neurons as evidenced by the conversion of AA to 5- and 12-HETE and PGE2
and PGF2 in nerve cell bodies and synaptosomes.71 Synaptic stimulation with histamine
was shown to induce the conversion of labeled3H-AA to 3H-12-HETE in cerebral ganglia.
It has been suggested that lipoxygenase metabolites may act as second messengers for
presynaptic inhibition of sensory neurons of the abdominal and pleuralganglia.72 It
appears that LPO products may impart a second messenger-typeregulation of the responses
produced by the molluscan inhibitory tetrapeptide FMRF amide (Phe-Met-Arg-Phe amide)
which opens S-channels (specialized 5-hydroxytryptamine (5-HT) sensitive K+ channels).
Aracidonic acid mimics the effect of FMRF amide and is converted to the hydroperoxide
12-HPETE (2 6) following FMRF amide stimulation.72'73 In addition, the lipoxygenase
inhibitor NDGA (nordihydroquariaretic acid) blocks the effect of both FMRF amide and
AA, while the cyclooxygenase inhibitor indomethacin has no effect. Additionally, 12-
HPE I E mimics the actions produced by both AA and FMRF amide, although it remains
unclear whether 12-HPETE or one of its many metabolites actually act as second
messengers.
7 4Several 12-HPETE derived compounds, including 12-KETE (12-
ketoeicosatetraenoic acid) (2 7) and hepoxilin A3 (8-hydroxy-11,12-epoxyeicosa-5,9,14-
trienoic acid, 2 8), appear to modulate the K+ S-channels in Aplysia neurons, while another
12-HPETE metabolite, 12-HETE (2 9), produces no response.75-78 It was suggested that
unlike other second messengers, eicosanoids may also function as first messengers,
facilitating direct communication between adjacent cells.69 Further, it is hypothesized that
this first messenger-type activity may relate to "long-term potentiation" phenomena as
observed in mammalian hippocampus derived NMDA -type glutamate receptors where
prolonged postsynaptic responses are observed following presynapticstimulation.74 It17
appears that the study of Aplysia neurochemistry may eventually lead to a better
understanding of neuropharmacological processes in higher animals.
Soft coral PGs have been shown to induce vomiting in reef fishes and have been
suggested to act as feeding deterents.79 Soft coral oxylipin chemistry has been extensively
reviewed.45 The PGs produced by soft corals are believed to derive from allene oxide
containing precursors, rather than from cyclooxygenase and the endoperoxide intermediate
PGH2 .45
Research into the chemical ecology of Mediterranean opisthobranchs has yielded a
great deal of information concerning the sophisticated, often chemically mediated,
defensive strategies that these shell-less molluscs use to avoid predation.80 -84 When
handled, the dorsal cerata of T. fimbria are autotomized. These appendages continue to
contract for up to 8 hours by way of epithelial smooth muscle fibers.85 PG-1,15-lactones
in the cerata are converted to their free acid form. PG free acids are well-characterized
inducers of smooth muscle contraction and relaxation in vertebrates. Simultaneously, a
mucous-slime containing high levels of PG-lactones is secreted from epithelial glands in the
cerata. Experiments have shown PG-1,15-lactones of the E (3 0) and A (3 1) series are
toxic to mosquito fish at concentrations of 1 and 10 pg m1-1, respectively.85 A dual role
for PGE-lactones in T fimbria has been suggested: (1) as direct acting ichthyotoxic defense
allomones; (2) as a source of PG free acids which contract the cerata and may facilitate
mucous release. PGs have also been demonstrated to participate in the osmotic regulation,
reproductive biology, and spawning of marine gastropod molluscs.45
Early studies in the search for the "barnacle hatching factor", a substance released
into the mantle cavity that stimulates hatching, suggested that a prostaglandin-like
compound might be responsible.86 Subsequent research elucidated the structure of the
hatching factor from Balanus balanoides as 10,11,12-trihydroxyeicosa-5,8,14,17-
tetraenoic acid (3 2).8718
With the exception of PGs and jasmonic acid derivatives, few examples of
carbocyclic oxylipins have been characterized from terrestrial sources.88 However, an
emergent theme in the marine environment appears to be that of complex carbocyclic and
heterocyclic oxylipin production.54 Many of these metabolites seem to be formed as a
result of uniquely marine biochemical processes acting upon hydroxy-fatty acid precursors
similar to those found in mammalian systems. Representatives of these highly
functionalized oxylipins have recently been isolated from many completely unrelated marine
organisms. The formation of these unusual metabolites and the co-isolation of
lipoxygenase-type metabolites has provided evidence which suggests that, in the algae,
prostaglandins and other carbocyclic oxylipins may result from further modifications of
hydroperoxide intermediates produced by lipoxygenase-type enzyme systems, rather than
from cyclooxygenases as in mammalian systems or from allene oxide intermediates as
demonstrated in most soft corals.53-55
General Thesis Contents
This thesis consists of five chapters and an appendix. Following this general
introduction, chapter two describes our efforts to discover new lead compounds from a
survey of the biomedical potential of marine algae and represents an update of an ongoing
investigation designed to assess the medicinal potential of marine algae. To date, a total of
over 300 species of macrophytic marine algae and over 250 strains of microalgae have been
cultured, extracted, analyzed by thin layer chromatography (TLC), and screened for bio-
activity. Evaluations were performed in-house for antimicrobial, molluscicidal,
ichthyotoxic, and brine shrimp lethality activities. Extensive pharmacological testing, with
the assistence of several key external collabors were done. Methods of evaluating samples
and significant findings will be discussed. Chapter two also outlines a series of bioassays
used in the isolation of novel biologically active natural products.19
The third chapter consists of an extensive investigation of carbocyclic-oxylipin
metabolism inConstantinea simplex,a temperate red alga evaluated as part of the Pacific
algal survey. Chapter three represents the most detailed study of marine cyclopropyl-
containing oxylipin chemistry to date. The results of my isolation and chemical structure
determination of these unique metabolites, trivially called constanolactones, the biosynthetic
implications, and biochemical significance of C.simplexfatty acid chemistry are
considered.
The occurrence of nakienones, new cytotoxic C-11 metabolites found in extracts of
blue-green algal(Synechocystissp.) material which was overgrowing living colonies of an
Acroporasp. of Okinawan staghorn coral, is described in chapter four. This chapter details
the isolation, spectroscopic chemical characterization, and biomedicinal evaluation of these
compounds.
Chapter five describes our recent discovery of potent new toxins, inhibitors of
cancer-associated enzymes, and exciting lead compounds for anticancer research.
Experimental methods and the investigation of recently characterized active metabolites are
described.
The structure elucidation of new sphingolipids and a heterocycle from the Oregon
marine spongeHalichondria paniceafollow the general thesis as part of an appendix. This
work appears in appendix form as some of the findings are the result of work initiated as an
undergraduate research project and the subject material may be considered outside the scope
of the general thesis.20
CHAPTER II.
A SURVEY OF MARINE ALGAE FOR BIOMEDICAL POTENTIAL
Abstract
I have participated in a drug discovery program designed to screen both
macrophytic and microscopic marine algae for inhibitors of cancer-related enzymes,
antitumor compounds, antiinflammatory substances, and other agents of potential
pharmaceutical utility. Over 1,500 lipid and aqueous extracts of marine plants and animals
were surveyed for biomedical potential. Assays designed to screen extracts for new types
of marine toxins have served to guide the isolation and identification of unique biologically
active compounds from marine algae.21
Introduction
Influenza, smallpox, and some sanitation-related bacterial diseases that once killed
millions of people no longer represent major causes of morbidity or mortality in modern
society. Heart disease, cancer, diabetes, AIDS, and an assortment of parasitic infections
(ie. drug resistant malaria, schistosomiasis) are now major causes of illness worldwide.
Only through increased efforts to develop new drugs and other effective means of treatment
for these conditions can we hope to relieve some of this burden. Additionally, competition
with insects and other organisms for crops has created a tremendous demand for new
environmentally and ecologically compatible insecticides, molluscicides, and nematocidal
agents.
The approach I have adopted is to envision natural products chemistry not
necessarily as an exploration for new sources of medicinal agents, but as a search for
chemical "ideas" or leads. For instance, the insecticide PADEN was developed from the
fly-toxic marine annelid compound nereistoxin and the antimetabolites Ara-C and Ara-A
were derived from chemical ideas generated by the discovery of sponge nucleosides
(Chapter 1). These chemical ideas, biologically or pharmacologically active metabolites
with novel structural features, serve as templates for the rational design of new drugs,
insecticides, and other biological products. Natural products are examined for structure-
activity relationships and used to guide synthetic efforts to produce products with enhanced
biochemical properties. This approach is, by design, ecologically and environmentally
preferable to the evaluation of plants and animals as new sources of crude materials or
commercial products. The cultivation of many terrestrial plants may be commercially
profitable, yet it is unlikely that many marine organisms, especially slow-growing marine
invertebrates, could be economically farmed and may therefore require ecologically
disastrous field harvest to provide the enormous quantity of materials that are necessary for
the product development and marketing of medicinal agents.22
Over half a million deaths are expected to occur in the U.S. each year as a result of
various forms of cancer.89 Cancer is currently second only to coronary disease as a cause
of death in the U.S. These statistics cannot even begin to demonstrate the immense pain
and suffering associated with this level of morbidity. A recent report entitled "A War Not
Won" points out that even when adjusted for changes in the population size and age,
National Cancer Institute (NCI) data suggests that despite the millions of dollars spent on
cancer research over the past few decades a 7 percent increase in cancer mortality rates
occurred between 1975 and 1990.89
Boyd, in a recent perspective on NCI new drug development, reported that
although chemotherapy may be the treatment of choice for many forms of cancer and has a
high cure rate for some rare forms of leukemia and lymphoma (50-75%), few agents are
effective for the treatment of most common tumors.90 Further, most of the approximately
40 cytostatic and cytotoxic agents target rapidly proliferating cells, often by similar
mechanisms, and are not useful for "solid mass" tumors such as those of the lung, colon,
breast, and prostate. These diseases currently account for most U.S. cancer deaths.
Characteristically narrow therapeutic margins and rapidly developing multidrug resistance
often seriously impair even the most effective forms of treatment. These limitations have
spurred considerable effort to discover new chemically diverse agents with novel
mechanisms of action.90 Thus, our research group initiated a drug discovery program
designed to assess the anticancer drug potential of marine algae.
Objectives
Two major themes, a biochemical evaluation of Pacific Northwest marine algae and
an investigation of cyanobacteria for new anticancer leads, comprise thebulk of our
research efforts. Since the summer of 1985 our group has conducted a survey of temperate23
marine macroalgae for their biomedical potential. What began initially as an investigation
of Oregon seaweed species developed over time into an extensive chemical exploration of
Pacific coast algae species collected over a far greater range. Specimens have since been
collected from central California, Oregon, Washington, British Columbia, and Alaska.
Four years ago our laboratory also became part of a NCI sponsored joint drug
discovery group.9° This NCNPDDG (National Cooperative Natural Products Drug
Discovery Group) program design brings academic, industrial, and government drug
research groups together to facilitate the investigation of innovative "high-risk" techniques
for the discovery of new anticancer agents. My role as a "primary" investigator in this
program was to collect, extract, isolate, and identify new chemotherapeutic leads from
marine cyanobacteria.
Materials and Methods
Small collections (ca. 2-8 L) of temperate marine algae were obtained from intertidal
and subtidal locations in northern California, Oregon, Washington, British Columbia, and
Alaska (Figures II.1 and 11.2). Specimens were frozen on site with dry ice for transport
back to our storage facility (-20 AC). Each sample was coded to indicate the date and site of
collection: two letter code indicating an Oregon site or three letter code indicating other
sites; date of collection; numerical designation. Voucher specimens from each collection
were taken and stored frozen (-20 °C) for future identification. Taxonomic classification of
uncertain species were performed by Dr. Gayle Hansen (Dept. of Botany and Plant
Pathology, Oregon State University).
Tropical algae collected from sites shown in Figure 11.2 were placed in 1 or 2 L
plastic bottles and preserved on site by immersion with isopropyl alcohol. Several
collections were preserved in either methanol or ethanol due to problems with local solvent
availability. Preserved specimens were kept frozen whenever possible throughout the24
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duration of collecting trips and stored at -20 °C until extracted following return to our
laboratory. Voucher specimens of preserved algae were removed prior to extraction.
Classification of taxonomically difficult macroalgae species were accomplished by Dr.
David L. Ballantine (Dept. of Marine Sciences, University of Puerto Rico). Mary A.
Roberts (College of Pharmacy, Oregon State University) classified cyanobacteria and other
microalgae.
Several selection criteria were employed to guide algal collection efforts. These
criteria varied somewhat for the evaluation of macroalgae and cyanobacteria. However
several key factors remained consistent. Organisms which were not previously
investigated for natural products were given high priority. Algae from genera known to be
rich in secondary metabolite production were also evaluated. Biodiversity was considered
in sample selection in order to take advantage of variation in biosynthetic potential.
Chemical-ecological interactions were also taken into consideration in the field. Algae with
little or no physical defense and which were growing in herbivore rich environments were
given high priority. Attempts were made to sample algae from a wide variety of habitats.
Therefore, specimens were collected from exposed high-surf conditions, intertidal splash
zones, sheltered coves, and low-intertidal locations. Subtidal habitats were harvested by
snorkeling or SCUBA. Estuaries, bays, and other brackish water environments were also
selected for sampling.
Extraction Method
Lipid extracts were produced in a standardized fashion as depicted in Figure 11.3.
Frozen algae collections (2-8 L) were macerated in CHC13/Me0H (2:1, v/v), allowed to
soak at least one hour, and filtered through cheese cloth. The algal material was placed in
fresh solvent (CHC13/Me0H (2:1, v/v)), heated to a gentle boil for up to 20 minutes, andFrozen algal specimen (2-8 L)
or
Isopropanol preserved algal specimen (1-2 L)*
*IPA is removed by filtration from
preserved specimens and
combined with aqueous extract
prior to sec-butanol partition.
1) macerated by blending in
CH2C12/Me0H (2:1, v/v)
2) filtered following soaking (1 h)
3) immersed in CH2C12/Me0H (2:1, v/v),
heated until boiling (ca. 40-50°) for
20 min., allowed to cool, and filtered
4) repeated extraction (2-3x)
filtered algal residue
cyanobacteria specimens are
soaked in Me0H/H20 (ca.
12 h) and filtered
aqueous extract
recombined
1) residual organic solvents
removed in vacuo
2) partition (H20/sec-butanol)
filtrate
partion (CH2C121H20)
aqueous extract
H2O fraction
aqueous extract
lipid extract
reduced in vacuo
sec-butanol fraction
reduced in vacuo
crude polar organic extract
crude lipid extract
Figure 11.3 Generalized Extraction Scheme.
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filtered. This process was repeated two to three times. The filtrate was partitioned with
water and the lipid fraction was reduced in vacuo and stored in Et20.
Alcohol preserved samples (1 to 2 L) were drained or filtered prior to extraction.
This alcohol was removed from the filtrate by evaporation in vacuo and added to the
aqueous extract.
Cyanobacteria collections were extracted as above. However, extracted algal solids
were soaked in Me0H/H20 (3:1, v/v) overnight, filtered, and the alcohol removed in
vacuo. These aqueous extracts were partitioned between sec-butanol and water. The sec-
butanol fractions were reduced in vacuo and stored in Me0H or EtOH.
In Vitro Antimicrobial Assays
Antimicrobial disc assay were performed according to standard protocols.91'92
Crude lipid extracts were dissolved in Et20 (polar and aqueous extracts were placed in
either Me0H or water) and applied to sterilized paper discs (Difco Lab., Detroit, MI) and
allowed to air dry. Extracts of algae collected after 1986 were quantitatively assayed at 2
mg/disc. These were applied to Mueller Hinton Agar which were inoculated withone of
the following pathogenic microorganisms: Bacillus subtilis (Bs); Candida albicans (Ca);
Escherichia coli (Ec); Pseudomonas aeruginosa (Pa); Salmonella typhimurium (St);or
Staphylococcus aureus (Sa). Assays were run with negative (air dried solvent) and
positive controls (streptomycin for bacteria and nystatin for C. albicans). The petri dishes
were incubated at 37 °C. After 12 to 15 hours zones of growth inhibition were measured
as total zone diameter and include the paper disc.
Ichthyotoxicity Assays
Observations of fish toxicity have lead to the discovery of important biologically
active compounds 93 and may suggest possible ecological interactions deserving further29
investigation. Insect antifeedants, antitumor agents, plant growth inhibitors, and
insecticides have been isolated from ichthyotoxic plants.93
Fish toxicity assays were performed using a modification of the method described
by Bakus and Green.94 The test organisms were small (ca. 3.5 cm) goldfish (Carassius
auratus). Stock solutions were prepared by dissolving crude lipid extracts in EtOH or
Me0H. Aqueous extracts were dissolved in distilled water. Stock solutions (20 or 50 pL)
were dissolved in 20 mL distilled water (30 mL beaker). Fish were added to each beaker
and monitored for 1 hour. Tests were performed in duplicate and run against alcohol (20
or 50 pL)-distilled water controls. End points were established as death (lack of breathing)
and inability to swim against a manually induced current for LD and EC measurement,
respectively.
Molluscicidal Assays
The freshwater mollusc Biomphalaria glambrata is an intermediate host for three
species of parasitic trematode blood flukes (schistosomes). Over 200 million people in
over 75 countries are infected with schistosomiasis(bilharzia).95 Chronic infection may
result in disturbances of the central nervous system, liver fibrosis, portal hypertension, and
possibly liver cancer.96 The difficulty and costs involved in treating these large groups of
people in remote impoverished areas has prompted a concerted effort by the World Health
Organization (W.H.O.) to look for new means of preventing infection by controlling the
snail vector.97
The molluscicidal potential of algae extracts were evaluated by a method similar to
the procedure described by Hostettmann et al., and recommended by the W.H.O.93'97
Crude extracts were dissolved in EtOH and diluted to 20 or 40 ml with distilled water in a
beaker to make a 100 µg/mL (100 ppm) solution. Two Biomphalaria glambrata (strain 13-
16-K89, courtesy Dr. Christopher J. Bayne, Prof. of Zoology, Oregon State University)30
were placed in each beaker and the beakers covered for the duration of the assay. The
condition of the molluscs were evaluated after 24 hours. Snails were considered dead
when no heart beat could be observed on microscopic investigation. Minimum lethal dose
requirements to kill the snails (LDioo) were recorded. Snails were disposed of by placing
them in isopropanol.
Brine Shrimp Lethality Bioassays
Brine shrimp lethality assays were routinely used as a rapid in-house screen for
selection and fractionation of toxic crude algal extracts. Brine shrimp (Artemia sauna
Leach) assays were run according to general methods developed by McLaughlin et al.98
Further description of this assay, its use in the discovery of physiologically active
compounds, and a discussion of its relevancy as a screen for cytotoxic agents is provided
in a recent review.99 Brine shrimp eggs were incubated in artificial sea water 24-36 hours
prior to assay. Crude algal extracts were dissolved in EtOH and diluted in test vials with
sea water to concentrations of 1000 (optional), 200, and 50 ppm for initial screening.
Assays were conducted in duplicate and with Et0H/sea water controls. Live brine shrimp
(n = 10-15) were added and the vials were stored at 37 °C for 24 hours at which time the
number of living and dead shrimp were recorded. Brine shrimp toxicity was then used to
guide extract fractionation and purification methods. Finally, purified active compounds
were serially diluted to concentrations where LD50 measurements could be obtained.
Thin Layer Chromatography Analysis
One-dimension thin layer chromatograms (TLC) on silica gel 60 F254 (E. Merck)
were developed in Me0H/CHCL3 (1:1, v/v) and either Et20/benzene (1:1, v/v) or
EtOAc/hexanes (1:1, v/v). Two-dimensional TLC was performed on 10 cm x 10 cm silica
gel sheets and developed first in Me0H/CHC13 (1:1, v/v), air dried, then developed in31
EtOAc/hexanes (1:1, v/v). Pigmented compounds were bracketed by pencil and color
coded. Ultraviolet absorptions were observed at 254 nm and recorded by circling with
pencil. The plates were sprayed with H2SO4 (50%) and gently heated on a hot plate.
Colorless compounds that charred following heating were assigned pencil check marks (f)
and coded by the color reaction observed. The following color codes were used: pk =
pink, pu = pr =purple, o = or =orange, y = yl = yellow, gr = gy = gray, g = green, br =
= brown, b1= bk = black, b = blue.
Following visual inspection, thin layer chromatograms were coded to indicate the
presence of potentially interesting new compounds. The chromatograms were coded as
follows: (+) lowest priority, primary metabolites; (++) minor secondary compounds
present, marginal interest factor; (+++) several minor secondary natural products present,
worthy of pursuit; (++++) major new compounds present, highest priority.
15-Lipoxygenase Enzyme Inhibition Assay
Lipoxygenases (LOs) convert arachidonic acid released from membrane
phospholipids into leukotrienes, hepoxilins, hydroxyeicosanoids, and other modulators of
the inflammation process which play a crucial role in both mammalian physiology and
disease.46 Therefore, inhibitors of lipoxygenase enzymes represent targets for the
development of new antiinflammatory agents. In collaboration with Syntex Research (Palo
Alto), we screened marine algae extracts for the ability to inhibit recombinant human 15-
LO. The ability of algal substances to inhibit the conversion of linoleic acid to 13(S)-
9Z,11Z-hydroperoxyoctadecadienoic acid (13-HPODE) was determined by colorimetric
assay. Extracts were considered active if they decrease the production of 13-HPODE to
less than 20% at 40 1.tg/mL.32
Anti-HIV Activity Assay
Human Immunodeficiency Virus (HIV-1) infected continuous human T-
lymphocytic cells were incubated (ca. 7 days) with dilutions of algal extracts (Syntex
Research). Differential toxicity between infected and mock infected cells was recorded.
Anti-HIV activity was confirmed by subsequent reverse transcriptase (RT) assay. EC50
levels were defined as the concentration of extract or compound which reduces RT counts
([311]-thymidine incorporation, scintillation spectrophotometer) by 50%, without
extract/compound-associated toxicity. Zidovudine (AZT) was used as a positive control.
Extracts which reached EC50 concentrations at greater than one dilution level below
minimal toxic concentration were considered active.
Anti-Herpes Simplex Assays
Monkey Vero cells infected with either Herpes Simplex I or II Viruses (HSV-I or
HSV-II) were incubated with algal extracts and observed for virus-associated
morphological changes and differential cellular toxicity (Syntex Research). Acyclovir was
used as a positive reference compound. Extracts were considered active if they reached the
effective concentration of extract required to inhibit virus-associated morphological cellular
changes to 50% (ED50), without causing cellular toxicity.
Inosine Monophosphate Dehydrogenase Inhibition Assay
Potential anticancer-type activity of marine algal extracts was evaluated (Syntex
Research) by a mechanism-based inosine 5'-monophosphate dehydrogenase (IMPDH)
enzyme inhibition assay .IMPDH converts inosine monophosphate (IMP) to xanthosine
5'-monophosphate (XMP), a rate-limiting enzyme in purine biosynthesis. The inhibition
of IMPDH has been shown to have anticancer and immunosuppressiveeffects.1 00,101
Crude extracts, chromatographic fractions, and pure compounds were evaluated for33
enzyme inhibitory activity using purified recombinant human IMPDH.
102NADH
production was used to spectrophotometrically (UV 340 nm) monitor enzyme activity
(Figure 11.4). Extracts with EC50s8 pg/mL were considered active.
IMPDH
IMP + NAD+ + H2O XMP + NADH + H+
Figure 11.4 Enzymatic Formation of Xanthosine Monophosphate and NADH From Inosine
Monophosphate and NAD in the Presence of IMP Dehydrogenase.
Protein Kinase Inhibition Assays
Protein Tyrosine Kinase Inhibition AssaysSignaling pathways which mediate the
effects of growth factors and oncogenes on cellular proliferation have recently become
targets for the development of unique mechanism-based anticancer drugs. Protein tyrosine
kinases (PTKs) have been implicated as oncogene products, phosphorylating tyrosine
residues of substrate proteins, in tumorigenic processes.1°3Protein tyrosine kinase
(pp60"-sr°) was isolated from Rous sarcoma virus-transformed rat cells and its activity
measured at Syntex by a modification of the method used by Goldberg.
104The IC50 is
defined as the concentration of extract or compound which causes a 50% decrease in
enzyme activity compared to solvent vehicle control. Extractswhich inhibited kinase
activity by45% at 50 pg/mL in initial ELISA assays were subsequently measured for
PTK inhibitory activity by the method described by Lee eta1.105
Protein Kinase C Inhibition AssayProtein kinase C (PKC, rat brain isoenzyme)
activity was quantified by measuring 32P incorporation fromy-32P ATP into synthetic
peptide substrates. Staurosporine was used as a positive inhibition control. Enzymatic
inhibition activities were expressed in % inhibition (1.0[(sample CPM basal
CPM)/(total CPM basal CPM)] x 100) as defined from radiolabel counts.34
Topoisomerase Inhibition Assay
In collaboration with Dr. Louis Barrows (University of Utah, Department of
Pharmacology & Toxicology) we examined lipid and aqueous extracts and purified
compounds from marine organisms for cytotoxicity in a series of tumor cell lines designed
to screen for agents interacting with DNA replication enzymes (topoisomerase I and II).
Two tumor cell lines were screened to evaluate the general cytotoxicity of an extract or
compound. KB (human epidermoid carcinoma) and HCT 116 (colonic carcinoma) cell
lines were among those selected to estimate general extract cytotoxicity. EM9
(topoisomerase I sensitive Chinese hamster ovary line), XRS-6 (topoisomerase II
sensitive), UV20 (DNA cross-linking agent sensitive), and BR1 (DNA repair competent)
cell lines were used to screen for compounds which have the ability to interact with DNA
repair mechanisms.
National Cancer Institute Assays
Throughout a ten year period from 1975 to 1985, in vivo P388 mouse leukemia
assays were used by the National Cancer Institute (NCI) for the preliminary screening of
crude extracts, chromatographic fractions, and pure compounds.9° Only a handful of new
anticancer drugs were discovered as a direct result of these tests and the methodology was
later revised. As discussed in chapter I, one limitation inherent in leukemia-based assays is
that the majority of neoplastic disorders are solid tumor cancers.Therefore, while P388
models may perhaps serve as screens for compounds which are cytotoxic to these rapidly
dividing leukemic tissues, they provide little or no selectivity for other forms of metastatic
disease.
Since 1985, the NCI has implemented a primary screening program using a battery
of in vitro disease-oriented human tumor cell lines organized into disease-specific
subpanels.9° Extracts are tested over a wide range of concentrations for cytotoxicityor35
antiproliferative activity.This in vitro 60-cell line panel is made up of tumors of the lung,
colon, kidney, ovary, breast, prostate, and brain, and includes several leukemias and
melanomas. The primary advantage of this disease-specific form of assay is that it is
designed to screen for relatively selective antitumor agents with specificity to individual
forms of neoplastic disease rather than testing for general cytotoxins.
Tumor cells are typically incubated for two days with plant or animal extracts at five
serially diluted concentrations (10-2 to 102 iug/mL). Pure compounds are initially evaluated
at a concentration range of from 10-8 to 10-4 M. Results are presented in the form of
disease-specific dose response curves or as mean bar graphs relative to the average
antiproliferative or cytotoxic effect in each assay (see Chapter V). Agents showing
selective cytotoxicity in specific tumor cell lines or disease-specific panels are subsequently
screened using in vivo human tumor xenograft models.
The NCI has developed a computerized pattern-recognition algorithm program
called COMPARE which compares the mean graph fingerprints of active extracts or pure
compounds with all other compounds in the NCI screening database.] °6 By matching test
substances with known compounds and anticancer agents COMPARE has provided
valuable correlations between compounds with similar mechanisms of action and provides
an indication as to whether the action of a test compound may be the result of a new
mechanism.
Criteria for Selection of Natural Product Projects
Natural product projects may be selected on the basis of any number of different
criteria. Often bioassay-guided fractionation of extracts considered active in any of the
previously mentioned biological or pharmacological assays may result in the discovery of
interesting new lead compounds. The isolation of curacin A (Chapter V) is an example of
the use of this technique. Alternatively, chromatographic separation and purification of36
compounds with unusual TLC characteristics, suggestive of a secondary metabolic origin,
have provided an equally rich diversity of projects. The discovery of the unique oxylipins
constanolactones A-G (Chapter III) are the result of TLC-guided isolation efforts.
Additionally, projects may be selected because of interesting observations provided by
ecological or toxicological leads from outside the laboratory or by a combination of these
criteria. The nakienones (Chapter IV) were discovered as a result of ecological
observations in the field, followed throughout the fractionation process by their unusual
TLC characteristics, and evaluated in pharmacological and toxicological assays.
Results and Discussion
Over 1,500 extracts (Table 11.1), representing nearly 300 species of macrophytic
marine algae (Chlorophyta: > 50; Chrysophyta: > 58; Rhodophyta.: > 163 spp.), numerous
microalgae (Table 11.2), and over 30 species of marine invertebrates were investigated for
new natural products and evaluated for biomedical potential. This effort represents a
continuation of the Oregon Seaweed Survey previously discussed in the M.S. Thesis of
Albert Lopez (1987)1°7 and other updates in print.20' 5 1 -5 5 The scope of previously
discussed research efforts has been expanded to include results obtained from the
evaluation of marine organisms collected in seven states and obtained from over 12
countries. These screening efforts have provided several dozen natural product projects
and are currently guiding the direction of new research.
Many of the marine algae species screened show some level of antimicrobial activity
(Table 11.3). This trend is consistent with previously reported marine algae survey
results.107 A total of 450 extracts (223 lipid, 175 aqueous) representing 196 species of
macrophytic algae were screened for antimicrobial activity. The majority of algae tested
possessed some degree of antimicrobial activity (Table 11.3). Typically, Gram (+) bacteria
were the most sensitive to the constituents of algal extracts (60% active against S. aureus,37
74% active against B. subtilis). However, only 3% of algae species were designated
"highly active" (disc assay zone of inhibition >18 mm in diameter) against these organisms.
Gram (-) organisms were the least effected, overall. Only 9% of the algae species tested
inhibited S. typhimurium growth in vitro. In general, extracts of red algae (Rhodophyta)
showed greater antimicrobial activity than those of the other groups tested (i.e. > 90%
inhibitory to B. subtilis).
Table II.1 Partial List of Worldwide Field Collection Sites for Tropical and Temperate
Marine Algae and Numbers of Representative Algal Groups Collected.
Site
Number of
Rhodophyta
collections
Number of
Chrysophyta
collections
Number of
Chlorophyta
collections
Number of
Cyanophyta
collections
(large scale)
Total number
of collections
per site
Caribbean
Anguilla (1993) 3 3
Costa Rica (1992) 6 6
Curacao (1992-1994) 21 10 24 241 (29) 327
Florida (1991) 3 2 2 17(1) 25
Puerto Rico (1987-1994) 10 1 3 61 (17) 92
San Martin (1993) 2 10 12
St. Croix, USVI (1989) 11 3 1 (1) 16
St. Thomas, USVI (1993) 1 1 10(2) 14
Tropical Pacific
Guam (1992-1994) 8 8
Tahitian Islands (1992) 15 4 6 61 (15) 101
Okinawa (1993) 7 2 6 50(4) 69
Temperate Pacific
Hokkaido, Japan (1993) 11 9 2 1 23
Yellow Sea, Korea (1993) 14 14
Pacific Northwest
Alaska (1987-1989) 29 3 2 34
British Columbia (1991) 12 3 15
California (1988-1993) 49 3 15 67
Oregon (1985-1993) 371 96 78 26 571
Washington (1988-1993) 51 21 6 20 98
Ship Bilge (1991) 6 6
Total 593 157 133 549 (69) 150138
Table 11.2 Genera of Microalgae in Survey.
Cyanophyceae
Chroococcales Aphanocapsa Mersmopedia
Chroococcus Microcystis
Gloeocapsa Synechocystis
Gloeothece Synechoccus
Chamaesiphonales Pleurocapsa
Hormogonales Anabaena Rivularia
Hormothamnion Scytonema
Lyngbya Schizothrix
Nostoc Spirulina
Oscillatoria Stigonema
Phormidiurn Symploca
Plectonema
Bacillariophyceae
C rytophyceae
Prymnesiophyceae
Xanthophyceae
Chlorophyta
Eugleophyta
Isthmia Naviula
Hemiselmis Ochromonas
Poterioochromonas
Coccolithus Ochrosphaera
Cricospheria Pavlova
Isochrysis
Mischococcus
Chlorococcum
Percursaria
Euglena
Pseudendoclonium39
Table 11.3 Summary of Antimicrobial Activity for Marine Macrophytic Algae Screened.
Test Organism
Number of
Rhodophyta
high/mod/low a (%)
Number of Number of
Chrysophyta Chlorophyta
high/mod/low a (%) high/mod/low a (%)
Total for algae
tested
high/mod/low a (%)
Gram (+)
Bacillus subtilis4/29/69 (3/21/69)2/7/23 (5/18/59)0/3/12 (0/14/57)6/36/104 (3/18/53)
Staphylococcus
aureus
4/17/56 (3/12/41)0/6/23 (0/15/59)2/1/9 (10/5/43)6/24/88 (3/12/45)
Gram (-)
Escherichia coli2/5/18 (2/4/13)0/1/5 (0/3/13)0/0/2 (0/0/10)2/6/25(1/3/13)
Pseudomonas
aeruginosa
0/4/9 (0/3/7)0/2/7 (0/5/18)0/0/3 (0/0/14)0/6/19(0/3/10)
Salmonella
typhimurium
1/2/6 (1/2/8)0/0/1 (0/0/5)0/0/0 (0/0/0) 1/2/7(1/2/6)
Fungi (yeast)
Candida
albicans
3/8/26 (2/6/19)0/2/6 (0/5/15)0/1/4 (0/5/19)3/11/36 (2/6/18)
Tested Species 139 39 21 196
a) Activity rated by zone of inhibition diameter observed in antimicrobial disc assay. High: > 18 mm;
Moderate: 12 to 18 mm; Low: 8 to 11.5 mm. Extracts were considered completely inactive if zone of
inhibition was less then 8 mm with a 6 mm test disc.
A handful of algal species were highly inhibitory to a multitude of pathogenic
organisms. Three red algae (Erythrophyllum delesserioides; Odonthaliaflocossa; 0.
washingtoniensis) were highly antimicrobial to the majority of organisms tested.
We have tested extracts from nearly 100 marine organisms in brine shrimp lethality
assays and found that more than 38% of those tested showed toxicity at a concentration of
50 ppm. Greater than 36% of the algae and a remarkable 50% of the invertebrate species
tested were toxic to brine shrimp. Some of the most potent brine shrimp toxic algae species
are shown in Table 11.4. The toxins responsible for this activity remain unknown for the
majority of these species.Table 11.4 Brine Shrimp Toxic Marine Algae.'
Rhodophyt a
Rhodophyceae
Bangiales
Bangiaceae
Porphyra nereocystis (lipid extract)
Porphyrella gardneri (lipid and aqueous extracts)
Ceramiales
Ceramiaceae
Microcladia sp. (lipid and aqueous extracts)
Delesseriaceae
Delesseria decipiens (lipid and aqueous extracts)
Rhodomelaceae
Laurencia spectabilis (aqueous extract)
Odonthalia washingtoniensis (lipid extract)
Gigartinales
Dumontiaceae
Dilsea califomica (lipid extract)
Farlowia mollis (lipid and aqueous extracts)
Endocladiaceae
Endocladia muricata (aqueous extract)
Gigartinaceae
Mazzaella splerulens, formerly Iridea spendens (aqueous extract)
Mazzaella sp. (lipid extract)
Gloiosiphoniaceae
Gigartina sp. (aqueous extract)
Gloiosiphonia capillaris (lipid and aqueous extracts)
Gloiosiphonia verticillaris (lipid and aqueous extracts)
Halymeniaceae
Prionitis lyallii (lipid and aqueous extracts)
Phyllophoraceae
Ahnfeltia plicata (lipid and aqueous extracts)
Plocamiaceae
Plocamium violaceum (lipid extract)
Solieriaceae
Opuntiella califbmica (lipid extract)
Gracilariales
Gracilariaceae
Gracilariopsis lemaneiformis (lipid extract)
Unknown
Calif. collection (aqueous extract)
Oregon collection, Callophyllis-type (lipid extract)
4041
Table 11.4 Continued. Brine Shrimp Toxic Marine Algae.'
Chrysophyta
Phaeophyceae
Desmarestiales
Desmarestiaceae
Desmarestia ligulata (lipid extract)
Fuca les
Fucaceae
Pelvetiopsis limitata (lipid extract)
Laminariales
Laminariaceae
Laminaria sinclairii (aqueous extract)
Lessoniaceae
Nereocystis luetkeana (lipid and aqueous extracts)
Chlorophyta
Bryopsidophyceae
Cladophorales
Cladophoraceae
Chaetomorpha linum (lipid extract)
Codiolophyceae
Acrosiphoniales
Acrosiphoniaceae
Acrosiphonia coalita (aqueous extract)
Cyanophyta
Cyanophyceae
Hormogonales
Oscillatoriaceae
Lyngbya majuscula, OUK 1 Jul 93 (lipid and aqueous extracts)
Lyngbya majuscula, NAC 15 Dec 93 (lipid and aqueous extracts)
Lyngbya majuscula, NSB 10/15 Dec 93 (lipid and aqueous extracts)
a) crude extracts toxic to brine shrimp (Anemia salina Leach) at 50 ppm.
However, brine shrimp lethality assays have provided exciting leads as summarized
in several publications.108109The investigation of curacin A (Chapter V) is an example
of a project in which brine shrimp lethality was used to guide the chromatographic
fractionation and isolation of exciting new lead compounds.42
Molluscicidal and ichthyotoxicity testing have proven an invaluable tools for the
detection and isolation of biologically active natural products. The isolation of two new
ichthyotoxic compounds and a novel snail toxin are described in chapter V.
Evaluation by thin layer chromatography (TLC) has proven an invaluable technique
for surveying algal extracts for new natural products. Once trained to recognize the often
subtle differences between the TLC characteristics of various algal primary metabolic
products (pigments, triglycerides, steroids, phospholipids, etc.) from those of secondary
metabolites (terpene, alkaloids, etc), TLC analysis provides a means to rapidly screen large
numbers of extracts for the presence of unusual chemical constituents.
Examination of over 200 species of marine algae by TLC suggests that these
organisms are a rich source of secondary natural products (Table 11.5). Remarkably, 25%
of the species chromatographed show the presence of major new compounds as indicated
by a (++++) rating. TLC analysis indicates that this trend is consistent throughout all three
groups tested (Chlorophyta, 26%; Rhodophyta 26%; Chrysophyta 21%). These findings
stress the exciting potential for further study in this area.
Table 11.5 Results from TLC Analysis of Macrophytic Marine Algae.
TLC Ratinga
++++
TLC Rating')
+ ++
TLC Rating'
++ or less
Total Species
Tested
Chlorophyta 10 8 21 39
Rhodophyta 33 24 69 126
Chrysophyta 10 6 32 48
Totals 53 38 122 213
TLCs were coded to indicate the presence of potentially interesting new compounds. The
chromatograms were coded as follows: a) (++++) major new compounds present, highest
priority; b) (+++) several minor secondary natural products present, worthy of pursuit; c)
(++) minor secondary compounds present, marginal interest factor; and (+) lowest
priority, primary metabolites only.43
Our discovery of the widespread occurrence of oxylipin chemistry in temperate
marine algae (Table 11.6) was made possible by recognition skills developed through years
of experience analyzing hundreds of organic extracts. Subsequently, unique bullet shaped
spots which often charred blue or other unusual colors with gentle heating, typically
observed by TLC analysis of algal extracts, soon became the signature of oxylipin
production. As previously described in the first chapter, what began as an early discovery
of the occurrence of mammalian immunoregulatory eicosanoids in red algae developed into
a vastly more complex appreciation of the structural diversity and novelty of marine
carbocyclic oxylipin chemistry. The study of new oxylipin structures encountered in
marine algae (Figure 11.5), chemotaxonomic differences in their oxidation (Figure 11.6),
their unique biosynthesis, and their potent biological functions has predominated the
scientific efforts of our group for the past five years and has been the subject of several
reviews.51 -55 Chapter III details an extensive investigation of carbocyclic-oxylipin
metabolism in Constantinea simplex, a temperate red alga evaluated as part of the our
Pacific algal survey. The C. simplex project is an example of a chemical study resulting
from a TLC analysis of algae extracts. The biological and ecological significance of this
class of oxidized fatty acid chemistry (Chapter I) remains an impetus for continued
research.
Extracts of over 125 species of marine organisms were screened for inosine 5'-
monophosphate dehydrogenase (IMPDH) inhibition activity. All 13 of the active extracts
(EC50 values less than 8 pg/mL) were from marine algae. Two chlorophytes, two
chrysophytes, four rhodophytes, four cryptophytes, and a cyanobacterium potently
inhibited IMPDH. Eight other algae (2 chrysophytes, 6 rhodophytes) and two marine
invertebrates inhibited IMPDH at slightly higher concentrations.Ho%
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Figure 11.6 Positional Patterns of Oxidation Observed in Marine Algal Oxylipins.46
Table 11.6 Algal Species Found to Contain Oxylipin Chemistry.
Rhodophyta
Rhodophyceae
Gelidiales
Gelidiaceae
Gelidium latifolium Bornet & Thuret
Cora llinales
Corallinaceae
Bossiella orbigniana Silva
Lithothamnion corallioides Crouan
Lithothamnion calcareum (Pallas) Areschough
Gigartinales
Dumontiaceae
Constantirtea simplex Setchell
Farlowia mollis (Harvey & Bailey) Far low & Setchell
Solieriaceae
Sarcodiotheca gaudichaudii (Montagne) Gabrielson
Gracilariales
Gracilariaceae
Gracilaria edulis (Gmelin) Silva (as G. lichenoides)
Gracilaria verrucosa = G. pacifica (Abbott)
Gracilariopsis lemaneiformis (Bory) Dawson, Acleto & Foldvik
Rhodymeniales
Rhodymeniaceae
Rhodymenia pertusa (Postels & Ruprecht) J.G. Agardh
Champiaceae
Gastroclonium subarticulaturn (Turner) Kutzing
Ceramiales
Ceramiaceae
Neoptilota asplenioides (Esper) Kylin ex Scagel, Garbary, Golden
& Hawkes
Ptilota filicina J.G. Agardh
Rhodomelaceae
Laurencia hybrida (DeCandolle) Lenormand
Laurencia spectabilis Postels and Ruprecht
Murrayella periclados (C. Agardh) Schmitz
Delesseriaceae
Cottoniella filamentosa Borgesen
Platysiphonia miniata (C. Agardh) Borgesen
Polyneura latissima (Harvey) Kylin47
Table 11.6 (continued) Algal Species Found to Contain Oxylipin Chemistry.
Chrysophyta
Phaeophyceae
Cordariales
Notheiaceae
Notheia anomala (Bailey & Harvey)
Laminariales
Laminariaceae
Eck Ionia stolonifera Okamura
Laminaria setchellii Silva
Laminaria saccharina (Linnaeus) Lamouroux
Laminaria sinclairii (Harvey ex Hooker f. & Harvey) Farlow,
Anderson & Eaton
Cymathere triplicata (Postels & Ruprecht) J.G. Agardh
Alariaceae
Alaria marginate Postels et. Ruprecht
Egregia menziesii (Turner) Areschoug
Chlorophyta
Bryopsidophyceae
Cladophorales
Cladophoraceae
Cladophora columbiana Collins
Codiolophyceae
Acrosiphoniales
Acrosiphoniaceae
Acrosiphonia coalita (Ruprecht) Scagel, Garbary, Golden &
Hawkes
Cyanophyta
Cyanophyceae
Oscillatoriales
Oscillatoriaceae
Lyngbya majuscula Harvey
Oscillatoria nigro-viridis Thwaites
Schizothrix calcicola (C. Agardh) Gomont48
Protein tyrosine kinase (PTK) inhibition assays have also effectively guided the
selection of natural product research projects. A total of 363 extracts, representing more
than two hundred species of marine organisms, were screened for PTK inhibition activity
(Table 11.7). Extracts which inhibited the enzyme PTK by at least 45% at the test
concentration of 501Jg/mL were considered active and worthy of further pursuit. The only
active macroalga, from nearly 170 screened, was a cold water kelp (chrysophyte).
However, extracts from five species of microalgae were potently PTK inhibitory ( 4,
chrysophytes; 1 cyanobacterium). Extracts of the cultured cryptophyte Poterioochromonas
malhamensis were the most active. Assay with P. malhamensis polar extracts showed
essentially 100% inhibition of PTK. Dr. Jian Lu Chen isolated unusual chlorinated
sulpholipids from this organism which were reponsible for this activity and are futher
discussed in chapter V.
Table 11.7 Results From Protein Tyrosine Kinase (PTK) Inhibition Assays.
Type of marine organism Number of species (or
culture strains) tested
Number of PTK activea
species
Chlorophyta
Rhodophyta
29
107
Chrysophyta 33 1
Bacillariophyceae 2
Cyanophyceae (60) 1
Crytophyceae (64) 4
Invertebrates 13
Angiosperms 2
a) Actives are defined as extracts which inhibit PTK 45% at 5014,/mL.
Conclusions
This survey of marine organisms for biomedical utility has resulted in the discovery
of widespread oxylipin production in marine algae, novel inhibitors of cancer-related49
enzymes, a new antimitotic agent, and potent marine toxins. Moreover,this work
continues to inspire innovative forms of research and suggests the exciting potential of
marine organisms, and algae in particular, as rich sources of exciting new natural products.50
CHAPTER III.
THE CHEMISTRY AND BIOSYNTHESIS OF CONSTANOLACTONES A-G, NEW
OXYLIPINS FROM THE OREGON RED ALGA CONSTANTINEA SIMPLEX
Abstract
Extracts of the Oregon marine alga Constantinea simplex were found to contain a
mixture of w6 and w3 unsaturated constanolactones, lactonized cyclopropyl-containing
oxylipin metabolites, that logically derive from arachidonic and eicosapentaenoic acids,
respectively. Detailed spectroscopic analysis of the isolated compounds, as natural
products and various ester derivatives, afforded the planar structures of seven structurally
related constanolactones. Constanolactones A-D possess 1,4-diol functionalities while
constanolactones E-G contain a vicinal diol functionality. The absolute stereochemistry at
all stereocenters in constanolactones A-D and at two stereocenters in constanolactones E
and F were determined by chiroptical measurements of various mono- and di-benzoate
derivatives and by comparable rotations within the two series (A-D and E-G). Isolation of
these various diastereomeric diols, as well as of two methanol adducts from CHC13/Me0H
extracts of C. simplex, leads us to speculate on the occurrence of highly unstable allylic
epoxides in this red alga.51
Introduction
Marine invertebrates45'11° and algae51-53are a rich source of oxidized, often
carbocyclic54, fatty acid metabolites which have recently become known as "oxylipins".111
Perhaps the most unusual oxylipins found to date in the Porifera have been isolated
from Halichondria okadai collected off the coast of Japan.112 Both spectroscopic and
degradative chemical evidence were used to elucidate the structures of two cyclopropyl and
lactone containing eicosanoids: halicholactone (1) and neohalicholactone (2) (Figure III.1).
Halicholactone (1) was reported to exhibit weak inhibitory activity against the 5-
lipoxygenase from guinea pig polymorphonuclear leukocytes (IC50 = 630 pM).112
However, a subsequent report detailing the three-dimensional structure of the w3
unsaturated neohalicholactone (2) describes it as a "potent lipoxygenase inhibitor", but no
additional experimental data was provided.113
The cyclopropane and lactone containing eicosanoid 3 has been isolated from the
soft coral Plexaura homomallal 14 and an unsymmetrical eicosanoid dimer aplydilactone (4)
has been isolated from lipid extracts of the Japanese sea hare Aplysia kurodai.115 '116 The
structure of 4 was established by spectroscopic analysis of the natural product, a diacetate
derivative, and several degradative fragments. By this methodology, the relative
stereochemistry of the trans-cyclopropyl group and double bond geometries were
determined. This unusual oxylipin dimer has been shown to produce a two-fold activation
of phospholipase A2 in vitro, however, only at very high concentrations (50 mM).
The isolation of the cyclopropyl lactone eicosanoid hybridalactone (5) from the
Rhodophyte Laurencia hybrida represented the first example of a carbocyclic oxylipin from
a marine alga.117 Brown algae and other red algae have since been demonstrated, chiefly
by the efforts of our group, to produce unusual carbocyclic and heterocyclic oxylipins.53'54
Prostaglandins of the A, E, and F series have been isolated from Japanese collections of theHO
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Figure III.1 Unusual Carbocyclic Oxylipins from Marine Organisms.
6118-120 The red alga Gracilaria verrucosa and Australian samples of G. lichenoides.
Japanese brown alga Ecklonia stolonifera (order, Laminariales) and, more recently, the
Oregon brown alga Egregia menziessi, also of the Laminariales, have been shown to
produce lactonized epoxyprostanoids, termed ecklonialactones A-E (A: 6, Figure
MA).121-123 The formation of these unique metabolites and the co-isolation of
53
lipoxygenase-type metabolites has provided evidence which suggests that, in the algae,
prostaglandins and other carbocyclic oxylipins may result from further modifications of
hydroperoxide intermediates produced by lipoxygenase-type enzyme systems, rather than
from cyclooxygenases as in mammalian systems or from possible allene oxide
intermediates as is believed for most soft corals.53-55
As part of our survey of marine algae for biomedical potential I initiated what would
soon become an extensive exploration of oxylipin metabolism in the Oregon red alga
Constantinea simplex Setchell.
Spring and early Summer collections of small (blade diameter typically 2-5 cm.) C.
simplex plants were obtained from exposed low-intertidal locations along the central
Oregon coast and were found to be the source of new lactonized cyclopropyl oxylipins
which I have named the constanolactones A-G.124'125 Extracts of large "older" individuals
(diameter > 6 cm.) collected from relatively non-exposed sites contained insignificant
oxylipin concentrations. The isolation of the constanolactones, in combination with
stereochemical analysis and examination of key biosynthetic processes,I26 provides
important clues to the unique mechanism of cyclopropyl-lactone formation in this alga. The
seasonal variation in C. simplex oxylipin chemistry is rather intriguing in regard to the life
cycle of this unusual red alga.
Constantinea simplex is a small (typically 2 to 10 cm dia.) "mushroom-shaped" red
alga which grows attached to low intertidal and subtidal rocks from California to Alaska.
Observation by Powell suggest that C. simplex produces only one blade per year.127 As54
the new blade grows from the apex of the stipe the old blade completes reproduction and
begins to erode. Old blade scars indicate that C. simplex live from seven to over fourteen
years.
Induction of new blade formation in C. simplex results from response to a short
day (SD) photoperiod of 11 to 12 hours for three to four weeks.128 Blade formation
begins from the tips of the stipes in September or October. Powell observed that the young
blade expands during the winter, matures to fertility the following summer, and is
subsequently shed as another new blade forms. He also was able to show that C. simplex
blades would continue to grow during a continuous period of darkness of four and one-half
months.128 Evidence suggests that the new blade growth is supported by carbohydrate
reserves resorbed from old blades. C. simplex blades complete the lag phase of their
growth during the winter, allowing them to out-compete other perennials which depend on
the increased light of spring and summer. These seasonal changes in the biochemical status
of C. simplex tissues are also reflected in the chemical composition of specimens collected
at different stages of development (see general methods in experimental).
Polyhedral crystalline particles 5 to 7 mm in diameter have been observed in the
medullary chloroplasts of C. subulifera and simplex.129 X-ray microanalysis identified
these crystals as the first phytoferritin particles found in marine algae.13° In C. simplex,
these particles are only found in the medullary and cortical cells of the old blade which is
also associated with numerous plastoglobuli and an abundance of floridian starch.
Phytoferritin was absent from young blades and were also low in floridian starch and
possessed few plastiglobuli. Phytopherritin is associated with impaired photosynthesis,
viral infection, and senescent conditions in higher plants.131 The formation of phytoferritin
in connection with the young blade's ability to utilize carbohydrate stores from old blades
was put forth as demonstrating that blade senescence in Constantinea is in some ways
similar to the senescence process of higher plant leaves.55
In the late 1970's, crude aqueous extracts of C. simplex, Cryptosiphonia woodii,
Farlowia mollis, as well as other members of the family Dumontiaceae (Rhodophyta) were
shown to possess antiviral activity against herpes simplex viruses I and H in cell culture.132
Highly sulphated polysaccharides which may have contained some protein molecules were
demonstrated to be responsible for this antiviral activity.132
Results and Discussion
As part of an extensive survey of the biomedical potential of seaweeds (Chapter H),
the crude lipid extract of C. simplex (Seal Rock, Oregon) was found by TLC to contain a
diversity of likely eicosanoid-type natural products giving colorful H2SO4 charring
reactions. Vacuum chromatography of the extract from a June collection yielded fractions
that were mixtures of related substances. Following acetylation, methylation, and HPLC
of one chromatographic fraction, two closely related new compounds (7 and 8) were
isolated as synthetic diacetate derivatives (9 and 10). Another vacuum chromatography
fraction was methylated prior to HPLC to yield minor amounts of three known oxylipins,
12-S-HETE (1 1, 0.1%), 12-S-HEPE (12, 0.015%) and 12- oxo -SZ, 8E, 10E-
dodecatrienoic acid (13, 0.044%), all isolated as their corresponding methyl ester
derivatives (1 4-1 6). Additionally, a third new oxylipin-peracetate derivative (17) was
isolated as a presumed isolation artifact (Figure 111.2).
Constanolactone A diacetate (9), lat3 = -5.4° (c = 3.05, CHC13), was a colorless
oil which gave a prominent (M + H -2H0Ac)+ by HR CIMS (CH4) at 301.2165 (0.3
mamu dev.) analyzing for C20H2902. The diacetate character of this derivative was readily
apparent from NMR and LR CIMS (obs. m/z 421 1(M+H)+, 6 %], 361 [(M+H-AcOH)+,
50 %], 301 I (M+H-2H0Ac)+, 100% I). Five of the seven degrees of unsaturation were
accounted for by four olefmic carbons and 3 ester carbonyls (Table 111.1), and thus, 9 was
bicyclic. As derivative 9 was unreactive to CH2N2 and showed the C-2 protons as a12
HO
13 R=H
16 R=CH3
7 R=H, R'=R"=OH
8 R=R"=0H, R'=H
9 R=H, R'=R"=0Ac
10 R= R " =OAc, R'=H
11 12S-HETE: w 6, R=H
12 12S-HEPE: co 3, R=H
14co 6, R=CH3
15co 3, R=CH3
COOR
AcOult
OAc
COOR
17
Figure 111.2 Oxylipin Chemistry Found in C. simplex.
COOMe
56Table III.1 1H and 13C NMR Data for Constanolactone Diacetates A (9), B (10) and hydrolysis product 17. a
#C
Derivative 9 Derivative 10 Derivative 17
13C (C6D6)e1H (CDC13)b 13C (C6D6)c1H (CDC13)b 1H (C6D6)b
1169.78f 169.97f
2 29.65 a)2.56 dt (11.6,5.6) 29.47 a)2.54 m 2.15 t (7)
b)2.4-2.5 m b)2.49 m
3 18.38 a)1.80 m 18.27 a)1.80 m a)1.75 m
b)1.9-2.05 m b)1.97 m b)1.68 m
4 27.68ha)1.98 m 27.56 a)1.98 m 1.45 m
b)1.6-1.7 m b)1.65 m
5 82.073.80 ddd (10.7, 7.4, 3.0) 81.53 3.82 ddd (10.0, 6.6,3.1) 2.68 dt (7, 7)
6 22.90d1.03 m 22.01d 1.2 m 0.55-0.68 m
7 8.1 a)0.625 ddd (8.8, 5.2, 5.2) 6.65 a)0.68 ddd (8.5, 5.2,5.2) a)0.3 ddd (8, 5, 5)
b)0.726 ddd (8.4, 5.2, 5.2) b)0.60 ddd (8.5, 5.2,5.2) b)0.55-0.68 m
8 21.2d 1.2-1.3 m 21.04d 1.2 m 1.0 m
9 75.91 4.90 ddd (6.9, 6.2, 1.1) 75.47 4.85 bdd (7.9, 2.7) 4.84 dd (7, 5, 7)
10131.45e5.68 dd (15.5, 6.2) 130.78e 5.72 m 5.9 dd (15,7)
11 129.73e5.81 ddd (15.5, 6.2, 1.1) 130.28e 5.70 m 5.75 dd (15, 7)
12 73.41 5.2-5.33 m 73.34 5.2 m 5.39 ddd (7, 7, 7)
13 32.72 a)2.35 m 32.76 a)2.35 m a)2.35 ddd (14, 7, 7)
b)2.45 m b)2.4 m b)2.45 ddd (14, 7, 7)
14124.0 5.2-5.33 m 124.01 5.2 m 5.45 m
15133.23 5.5 bdt (10.9, 7, 3) 133.33 5.5 bdt (10.8, 7.1) 5.5 bdt (10, 7)
16 27.69h1.95-2.05 m 27.69 2.02 m 2.0 bdt (7, 7)
17 29.48 1.21-1.36 m 29.58 1.35 m 1.3 m
18 31.78 1.21-1.36 m 31.76 1.35 m 1.3 m
19 22.93d1.21-1.36 m 22.90 1.30 m 1.25 m
20 14.26 0.886 t(6.7) 14.24 0.885 t (6.7) 0.90 t (7)
OAc169.50f 169.49f
20.82g2.08i 20.89g 2.06sh 1.76 s
169.00f 169.45f
20.71g2.071 20.76g 2.1sh 1.70 s
OMe 3.3558
complex second order pattern, one of the cycles involved lactonization of the carboxylic
acid. The final degree of unsaturation was present as a cyclopropyl ring as revealed by
characteristic 1H NMR resonances at 0.625, 0.726, 1.03 and 1.2 ppm (Figure 111.3).
Hence, 9 was a 20-carbon eicosanoid with 1 lactone, 2 secondary acetates, 2 olefins, and a
cyclopropyl ring.
The location of these functional groups followed from analysis of the 1H-1H COSY
in CDC13 (Figure 111.4) in which it was possible to define the spin system throughout the
entire carbon skeleton (Table III.1). Coupling constants for the C10-C11 (15.5 Hz) and
C14-C15 (10.9 Hz) olefins defined them as E and Z, respectively. Further, couplings
between the C6-7-8 cyclopropyl protons defined a trans (S*, S*)geometry (16-7a = 5.2
Hz, .45_7b = 8.4 Hz, J7a_76 = 5.2 Hz, J7a_8 = 8.8 Hz, J76_8 = 5.2 Hz). Relative
stereochemistry at C5, C9 and C12 remained uncertain, however, I speculated that C12
was probably S based on the co-occurrence of other 12-S eicosanoids in this alga.
Derivative 10 of constanolactone B (8), [c(]1233 = -4.8° (c = 2.08, CHC13) gave a
small (M+H)f at 421.2590 and a large (M + H 2 x AcOH)+ fragment ion at 301.2168
(pos. CI, CH4) which analyzed for C2 4H3 706 (0.0 mamu dev.) and C2 0F12 902 (0.0 mamu
dev.) by HR mass measurement, respectively. Again, the diacetate character of this
derivative was readily confirmed by NMR (Table 111.1). In fact, the spectral data for 10
were nearly identical to that obtained for derivative 9, and extensive 1H-11-1 COSY defined
the location of all functional groups in 10 just as in 9 (Figure 111.5). Differences between
the two compounds in their a) coupling constants to H9 (9, J8.9 = 6.9 Hz, J9-10= 6.2 Hz;
1 0, J8_9 = 7.9 Hz, J9_10 = 2.7 Hz), b) 13C NMR chemical shifts at C5, C7, and C9, and c)
1H NMR shifts at H6 through H11 (Table 111.1) indicated that constanolactone B diacetate
(10) was the C9 epimer of constanolactone A diacetate (9).
Further insight as to the position of lactonization in constanolactone A, and hence of
B as well, was afforded by isolation of the ring opened hydrolysis product (17) as an60
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Figure 111.4 COSY Spectrum of Constanolactone ADiacetate (9) in CDC13.AcO"
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Figure 111.5 COSY Spectrum of Constanolactone B Diacetate (10) in CDC13.62
artifact (Table 111.1). This was apparently formed during workup of the acetylation
reaction since acetates were present at C9 and C12 but not at C5. Further, because 17
contained a methyl ester, opening of the lactone must have occurred prior to treatment with
CH2N2. Proof that it was the C5 alcohol which was free in 17 followed from 1H NMR
analysis of acetylation product 18 in which the C5 methine shifted from 2.65 to 4.35 ppm
(Figures 111.6 and 111.7).
AcO'
17
Ac20Pyridine
OAc
18
CO2Me
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Figure ll1.6 Formation of 18
Since the initial isolation of constanolactones A (9) and B (10), additional intertidal
collections of C. simplex collected between 1989 and 1993 from the Oregon coast have
been similarly extracted and analyzed for oxylipins. Constanolactones A (7) and B (8)
were re-isolated during this effort as natural products by a combination of normal and
reversed phase HPLC and their stereochemistries deduced by various spectrochemical
techniques. The identities of 7 and 8 were assigned spectroscopically and confirmed by
acetylation and comparison by 1H-NMR with authentic samples of 9 and 1 0.-Ws -0Ac
1 1 I 5.5 5.0 4.5
-0Ac
.
4.0 3.5
1 i r 3.0 2.5 2.0 1.5 1.0 .5 0.0 PPM
Figure 111.7 1H NMR Spectrum of Acetylation Product18 in C6D6.64
The relative stereochemistry of C-5 to C-9 in constanolactone A and B was
spectroscopically deduced using the diacetate derivatives 9 and 10. Coupling constants
between the C-6-7-8 protons defined the trans (S*, S*) geometry of the cyclopropyl group
in 9 (./6-7a = 5.2 Hz, J6-7b = 8.4 Hz, i7a-7b = 5.2 Hz, .i7a-8 = 8.8 Hz, J7b_8 = 5.2 Hz) and
10 (67a =5.2 Hz,7b =8.5 Hz, ./.7a7b =5.2 Hz, ./.7a8 =8.5 Hz, ../.7b8 =5.2 Hz).
Further, in both 9 and 10, significant nOe interactions were observed from H-5 to H-7a
and H-8, as well as from H-5 to H-3b and H-4a. However, the nOe profile of 9 and 10
were significantly different in the region proximate to C-9. NOe interactions in 9 were
observed from H-8 to H-7a and H-10, and from H-9 to H-6 and H-7b (Table 111.2, Figure
111.8). Compound 10, the C-9 epimer of 9, exhibited nOe interactions between 11-5, H-6
and H-7b and the overlapping resonance observed for the olefinic protons H-10 and H-11
(Table 111.3, Figure 111.9). The structurally related metabolite 3 has recently been
synthesized and its relative configuration assigned.134 A 5R*, 6S*, 8S* configuration in 9
and 10 was shown by direct spectroscopic comparison of the C-5 proton resonance of 9 (6
3.80 ddd, 10.7, 7.4, 3.0 Hz) and 10 (6 3.82 ddd, 10.0, 6.6, 3.1 Hz) with synthetic 3 (6
3.88 ddd, 10.2, 7.5, 3.3 Hz) as well as with the 5R*, 6S*, 8S* (5 3.90 ddd, 10.6, 7.7,
3.2 Hz) and 5S*, 6S*, 8S* (5 4.06 ddd, 10.2, 6.8, 3.2 Hz) 2,4-dinitrophenylhydrazine
derivatives of 3, prepared as intermediates in the synthesis of 3.134 I therefore deduce a
relative configuration of 5R*, 6S *, 8S*, 9S * in 9 and SR *, 6S *, 8S*, 9R * in 10.
The stereochemistry at C-12 in both 7 and 8 was determined by forming semi-
synthetic (-)-menthoxycarbonyl (MC) derivatives followed by ozonolysis and comparison
with standards using 1H NMR and GC-MS. The bis-MC derivative (2 0) was prepared by
treatment of 7 with an excess of (-)-menthoxycarbonyl chloride (19) and isolated by
elution over silica gel. The presence of two MC-esters in 2 0 was confirmed by 1H NMR
shifts for H-9 and H-12 at 54.83 and 5.10, respectively, a downfield shift of 1 ppm
compared with those of 7, clearly indicating esterification of both free hydroxyl groups65
Table 111.2 Key 1H-1H NOESY Correlations for Constanolactone A Per-acetate (9).
Proton # NOESY Correlations
H-3b H-4, H-5, H-8
H-5 H-7a, H-8, H-12 or H-14
H-6 H-7b, H-9
H-7a H-8
b H-9
H-8 H-9, H-11
H-9 H-10, H-11
H-10 H-12 or H-14
H-11 H-12 or H-14
H-12 H-13a, H-15, H-16, H6- (17 -19), -OAc
H-13a H-16
b H-16, -OAc
H-14 H-15, H-16, H6- (17 -19), -OAc
H-15 H-16
H-16 H6-(17-19), -OAc
H6-(17-19) H-20
Table 111.3 Key 1H-1H NOESY Correlations for Constanolactone B Per-acetate (1 0).
Proton # NOESY Correlations
H-3 H-4a
H-4a H-5
H-5 H-6* or H-8, 11-7a*, H-10 or 11-11, H-12
H-6 or H-8 H-7a, H-7b*, H-9, H-10 or H-11
H-7b H-9, H-10 or H-11
H-9 H-10 or H-11
H-10 or H-11 H-12, H-13a, H-13b, H-15, H-16
H-12 or H-14 H-13a, H-13b, H-15, H-16
H-13a H-14, H-16
b H-14
H-15 H-16
H-16 H-17 or H-18, -OAc
H6-(17-19) H-20, -OAc
* Confirmed by nOe Difference Spectroscopy (NOEDS).66
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Figure 111.8 Depiction of Selected NOESY Correlations for Per-acetate
Derivative of Constanolactone A (9).
OAc
Figure 111.9 Depiction of Selected NOESY Correlations for Per-acetate
Derivative of Constanolactone B (10).67
(Figure III.10). Ozonolysis of the bis-MC derivative 2 0, followed by an oxidative work-
up with peracetic acid, methylation, and preparative TLC purification resulted in a 30%
yield of dimethyl-MC-malate derivative 21 (Figure III.11). The 1H NMR spectra of the
synthetic standards, 2S (21) and 2R (2 2) dimethyl-MC-malate, showed them to be
differentiated by the chemical shift dispersion of the ester methyl groups 16 3.778 and
3.722 (6,6 = 0.056) in 21; 6 3.792 and 3.720 (A6 = 0.072) in 2 21. As obtaining baseline
separation of these malate derivatives by GC is sometimes problematic, this 1H NMR
method is a useful alternative when sample size permits (I estimate a reliable 1H NMR
determination can be made on as little as 50 pg of malate derivative). Comparison of the
1H-NMR spectra of the two standard dimethyl-MC- malates with that produced from
constanolactone A (7) showed the latter to be identical to that prepared from L-malate,
thereby establishing the C-12 stereochemistry in 7 as S (Figure 111.12-14). These results
were confirmed by GC retention times as synthetic S- and constanolactone A-derived
dimethyl-MC-malates (21) coeluted (tR = 26.34 min) while the R derivative 22 had a
longer retention time (tR = 26.46 min).
Constanolactone B diacetate (10) was saponified and then converted to the MC
derivative, ozonized and methylated to yield the C-11 to C-14 fragment as a dimethyl-MC-
malate derivative. This derivative was analyzed by GC using conditions giving baseline
separation of the two malate enantiomers and showed a peak only at the retention
time corresponding to the S-malate (2 1).
The absolute stereochemistry at C-9 in constanolactone A (7) was determined by
circular dichroic (CD) analysis of mono- and bis-p-bromobenzoate derivatives of 7.
Treatment of 7 with 4-bromobenzoyl chloride and a catalytic quantity of 4-
dimethylaminopyridine yielded the bis-(p-bromobenzoate) 2 3 and the mono-p-
bromobenzoate mono-acetate derivative 2 4, presumably a trans-esterification product of
mono-(p-bromobenzoate) 2 5 and EtOAc during work-up (Figure 111.15). The C-12i)69
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Figure 111.11 Formation of Methyl-(-)-Menthoxycarbonyl Malate Derivative (21) from
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Figure 111.12 1H NMR Spectra of Authentic R-Standard Dimethyl-Menthoxycarbonyl-
Malate (2 2) in CDCI3.
Figure 111.13 1H NMR Spectra of Dimethyl-Menthoxycarbonyl-Malate (2 1) from
Ozonolysis of (2 0), in CDC13.
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Figure 111.14 1H NMR Spectra of Authentic S-Standard Dimethyl-Menthoxycarbonyl-
Malate (2 1) in CDCI3.71
23 R=H, R'=R"=0C0C6H5Br
24 R=H, R1=0C0C6H5Br, R "=OAc
25 R=H, R'= OCOC6H5Br, R"=OH
Figure 111.15 Structures of Constanolactone A p-Bromobenzoate Derivatives.
acetate and C-9 p-bromobenzoate substitutions were assigned based upon a comparison of
the a-ester 1H NMR resonances in 2 4 with those of the diacetate derivative 9. In both H-
12 resonated at 65.3 while in mixed ester 2 4 H-9 was downfield (65.17) compared to
diacetate 9 (64.90). While the CD spectrum of bis-(p-bromobenzoate) 2 3 was not reliably
interpretable because of free rotation in centers separating the various chromophores, the C-
9 allylic p-bromobenzoate chromophore in mixed ester 2 4 was ideally suited for
determination of the C-9 stereochemistry by exciton chirality.135 The combination of a
negative nondegenerate p-bromohenzoate Cotton effect (0E -7.3) at 244.5 nm in 2 4, and a
preferred rotomer conformation for C-9-C-10 in which the C-H and C=C bonds eclipse as
indicated by a 3419-H10= 5.3 Hz (typically 5.2-9.2 Hz),I36'137indicated a left-handed
helicity between these groups and defined the stereochemistry at C-9 as S (Figures 111.16
and 111.17).
The uncertain origin of the mixed ester 2 4 prompted us to repeat the
bromobenzoylation of 7 in the absence of 4-dimethylaminopyridine catalyst in the hopes of
producing the C-9 mono-p-bromobenzoate 2 5. Following workup, derivative 2 5 was
isolated by silica gel flash chromatography and HPLC. Its identity as the C-9 mono-p-
bromobenzoate was effectively revealed by the chemical shifts of the C-9 (65.07) and C--9
24
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Figure 111.16 CD Spectrum of 12-Acetoxy-9-(p-Bromobenzoy1)-ConstanolactoneA (2 4) in EtOH.73
Figure 111.17 Newman Projection of Predicted Favored Rotamer of 9-(p-Bromobenzoate)
Derivatives 2 4 and 2 5 Used in CD Analysis for Determination of Absolute
Stereochemistry.
12 (M.20) proton resonances in comparison with the natural product 7 (C-12= 64.17) and
bis-(p-bromobenzoate) 2 3 (C-9 = 65.17). A relatively large C-9 to C-10 3JHH= 6.2 Hz
and similar CD spectrum to that of 2 4 (Ae -4.6 at 242 nm) confirmed the 9S
stereochemistry of 2 5, as above. Therefore, taking into consideration the relative
configuration as assigned by NOESY and coupling constants, the C-12 stereochemistry
from analysis of the chiral MC-derivative 21, and the above CD analysis, the absolute
configuration of 7 is 5R, 6S, 8S, 9S, 12S. Since constanolactone B (7) is the C-9 epimer
of 7 and yields the same chiral MC-derivative (21) upon reaction with (-)-
menthoxycarbonyl chloride (19) followed by ozonolysis, the absolute configuration of 8
may be assigned as 5R, 6S, 8S, 9R, 12S.
Further investigation of minor compounds obtained from acetylation of a crude
mixture of constanolactone natural products resulted in the isolation and identification of
two new constanolactone analogs (2 6 and 2 7) as synthetic diacetate derivatives (2 8 and74
2 9) (Figure 111.18). The new derivatives 2 8 and 2 9 possess nearly identical 1H and 13C
NMR features to the diacetates of constanolactone A (9) and constanolactone B (10).
Further, by MS, these diacetate derivatives were 2 mass units smaller than constanolactone
A diacetate (9) and constanolactone B diacetate (1 0), and hence, each possessed one
additional olefinic bond. The location of the new olefin was revealed through signals for
an additional two proton bis-allylic triplet at 2.78 ppm and a downfield and sharp C-20
methyl triplet (Figures 111.19 and 111.20, Table 111.4), thus defining 2 8 and 2 9 as co-3
unsaturated analogs of 9 and 1 0, respectively. Relative stereochemistry in diacetate 2 8
and 2 9 was assigned the same as in 9 and 10 based on the near superimposability of 1H
and 13C NMR shifts and coupling constants for all pertinent regions of the spectra (Table
111.1 and Table 111.4). Additionally, the CD spectrum for 3 0, the synthetic bis-(p-
bromobenzoate) derivative of 2 7, was nearly identical to that of 3 1, the bis-(p-
bromobenzoate) derivative of constanolactone B (8), indicating that they possess the same
overall absolute stereochemistry.
R"
26 R=H, R'=R"=OH
27 R= R " =OH, R'=H
28 R=H, R'=R"=0Ac
29 R= R " =OAc, R'=H
30 R=R"=0C0C6H5Br, R'=H
31 R= R "= OCOC6H5Br, R'=H
Figure 111.18 Structures of Constanolactone C, D, and B Derivatives (2 6-3 0 and 31).J
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Figure 111.19 1H NMR Spectrum of Constanolactone C Diacetate (2 8) in CDCI3.
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Figure 111.20 1H NMR Spectrum of Constanolactone D Diacetate (2 9) in CDC13.76
Table 111.4 1H and 13C NMR Data for Per-acetates of Constanolactones C (2 8) and D
(2 9).
Con stanolactone C per-acetate (2 8)
Position 1H (CDC13) 13Ca
Constanolactone D per-acetate (2 9)
1H (CDC13) 13Ca
1 NA NA
2a2.40 ddd (17.7, 8.5,6.8)29.52 2.44 ddd (17.5, 8.4, 6.8) 29.52
b2.56 bdt (17.7, 6.6) 2.55 bdt (17.5, 7.4)
3a1.80 m 18.42 1.80 m 18.28
b1.96 m 1.94 m
4a1.60 m 27.87 1.65 m 27.79
b2.0 m 2.0 m
5 3.80 ddd (10.5, 7.4,3.1)82.30 3.82 ddd (10.0, 7.2, 3.1) 81.91
6 1.2-1.3 m 20.75b 1.20 m 21.71e
7a0.62 dt (8.6, 5.3) 7.62 0.59 dt (8.6, 5.5) 6.73
b0.73 dt (8.8, 5.3) 0.68 dt (8.5, 5.5)
8 1.04 m 20.75b 1.2 m 21.22e
9 4.91 dd (7.2, 5.6) 75.30 4.85 bdd (7.9, 2.6) 75.49
10 5.69 ddd (15.7, 5.6,0.9)130.89 5.71 m 130.42
11 5.82 ddd (15.7, 6.0,1.0)129.16 5.71 m 129.45
12 5.29 m 73.06 5.3 m 73.01
13 2.4 m 32.22 2.4 m 32.31
14 5.26-5.4 m 123.78 5.2-5.4 m 123.63
15 5.47 dtt (10.8, 7.3,1.5)131.29 5.49 dtt (10.7, 7.2, 1.5) 131.38
16 2.78 t (7.1) 25.64 2.78 t (7.2) 25.64
17 5.26-5.4 m 126.79 5.2-5.4 m 126.79
18 5.26-5.4 m 132.17 5.2-5.4 m 132.16
19 2.0 m 20.54 2.0 m 20.10
20 0.98 t (7.5) 15.24 0.98 t (7.5) 14.23
Acetate Esters Acetate Esters
2.07 s 20.09d 2.06 s 20.30e
2.08 s 20.09d 2.09 s 21.22e
a) 13C NMR data from 13C DEPT (135°); (b-e) Assignments may be interchanged.77
A subsequent collection of C. simplex yielded, following extraction with warm
CHC13/Me0H, silica gel chromatography and HPLC, two additional constanolactone-
related products, 32 (0.02%) and 3 3 (0.049%) (Figure 111.21). Their structures were
elucidated principally by comparison of NMR data with that of constanolactone A (7) and
B (8). The only significant differences between the NMR spectra of these new compounds
and the natural products 7 and 8 were a new three proton methyl singlet resonance at 3.32
ppm in 3 2 and at 3.27 ppm in 3 3, and an upfield shifted C-9 proton (AO = 0.3 ppm in 3 2
and AO = 0.53 in 3 3, Figure 111.22, Table 111.5). Hence, these new compounds were the
C-9 methyl ether analogs of 7 and 8, respectively, and presumably arise as solvolysis
artifacts produced during extraction with Me0H. The significance of this finding is
discussed in more detail below.
R"
32 R=H, R'=OCH3, R"=OH
33 R=OCH3, R'=H, R"=OH
Figure 111.21 Structures of 9 -OMe Analogs of Constanolactone A and B (3 2 and 3 3).
Three additional metabolites were isolated from the same collection of C. simplex
which yielded the original per-acetate derivatives constanolactone A (9) and B (1 0). A
silica gel vacuum chromatographic fraction eluting with 45% EtOAc in hexanes was
acetylated to give, following additional purification by normal-phase HPLC, three new
constanolactones, E-G (34-36), as diacetate derivatives (3 7-3 9) (Figure 111.23). Since
both the proton and carbon count and mass spectrum for 3 7 and 3 8 were identical with32
OMe
5.6 5.0 4.ff 4.0 3.5 3.0
PPM
2.5 2.0 t.5 1.0
Figure 111.22 1H NMR Spectrum of 9-0-Methyl Constanolactone A (3 2) in CDC13.79
Table 111.5 1H and 13C NMR Data for C-9 Methyl Ethers of Constanolactones A (3 2) and
B (3 3) in CDC13.
Position
Derivative 3 2
1H 13Ca
Derivative 3 3
1H
1 NA
2a
b
2.44 ddd (17.6, 8.5, 6.8)
2.55 dddd (17.6, 7.0, 5.3,1.3)
29.01 2.44 ddd (17.7, 8.3,
2.55 ddd (17.7, 6.9,
6.8)
6.7)
3a 1.80 m 18.16 1.80 m
b 1.96 m 1.98 m
4a 1.67 m 27.46 1.68 m
b 2.0m 2.04m
5 3.82 ddd (10.2, 7.2, 3.1) 82.96 3.70 td (9.5, 3.3)
6 1.11 m 20.68 1.09 m
7a 0.52 dt (8.4, 5.4) 5.24 0.65 dt (8.5, 5.2)
b 0.58 dt (8.6, 5.4) 0.79 dt (8.7, 5.3)
8 1.6 m 20.69 1.65 m
9 3.42 bt (6.9, 5.7) 81.69 3.12 bt (7.0)
10 5.57 ddd (16.2, 6.9, 1.1) 135.19 5.66 m
11 5.72 ddd (16.2, 5.7, 0.6) 124.01 5.66 m
12 4.18 bq (6) 71.39 4.19 bq (6.1)
13 2.32 bq (6.2) 35.10 2.34 m (9 lines)
14 5.37 dtt (10.9, 6-7.5, 1.6) 129.05 5.39 bdt (10.9, 7.1)
15 5.55 m 133.50 5.54 bdt (10.9, 7.3)
16 2.0 m 27.24 2.0 m
17 1.35 m 29.35 1.35 m
18 1.3 m 31.31 1.3 m
19 1.3 m 22.34 1.3 m
20 0.89 t (6.8) 13.83 0.89 t (6.8)
OMe 3.32 s (3H) 56.09 3.27 s (3H)
a) 13C NMR data from 13C DEPT (135°)80
those of the per-acetate constanolactone derivatives 9 and 10 (C,,4H3 606), it was apparent
that 3 7 and 3 8 were either regio- or stereochemical isomers of 9 and 1 0. By 1H and 13C
NMR, the C-1 to C-8 portion of both 3 7 and 3 8 were the same as in 9 and 10 (Table 111.1
and Table 111.6). However, from COSY analysis, the new compounds differed from 9
and 10 in the C-9 to C-12 region. This was reflected by a downfield shift of the C-8
methine proton (61.6 and 1.54 in 3 7 and 3 8, respectively, versus 61.2-1.3 in 9 and 1 0),
C-9 and C-10 protons occurring at shifts typical for an olefin, and the C-11 and C-12
protons occurring at shifts consistent with these positions bearing acetoxy groups (Table
111.6). The C-9-C-10 olefin in both 3 7 and 38 was of a trans geometry as revealed by a
JI-19-H1 0 =15 Hz coupling constant. The 1H NMR spectrum of derivative 3 9,
constanolactone G diacetate, was highly analogous to that of 3 8, differing only in the
absence of the methylene band at 61.30-1.35 and the presence of additional olefinic and
bis-allylic resonances, thus defining derivative 3 9 as the w -3 analog of constanolactone F
diacetate (3 8).
0 0
34 R=R"=0H, R'=H
35 R=H, R'=R"=OH
37 R= R " =OAc, R'=H
38 R=H, R'= R " =OAc
R'
R"/ d\
36 R=H, R'=R"=OH
39 R=H, R'= R " =OAc
Figure 111.23 Structures of Constanolactones E, F, G (3 4-3 6) and Derivatives (3 7-3 9).
Constanolactones E (3 4) and F (3 5) were subsequently isolated as natural products
from another extract of frozen C. simplex (May 1992). The diols 3 4 and 3 5 wereTable III.6 111 and 13C NMR Data for ConstanolactonesE (3 4) and F (3 5) and Diacetate Derivatives (3 7)and (3 8)
in CDC13.a
Constanolactone E (3 4)
Position 114 13C
Constanolactone E diacetate (3 7)
114 13C
Constanolactone F (3 5)
LH 13C
Constanolactone F diacetate (3 8)
1H 13C
1
2a2.46 ddd (17.6, 8.5,
b2.57 bdt (17.6, 6.3)
3a1.8 m
b1.94 in
4a1.7 m
b2.0 m
53.79 ddd (10.2, 7.8,
61.12 m (7 lines)
7a0.72 dt (8.8, 5.3)
b0.77 dt (8.4, 5.3)
81.59 m (7 lines)
95.4 bdd (15.7, 8.1)
105.63 dd (15.7, 6.8)
114.10 dd (6.8, 3.8)
123.66 m (5 lines)
132.25 m
145.37 m
155.5 m
162.0 in
171.35 in
181.3 m
191.3 m
200.89 t (6.8)
COQ
COCH3
7.0)
3.1)
171.50
29.26
18.40
27.74
83.25
10.64
19.32
135.64
124.74
74.84
73.90
29.93
126.37
133.54
27.39
29:50
31.47
22.53
14.03
2.46 ddd (17.7, 8.7, 7.0)
2.57 dt (17.7, 6.6)
1.8 m
1:94 131
1.66 td
2.0 in
3.78 ddd (9.6, 7.7, 3.1)
1.12 m
0.71 dt (8.7, 5.2)
0.79 dt (8.6, 5.2)
1.6 in
5.39 dd (15.4, 8.2)
555 dd (15.4, 7.6)
5.29 in
5.03 td (6.0, 3.7)
2.28 in
5.27 m
5.49 bdt (10.8, 6.8, 1.5)
2.0 m
1.35 m
1.3 in
1.3 m
0.89 t (6.8)
2.04
2.05 s
171.32
29.16
18.45
27.81
82.99
24.87
10.75
19.25
138.65
122.16
74.81
73.70
28.05
123.37
133.26
27.37
29.51
31.47
22.55
14.04
21.04
21.17
170.45
169.93
2.46 ddd (17.8, 8.6,
2.57 ddd (17.8, 7.9,
1.8-2.0 m
1.66 in
1.99 in
3.78 ddd (10.2, 7.8,
1.11 in (7 lines)
0.71 dt (8.7, 5.2)
0.76 dt (8.5, 5.3)
1.57 in
5.39 dd (15.5, 8.2)
5.57 dd (15.5, 6.8)
3.91 t (63)
3.48 dd (6.3, 5.7)
2.25 in
5.4 m
5.55 In
1.98 m
1.35 m
1.3 m
1.3 in
0.89 t (6.7)
6.9)
6.5)
3.1)
171.50
29.29
18.45
27.79
83.29
24.95
1050
19.35
135.51
127.96
75.13
74.20
31.05
124.54
133.53
27.39
2953
31.52
22.55
14.06
25 -2,6 m
1.8-2.0 in
1.66 m
1.99 m
3.74 ddd (10.8, 7.4,
1.12 m (7 lines)
0.68 dt (8.6, 5.2)
0.75 dt (8.6, 5.2)
154 m
5.4 in
5.3-5.5 m
5.31 m
4.99 q (6.2)
2.30 bt (6.5)
5.3 m
5.48 in
1.98 in
1.35 m
1.3 m
13 m
0.89 t (6.7)
2.06 s
2.07 s
3.1)
171.40
29.16
18.43
27.78
83.15
24.94
10.59
19.37
138.16
123.01
74.19
73.71
2854
123.01
133.46
27.29
29.51
31.49
2234
14.04
21.14
20.95
170.38
169.9482
slightly less polar than constanolactone A (7) and B (8), eluting with 50% EtOAc in
hexanes from silica gel and were readily purified by normal-phase HPLC. Overlapping
olefinic/a-acetoxyl regions in derivatives 3 7 and 3 8 were resolved in the 1H NMR spectra
of natural products 3 4 and 3 5 (Table 111.6), allowing for straight forward deduction of the
C-8 to C-12 region of these molecules (Figures 111.24 and 111.25). The difference in1H-
11-1 coupling constants between H-11 and H-12 in the vicinal-diols 3 4(3 J11-12 =3.8 Hz)
3J11-12 , and 3 5 ( = 6.3 Hz) suggested an erythrolthreorelationship for these two
compounds. The relative configurations at C-5, C-6, and C-8 in vicinal-diols 3 4-3 6 were
deduced to be identical to that in constanolactones A-D (5R*, 6S*, 8S*) by comparison of
the 1H and 13C NMR of authentic 7-1 0 with the C-5 to C-8 region in 34 and 3 5 and the
per-acetate derivatives 3 7-3 9.
A series of derivatives of 3 4 and 3 5 were produced in order to further investigate
the stereochemistry at C-11 and C-12. Treatment of 3 4 or 3 5 with 2,2-dimethoxypropane
gave the methyl ester acetonide derivatives of constanolactone E (4 0)and F (41) (Figure
111.26). A relatively small3H11-1-112value (6.2 Hz) and dissimilar magnetic environment
of acetonide methyl groups (46.6 = 0.14 ppm) were indicative of an erythro configuration in
derivative 4 0, while a relatively large H-11 to H-12 3JHH value (8.1 Hz) and similar
magnetic environment of acetonide methyl groups (Ao = 0.007 ppm) established the diol
configuration in derivative 41 as threo (Figures 111.27 and111.28).138
The absolute stereochemistry of C-11 and C-12 in constanolactones E (3 4) and F
(3 5) were determined by CD analysis of the corresponding bis- (p- bromobenzoate)
derivatives, 4 2 and 4 3 (Figure 111.29). The structures of the bis-(p-bromobenzoate)
derivatives 4 2 and 4 3 were confirmed by UV,1H-NMR, and CIMS. However, for both
derivatives, the CD spectra showed a weak positive homochromophoric exciton coupling
(Figure 111.30). Apparently, the two bis-(p-bromobenzoate) derivatives adopt different
conformations so as to both give weakly positive split Cotton effects. However, in34
83
5.5 5.0 4.5 4.0 3.5 3.0
PPM
2.5 2.0 1.5 1.0
Figure 111.24 IH NMR Spectrum of Constanolactone E (3 4) in CDC13.
35
L_
5.5 5.0 4.5 4.0 3.5 3.0
PPM
2.5 2.0 1.5 1.0
Figure 111.25 iH NMR Spectrum of Constanolactone F (3 5) in CDC13.84
II
H3C00`
40 41
Figure 111.26 Structures of Methylated Acetonide Derivatives 4 0 and 4 1.
derivative 4 3, a pronounced bathochromic shift in the CD maxima (Amax= 255, 240 nm)
was observed.I interpret this to signify that the C-11 benzoate shows exciton coupling
both to the C-12 benzoate (positive) and C-9-C-10 olefin (negative, Ae + 5.4, -11.8; Amax
= 255, 240nm).135 A computerized simulation in which the negative C-9 benzoate to C-
10-C-11 olefin coupling observed for compound 2 5 was mathematically subtracted from
the curve obtained for 4 3 produced a symmetrical CD curve with maxima more typical of
benzoate to benzoate couplings (Amax = 238, 253 nm, Figures 111.30 and 111.31).
Similarly, bis-(p-bromobenzoate) derivative 4 2 gave anomalous intensities in its CD
spectrum (De +9.1; Amax = 252.5 nm) which I interpret to be due to a positive C-11
benzoate to olefin coupling which overlaps a positive benzoate-benzoate coupling. In both
derivatives 3 2 and 3 3 relatively large C-9 to C-10 proton coupling constants of 8 Hz and 7
Hz, respectively (typically 5.2-9.2 Hz),136-137 established the preferred rotomer
conformations, in each case, with eclipsed C-H and C=C bonds. Thus, in derivative 4 2
the positive C-11 p-bromobenzoate to olefin coupling indicates a right-handed helicity5.5 5.0 4.5 4.I0 3.I0
FPI(
2.5 2.0 1.5 1.0
Figure 111.27 1H NMR Spectrum of Acetonide of Methyl Constanolactone E (4 0) in
CDC13.
MeO
11
12
5
41
5.5 .5 - 4.0 3.5 2.5 2.0 1.5 1.0
Figure 111.28 1.11 NMR Spectrum of Acetonide of Methyl Constanolactone F (41) in
CDCI3.86
42 R=R"=0C0C6H5Br, R'=H
43 R=H, R'=R"=0C0C6H5Br
Figure 111.29 Structures of Constanolactone E and F Bis-(p-Bromobenzoate)
Derivatives.between these groups and defines the stereochemistry at C-11 as R while the
negative C-11 p-bromobenzoate to olefin coupling in 43 indicates a left handed helicity or
11S stereochemistry (Figure 111.32). As the relationship between alcohols in 3 4 and 3 5
was shown to be erythro and threo, respectively, from analysis of the acetonide derivatives
4 0 and 4 1, the absolute stereochemistry at C-11 and C-12 is given as 11R, 12S for
constanolactone E (3 4) and 115, 12S for constanolactone F (3 5). Thus, the overall
stereochemistry in constanolactone E (3 4) is defined as 5R*, 6S*, 8S*, 11R, 12S, and
constanolactone F (3 5) as 5R*, 6S*, 8S*, 11S, 12S.
It has been suggested that these carbocyclized 20 carbon compounds may be the
ultimate result of an involved form of arachidonic acid metabolism, but no conclusive
evidence was available.
112,115,124,139inerefore, I initiated an investigation of in vitro
arachidonic acid (4 4) metabolism in Constantinea simplex. Crude C. simplex enzyme
preparations were produced by macerating and "defatting" algal tissues at low temperatures
in non-denaturing solvents (c, -70 °C, CO2(s)/acetone). This process was repeated until87
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Figure 111.30 CD Spectrum of Bis- (p- Bromobenzoyl)- Constanolactone F (4 3) in EtOH.
-12
210 220 230 240 250 260
wavelength,nm
270 280 290
Figure 111.3 1 CD Spectral Simulation of Bis- (p- Bromobenzoyl)- Constanolactone F (4 3)
in EtOH, with Olefin-p-Bromobenzoyl Exiton Coupling Mathematically Subtracted.88
42
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Figure 111.32 Newman Projections of Predicted Favored Rotamers of Bis-(p-
Bromobenzoate) Derivatives 4 2 and 4 3 Used in CD Analysis for Determination of
Absolute Stereochemistry.
nearly all pigments, lipids, and other acetone soluble compounds were removed. The
pulverized-extracted algal material was then dried under a nitrogen stream to form an
acetone-extracted powder or "acetone powder" (AP). The AP was placed in pH 7.4 buffer
and incubated with exogenous arachidonic acid (AA, 4 4) and used in a series of
experiments to examine the mechanism of constanolactone biosynthesis.89
Chloroform extracts of dry "AP alone" were shown to produce no detectable
hydroxyeicosanoids by TLC analysis (no UV-active and/or blue charring spots with 50%
H2SO4, Figure 111.33). However, extracts from buffer incubated "AP alone" (without
added AA) contained traces of oxylipin products (TLC, blue charring spots, Rf=0.55,
0.47). These findings suggest that low levels of substrate may either be only sparingly
acetone soluble or tightly bound to the enzyme powder. Incubation of the "AP alone" in
buffer allows for the enzymatic conversion of endogenous substrate to eicosanoid-type
products.
Incubation experiments were performed and the products (constanolactones A and
B) were acetylated (Ac20/Pyridine, ca. 12h) and analyzed by normal phase HPLC with
differential refractometer detection at a constant flow rate. Enzyme products were
quantified by HPLC area under the curve measurements coupled with actual recovered
product masses.
HPLC analysis of "AA + AP" incubations indicate that, at a given temperature,
constanolactone product formation is directly proportional to the quantity of AA substrate
added to each treatment. Incubations were conducted at 1 °C, 9 °C, and 25 °C using a
range of AA substrate levels (0.0 mg, 0.1 mg, 1.0 mg, and 10.0 mg per incubation).
Greater than five fold increases in the formation of eicosanoid products were observed at
25 °C when AA substrate levels were incrementally increased from a control level of 0.0
mg up to 10.0 mg (Figure 111.34). "AA + boiled AP" treatments yielded significant
quantities of AA and none of the metabolites associated with active AP incubations,
suggesting that the formation of the constanolactones is the result of a heat labile, substrate
and temperature dependent, enzyme mediated process (Figure 111.33).
Additionally, it has been suggested that carbocyclic algal oxylipins may result from
a lipoxygenase-initiated peroxidation of AA (4 4, Figure 111.35).45, 51-54Incorporation of
molecular oxygen from a dioxygenase into key hydroperoxide intermediates (i.e. 12-No Substrate Arachidonic Acid (44)
1) C. simplex Acetone Powder
Incubation, pH 7.4 Buffer, 20°
2) Extracted 4x (CHC13)
7 and 8
(Trace only)
7 and 8
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,
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.---, - .-
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Arachidonic Acid (44)
1) Boiled C. simplex Acetone Powder
(98-100°, 10 min) prior to Incubation
2) Boiled C. simplex Acetone Powder,
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"No Oxylipins"
Figure 111.33 C simplex Acetone PowderIncubations and HPLC Analysis.0.4
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Figure 111.34 Mean Production of Constanolactones A and B in Cell-Free Acetone Powder
Incubation at 25 °C (n = 2).
hydroperoxyeicosatetraenoic acid (4 5), 12-HpETE) may therefore be evaluated by1802-
labeling during carbocyclic-oxylipin formation. Biosynthetic experiments with marine
macroalgae have traditionally encountered difficulties with poor cell wall penetration of
exogenously supplied substrates and competition with endogenous substrate pool s.14°
Fortunately, I have been able to avoid these obstacles through the use of these cell-free
systems. The successful incorporation of exogenously supplied 4 4 suggested the
possibility of further probing the intermediacy of a lipoxygenase-type enzyme in the
formation of 7 and 8.b
COOH /**- > k..2.0or
12-LPOas",
Arachidonic Acid (44)
or Eicosapentaenoic Acid
HOtu
12S-HpETE (45)
or 12S-HpEPE
<=1
COOH
bI>
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9:
COOH
1&' HepoxilinB3 or B4 (18)
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Epoxy-cation
7 A:R=OH,R'=H
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28 C: (c.0-3) R = OH, R' = H
29 D: (co-3) R = H, RI = OH
34 E: R =OH, R' = H
35 F:R=H,R'=OH
36 G: (0)-3) R = H, Re = OH
Figure 111.35 Biosynthetic Proposal for Origin of C. SimplexCyclopropyl-Lactones.93
Arachidonic acid (4 4) was incubated with the C. simplex acetone powder in a
closed vessel enriched with 1802 (180, 50,Following extraction and methylation of the
products (as above) the oxylipins were analyzed by GC-EIMS of their corresponding bis-
trimethylsilyl (TMSi) ethers (4 6 and 4 7). Incorporation of labeled 02 was observed by
analysis of isotopic abundance patterns in key MS fragments in labeled and non-labeled
products. Significant incorporation of one 180 was achieved as evidenced by an
enhancement of the ion at m/z 371 [M CH3 (CH,)4CH=CHCH2 + 2]+ (28±1% incorp.),
corresponding to cleavage a to the C-12 TMSi ether (Figure 111.36). Unfortunately the
position of 180-label substitution was not clearly identifiable by the fragmentation pattern.
Catalytic hydrogenation (H2, PtC12) of 180-labeled and unlabeled control incubation
products afforded constanolactone derivatives which were re-silated to form a mixture of
10,11,14,15-tetrahydro-TMSi ethers (4 8 and 4 9). These compounds exhibited highly
definable ELMS fragmentation patterns useful for locating the position of isotopic
substitution (Figures 111.36111.38). Again, enhancement of the C-12 a-cleavage ion now
at m/z 373 IM CH3(CH2)7 + 2r (35±6% incorp.) was observed. Additionally, two other
major fragments showed critical isotopic abundance patterns from which the substitution of
the label was clearly definable. First, a C-12 a-cleavage ion at m/z 215 [M
CH3(CH2)7COSi(CH)31+ which showed a high level of 180 incorporation by the increased
abundance of a peak at m/z 217 [M CH3(0-12)7COSi(CH)3 + 21+ (30±8% incorp.)
(Figures 111.37 and 111.38), placing the 180 label at C-12. Further support was provided
by the presence of a major fragment at m/z 241 [C12H2103Sij+ resulting from a breaking of
the C-9 to C-10 bond by an a- cleavage mechanism which is intensified by the TMSi ether
substituent at C-9. This C-1 to C-9 containing fragment showed no enhancement of the
peak at m/z 243 [C12H2103Si + 2]+ over that of natural abundance.
Thus, the C-12 hydroxyl group derives from the incorporation of molecular oxygen
and is consistent with a mechanism which involves the intermediacy of a lipoxygenase-type94
Arachidonic Acid (44)
1) C simplex Acetone Powder Incubation,
pH 7.4, 21.5 °C, Oxygen-1802 (180: 50%)
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Figure 111.36 Formation of 180-Labeled Derivatives 48 and 49 which
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Figure 111.37 EI Mass Spectrum of Unlabeled Hydrogenated Methyl TMSi-Ether Derivative 48.
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Figure 111.38 EI Mass Spectrum of 180-labeled Hydrogenated Methyl TMSi-Ether Derivative 48.96
peroxidation of fatty acid precursors. Additionally, the absence of any label of the oxygen
at C-9 is consistent with the formation of, and subsequent non-stereospecific 1,4-addition
of water to, a reactive allylic epoxide intermediate (Figure 111.35).
The red marine alga Constantinea simplex utilizes arachidonic and eicosapentaenoic
acids to produce both simple (i.e. 12S-hydroxyeicosatetraenoic acid (1 1), 12S-
hydroxyeicosapentaenoic acid (12))124 as well as highly functionalized oxylipins (e.g.
constanolactones A-G). I have demonstrated that these metabolites could biogenetically
derive from a mechanism consistent with a lipoxygenase-initiated oxidation of
polyunsaturated fatty acid precursors.52'53 Key to my hypothesis (Figure 111.35), and in
common with additional suspected routes of oxylipin metabolism in other algae,123 is the
formation of an epoxy-cation intermediate in which the cation induces cyclopropyl and
lactone ring formation. This leads in turn to the formation of an allylic epoxide, a potential
end product of the enzymatic pathway. As both epimers at C-9 in the 1,4-diols
(constanolactones A-D) and C-11 in the 1,2-diols (constanolactone E, F) were isolated, it is
possible that these diol products result from non-enzymatic hydrolysis (1,2 or 1,4) of the
a, I3-unsaturated epoxide intermediate. This hypothesis is substantiated by my isolation of
the two epimeric C-9 methyl ether derivatives (3 2 and 3 3), presumed Me0H solvolysis
products of an allylic epoxide, and are formed in the extraction process (Figure 111.39).
An analogous biogenetic hypothesis has been proposed (Figure 111.40)45'139 for the
formation of the sponge metabolites halicholactone (1) and neohalicholactone (2).112,113
However, the sponge metabolites are proposed to derive from the 15-lipoxygenase
metabolites 15-hydroperoxyeicosatetraenoic acid (15-HpETE) and 15-
hydroperoxyeicosapentaenoic acid (15-HpEPE) rather than from 12-HpETE 4 5 and 12-
hydroperoxyeicosapentaenoic acid (12-HpEPE) as in C. simplex.Further, isolation of the
w-3 unsaturated constanolactones C (2 6) and D (2 7) from this red alga is informative as
these were proposed as biogenetic precursors to aplydilactone (4, Figure 111.41),45 a non-97
\.7
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Figure 111.39 Proposal for Origin of C. simplex 9 -OMe Constanolactone Derivatives (3 2
and 3 3).98
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Figure 111.40 Proposed Biogenesis of Halicholactones.99
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Figure 111.41 Proposed Formation of Aplydilactone (4) from w3 Unsaturated
Constanolactone Precursors.100
symmetrical oxylipin dimer isolated from the herbivorous mollusc Aplysia kurodai.115,116
As Aplysia are well known assimilators of algal natural products, these metabolites may be
formed from dietary precursors.82
It is interesting to note that oxylipins containing cyclopropyl and lactone rings are a
growing class of marine-derived natural product, having now been isolated from red54 and
brown algae,139 sponges,112,113opisthobranch molluscs,115'116 and corals.114 It has
been suggested that if these findings parallel other cases of novel oxylipin discovery, first
in primitive creatures and latter in mammalian systems,141,142then I may perhaps anticipate
isolation of this structure class from yet more complex life forms in the future.45
Experimental
General Methods. Spring and early Summer collections of small (blade diameter
typically 2-5 cm.) C. simplex plants were obtained from exposed low-intertidal locations (-
0.3 to -0.8 M) at Seal Rock and Boiler Bay, Oregon. These were frozen on site with
CO2(s) and stored frozen prior to extraction (CHC13 /MeOH 2:1 or CH2C12/Me0H 2:1).
Extracts of large "older" individuals (diameter > 6 cm.) collected from relatively non-
exposed sites contained an insignificant oxylipin content. UV spectra were recorded on a
Hewlett Packard 8452A diode array spectrophotometer and IR spectra were recorded on a
Nicolet 510 FT-IR spectrometer. CD measurements were obtained on a Jasco 41A
spectropolarimeter. Low resolution mass spectra were obtained on either a Varian MAT
CH7 spectrometer or by GC-MS using a Hewlett Packard 5890 Series II gas
chromatograph and a 5971 mass selective detector. FIRMS were obtained on a Kratos MS
50 TC. HPLC was performed using a M-6000 pump, U6K injector, and either a R401
differential refractometer or a lambda-Max 480 lc spectrophotometer. NMR data were
obtained on either Bruker AC 300 or Bruker AM 400 spectrometers. 1H NMR spectra
were acquired with tetramethylsilane (TMS) as an internal chemical shift reference.13C101
spectra were referenced to the center line of CDCI3 at 77.0 ppm.13C assignments are
based on 1H-13C HETCOR, DEPT multiplicity data, and comparison with previously
identified constanolactone derivatives. TLC-grade (10-40 pm) silica gel was used for
vacuum chromatography and Kieselgel 60 silica (40-63 pm) was used for flash
chromatography.Aluminum-backed thin-layer chromatography sheets were used for
TLC, and all solvents were distilled prior to use.
Isolation of Constanolactones A (7) and B (8). Approximately 8 L of frozen C.
simplex (400 g extracted dry weight) was repetitively extracted (3X, as above), to yield
12.49 g of a dark green oil. The extract was subjected to silica gel vacuum
chromatography, using a stepwise gradient from 0 to 100% (v/v) EtOAc in hexanes.
Fractions eluting with EtOAc concentrations greater than 50% were determined by TLC to
be of similar composition, and were pooled. This combined fraction was further purified
by silica gel flash chromatography, using a stepwise gradient from 10 to 100% (v/v)
Me0H in CHC13. Reversed-phase chromatographic separation (Sep-Pak® C18 cartridge,
85% (v/v) Me0H in H2O) proved necessary in order to remove significant amounts of co-
eluting glycolipid impurities. The natural products were then isolated by NP-HPLC (10-
pm Phenomenex Maxsil Si column; 500 x 10 mm; 20% (v/v) isopropanol in hexanes;
differential refractometer detection; flow rate at 6.0 mUmin) to yield constanolactone A (7
12.4 mg, 0.10%) and B (8 15.8 mg, 0.13%).
Constanolactone A (7). Oil: lc% +1.4° (c 1.00, Me0H); [a]r, -3.8° (c 1.31,
CHC13); IR (neat) 3320, 2958, 2924, 1712, 1258, 1248, 1099, 1045, 1031 cm 1; 11-1
NMR: (300 MHz, CDC13) 6 5.78 (m, 2H, H-10 and H-11), 5.54 (dt, 1H, J = 10.8, 7.3,
H-15), 5.39 (dt, 111, J = 10.8, 7.2, H-14), 4.17 (dt, 1H, J = 4.6, 6.1, H-12), 3.72 (m,
2H, H-5 and H-9), 2.56 (dt, 1H, J = 17.8, 6.4, H2b), 2.44 (ddd, 1H, J = 17.8, 8.5, 6.9,
H2a), 2.32 (bq, 2H, J = 6.7, H-13), 2.05 (m, 2H, H-16), 1.99 (m, 1H, H4b), 1.96 (m,
1H, H3b), 1.80 (m, 1H, H-3a), 1.68 (ddd, 1H, J = 13.2, 9.9, 4.5, H-4a), 1.35 (m, 21-1,102
H-17), 1.3 (m, 411, H-18 and H-19), 1.20 (m, 1H, H-8), 1.02 (m, 1H, H-6), 0.88 (t,
3H, J = 6.7, H-20), 0.75 (dt, 1H, J = 8.7, 5.3, H-7b), 0.61 (dt, 11-1, J = 8.5, 5.3, H-7a);
(300 MHz, C6D6) 6 5.97 (m, 2H, H-10 and H-11), 5.67 (dt, 1H, J = 10.9, 6.8, H-15),
5.56 (dt, 1H, J = 10.9, 7.0, H-14), 4.30 (dt, 1H, J = 4.3, 6.4, H-12), 3.75 (dd, 1H, J =
6.9, 4.3, H-9), 3.12 (td, 1H, J = 8.9, 3.4, H-5), 2.5 (m, 2H, H-13), 1.98-2.13 (m, 8H,
11-2 to H-4, and H-16), 1.32 (m, 2H, H-17), 1.25 (m, 4H, H-18 and H-19), 1.1 (m, 1H,
H-6), 0.88 (t, 3H, J = 6.9, H-20), 0.81 (m, 1H, H-8), 0.62 (dt, 1H, J = 8.7, 5.2, H-7b),
0.32 (dt, 1H, J= 8.5, 5.2, H-7a); 13C NMR: (75 MHz, CDC13) 6 171.70 (C-1), 133.65
(C-15), 133.17, 131.74, 124.48 (C-14), 83.77 (C-5), 74.07 (C-9), 71.59 (C-12), 34.95
(C-13), 31.46 (C-18), 29.48 (C-2), 29.25 (C-17), 27.71, 27.38, 23.36 (CH, C-6 or C-8),
22.52 (C-19), 20.31 (CH, C-6 or C-8), 18.29 (C-3), 14.03 (C-20), 7.50 (C-7); (75 MHz,
C6D6) 6 171.06 (C-1), 134.03 (C-15), 132.38, 132.13, 126.00 (C-14), 83.52 (C-5),
74.00 (C-9), 71.91 (C-12), 35.86 (C-13), 31.86 (C-18), 29.78 (C-2), 29.49 (C-17),
27.84, 27.68, 23.70 (CH, C-6 or C-8), 22.98 (C-19), 20.43 (CH, C-6 or C-8), 18.32 (C-
3), 14.32 (C-20), 7.61 (C-7); CIMS (CH4, positive ion) m/z [M+H H201+ 319 ((73),
[M+H 2(H20)1+ 301 (100), 283 (11), [M+H C811151+ 225 (11), 217 (10), 207 (12),
163 (23), 111 (10); FABMS (glycerol, negative ion) m/z12(M)-Hr 671.4 (8), 519.3 (12),
[M-H + glycerol]- 427.3 (100), [M-H + H2Of 353.3 (18),[M-H1- 335.2 (78), [M-H
C8H151 223.1 (21); HR-FABMS (glycerol, negative ion), obs. 335.2221 calc for
C20H3104 335.2220 [M-111-.
Constanolactone B (8). Oil: [alp +10.2° (c 1.00, Me0H); IR (neat) 3390, 2955,
2925, 1727, 1725, 1716, 1243, 1035, 972 cm-1;1H NMR (300 MHz, CDC13) 6 5.76 (m,
2H, H-10 and H-11), 5.54 (dt, 1H, J = 10.9, 7.2, H-15), 5.38 (dt, 1H, J= 10.9, 7.2, H-
14), 4.15 (m, 111, H-12), 3.73 (ddd, 1H, J = 10.0, 7.8, 2.9, H-5), 3.65 (m, 1H, H-9),
2.56 (dt, 1H, J = 17.7, 6.6, H2b), 2.45 (ddd, 1H, J = 17.7, 8.5, 6.9, H2a), 2.3 (m, 2H,
H-13), 2.04 (m, 211, H-16), 2.0 (m, 1H, H4b), 1.93 (m, 1H, H3b), 1.82 (m, 1H, H-3a),103
1.7 (ddd, 1H, H-4a), 1.35 (m, 2H, H-17), 1.3 (m, 4H, H-18 and H-19), 1.13 (m, 2H,
H-8 and H-6), 0.89 (t, 3H, J = 6.7, H-20), 0.61 (dt, 11-1, J = 8.7, 5.3, H-7b), 0.56 (dt,
1H, J= 8.7, 5.3, H-7a); (300 MHz, C6D6) 6 5.96 (m, 2H, H-10 and H-11), 5.65 (dt,
1H, J = 11.0, 7.0, H-15), 5.56 (dt, 1H, J = 11.0, 7.0, H-14), 4.30 (dt, 1H, J = 5.6, 6.3,
H-12), 3.70 (dd, 1H, J = 6.9, 5.3, H-9), 3.21 (td, 1H, J = 9, 3.3, H-5), 2.56 (dt, 1H, J
= 14.4, 6.7, H-13b), 2.45 (dt, 1H, J = 14.4, 6.5, H-13a),2.1 (m, 4H, H-2 and H-16),
1.34 (m, 2H, H-17), 1.1-1.4 (m, 4H, H-3 and H-4), 1.26 (m, 4H, H-18 and H-19), 1.1
(m, 2H, H-6 and H-8), 0.88 (t, 3H, J = 6.9, H-20), 0.47 (dt, 1H, J = 8.7, 5.1, H-7b),
0.27 (dt, 1H, J = 8.7, 5.1, H-7a); 13C NMR (75 MHz, CDC13) 6 171.78 (C-1), 133.23
(C-15),133.23, 131.68, 124.43 (C-14), 83.63 (C-5), 74.01 (C-9), 71.66 (C-12), 35.10
(C-13),31.44 (C-18), 29.45, 29.23,27.73,27.37, 23.34 (CH, C-6 or C-8), 22.50 (C-
19), 21.23 (CH, C-6 or C-8), 18.31(C-3),14.02 (C-20), 6.62 (C-7); (75 MHz, C6D6) b
171.38 (C-1), 133.90 (C-15), 132.74, 132.29, 126.00 (C-14), 83.56 (C-5), 74.20 (C-9),
72.26 (C-12), 35.83 (C-13), 31.87 (C-18), 29.78, 29.54, 27.85, 27.66, 23.83 (CH, C-6
or C-8), 22.99 (C-19), 21.32 (CH, C-6 or C-8), 18.33 (C-3), 14.34 (C-20), 6.77 (C-7);
CIMS (CH4, positive ion) [M+H H201+ miz 319 (56), [M+H 2(H20)]+ 301 (100), 283
(10), [M+H C8H151+ 225 (9), 217 (8), 207 (14), 163 (18), 111 (10).
Isolation of Constanolactones A-B Per-acetate Derivatives (9 - 1 0) , Hydroxy- or
Oxo-Oxylipin Methyl Ester Derivatives (14 -16), Diacetate Derivative (17), and C-D Per-
acetate Derivatives (2 8-2 9) .Frozen C. simplex (collected at Seal Rock, Oregon, 620 g
extracted dry weight alga) was extracted with CH2CL2/Me0H (2:1), to yield 2.0 g of a dark
green oil. The extract was subjected to silica gel vacuum chromatography, using a
stepwise gradient from 0 to 100% (v/v) EtOAc in hexanes. TLC analysis of the fractions
suggested the presence of likely eicosanoid-type natural products giving colorful (blue,
yellow, red) Cu(OAc)2 or H2SO4 staining reactions. The fractions eluting with 20 to 50%
(v/v) EtOAc in hexanes were combined and further purified by a second silica gel vacuum104
chromatography, also using a stepwise gradient from 0 to 100% (v/v) EtOAc in hexanes.
The fraction which now slowly eluted with 10% (v/v) EtOAc in hexanes was reduced in
vacuo. Following derivatization (CH2N2/Et20) and NP-HPLC (dual 10-gm Waters p-
Porasil silica columns; (2x) 300 x 3.9 mm; refractive index detection; 5% (v/v) EtOAc in
hexanes; flow rate 1.5 mL/min) minor amounts of three known oxylipins were isolated:
Methyl 12-S-HETE (14, 2.0 mg, 0.1%), Methyl 12-S-HEPE (15, 0.3 mg, 0.015%) and
Methyl 12-oxo-5Z, 8E, 10E-dodecatrienoate (16, 0.9 mg, 0.044%). Another vacuum
chromatography fraction (146 mg, 80% EtOAc/hex) was treated with Ac20/pyr followed
by CH2N2/Et20 and NP-HPLC (10-pm Alltech RSIL silica column; 500 x 10 mm;
refractive index detection; 35% (v/v) EtOAc in hexanes; flow rate 9.0 mL/min) to yield
three closely related new compounds (7, 32.7 mg, 1.6%; 8, 39.9 mg, 2.0%; 9, 2.3 mg,
0.11%) and the diacetate derivative 17 (2.3 mg, 0.12%). Further investigation of less
abundant acetylated derivatives isolated from the same HPLC fractionation yielded two
additional constanolactone per-acetate derivatives, 28 (4.2 mg, 0.17%) and 2 9 (5.7 mg,
0.23%).
Constanolactone A Per-acetate (9). Additionally, the following correlations were
observed by 1H-1H NOESY (400 MHz, degassed CDC13) H-2a (H-2b), H-3a (H-3b), H-
3b (1-1-4, 5, 8), H-5 (H-7a, 8, 12 or 14), 11-6 (H-7b, 9),11-7a (H-8), H-7b (H-9), H-8
(H-9, 11), H-9 (H-10, 11), H-10 (H-12 or 14), H-11 (H-12 or 14), 11-12 (H-13a, 15, 16,
H6-17-19, -OAc), 13a (H-16), 13b (H-16, -OAc), H-14 (H-15, 16, 17-19, -OAc), H-15
(H-16), H-16 (H6-17-19, -OAc), H6-17-19 (H-20).
Constanolactone B Per-acetate (10). Correlations observed by 1H-1H NOESY
(400 MHz, degassed CDC13) H-2a (H-2b), H-3 (H-4a), H-4a (H-4b, 5), H-5 (H-6* or 8,
7a*, 10 or 11, 12), H-6 or 8 (H-7a, 7b*, 9, 10 or 11), H-7a (H-7b*), H-7b (H-9*, 10 or
11), H-9 (H-10 or 11), H-10 or 11 (H-12, 13a, 13b, 15, 16), H-12 or 14 (H-13a, 13b,105
15, 16), 13a (H-14, 16), 13b (H-14), H-15 (H-16), H-16 (H-17 or 18, -OAc), H6-17-19
(H-20, -OAc); *confirmed by nOe Difference Spectroscopy.
Methyl 12S-Hydroxyeicosa-5Z, 81 10E, 14Z-tetraenoate (1 4). Oil: [all% = +8.0°
(c 0.22, Acetone); 1H (400 MHz, C6D6) 6 6.72 (dd, 1H, J = 15, 11, 11-10), 6.04 (t, 1H,
J = 11, H-9), 5.69 (dd, 1H, J = 15, 6.5, H-11), 5.51 (m, 2H, H-14 and H-15), 5.39 (m,
2H, H-6 and H-8), 5.27 (bdt, 114, J = 10, 7.3, H-5), 4.15 (m, 1H, 11-12), 3.34 (s, 3H,
OCH3), 2.89 (dd, 2H, J= 6, 5, H-7), 2.36 (m, 1H, H-13b), 2.30 (m, 1H, H-13a), 2.07
(t, 2H, J = 7.3, H-2), 2.01 (bq, 2H, H-19), 1.94 (bq, 2H, H-3), 1.69 (bd, 11-1, J= 6,
OH), 1.56 (5-lines, 2H, H-3), 1.2-1.35 (m, 4H, H-18 and H-19), 0.90 (t, 3H, J = 7.4,
H-20); EIMS (70 eV) m/z [M H20]+ 316 (4), [M OMer 303 (4), [M C8H131+ 223
(100), 205 (51), 191 (45), 179 (15), 173 (41), 163 (73), 145 (36), 131 (45), 119 (17),
107 (40), 91 (27), 79 (40), 67 (34), 55 (38), 41 (32).
Methyl 12S-Hydroxyeicosa-5Z, 81 10E, 141 17Z-pentaenoate (1 5). Oil: [a]17=
+10.5° (c 0.33, Acetone); 1H (400 MHz, C6D6) 6 6.72 (dd, 1H, J = 15, 11, H-10), 6.04
(t, 11-1, J = 11, H-9), 5.67 (dd, 1H, J = 15, 6.5, H-11), 5.51 (m, 2H, H-14 and H-15),
5.39 (m, 4H, H-6, H-8, H-17, and H-18), 5.27 (bdt, 1H, J= 10, 7.3, H-5), 4.13 (m,
1H, H-12), 3.34 (s, 3H, -OCH3), 2.89 (dd, 2H, J= 6, 5, H-7), 2.80 (t, 2H, J= 6, H-
16), 2.36 (m, 1H, H-13b), 2.30 (m, 1H, H-13a), 2.07 (t, 2H, J = 7.3, H-2), 1.99 (bq,
21-1, H-19), 1.94 (bq, 2H, 14-3), 1.67 (bd, 1H, J= 6, -OH), 1.56 (5-lines, 2H, H-3),
0.90 (t, 3H, J = 7.4, H-20).
Methyl 12- Oxo -5Z, 8E. 10E-Dodecatrienoate (16). Oil: UV (EtOH) XMeOH273 nm
(log e 4.36); 1H (400 MHz, C6D6) 6 9.4 (d, 1H, J= 8, H-12), 6.4 (dd, 1H, J= 13, 10,
H-10), 5.92 (dd, 1H, J = 13, 8, H-11), 5.82 (bdd, 1H, J = 13, 10, H-9), 5.62 (dt, 1H, J
= 13, 6, H-8), 5.31 (dt, 1H, J = 10, 6, H-6), 5.22 (dt, 1H, J = 10, 6, H-5), 3.35 (s, 3H,
-OCH3), 2.55 (t, 2H, J = 6, H-7), 2.06 (t, 2H, J = 6, H-2), 1.86 (q, 2H, J = 7, H-4),
1.55 (5-lines, 2H, 11-3).106
Bis-( Menthoxycarbonyl )- Constanolactone A (2 0). Constanolactone A (7, 2.6 mg,
7.7 iumol) was dissolved in a toluene/pyridine mixture (5:1, 120 pL), 100 !IL of CHC13
was added to prevent precipitation of solids in flask, an excess of (-)-menthoxycarbonyl
chloride (1 9, 50 pL of a 1.0 mM solution in toluene) was added, the flask was purged
with N2, sealed (flask occasionally opened to monitor reaction by TLC), and stirred (1.5 h,
23 °C). The reaction was stopped with the addition of 3.0 mL Me0H and evaporated
under vacuum. The product was dissolved in 100% hexanes and applied to a small silica
column. Components eluting in both 100% hexanes and 3% (v/v) EtOAc in hexanes were
removed. The following fraction eluting with 10% (v/v) EtOAc in hexanes was evaporated
to yield 2 0 (4.9 mg, 7.0 gmol, 90.4% yield). Oil: IR (neat) 2956, 2929, 2871, 1737,
1458, 1369, 1285, 1254, 1037, 956 cm-I-; I-H NMR: (300 MHz, CDC13) 6 5.87 (m, 1H, J
= 15.8, 6.2, H-11), 5.75 (dd, 1H, J = 15.8, 5.8, H-10), 5.51 (bdt, 1H, J = 10.9, 7.2, H-
15), 5.32 (bdt, 1H, J = 10.9, 7.2, H-14), 5.10 (q, 1H, J = 6.2, H-12), 4.83 (bt, 1H, J =
6.6, H-9), 4.50 (m, 2H, 7 lines), 3.93 (ddd, 1H, J = 10.5, 6.4, 3.0, 1-1-5), 2.55 (dt, 1H,
J = 17.8, 6.2, H2b), 2.42 (ddd, 1H, J = 17.8, 8.3, 6.9, H2a), 1.9-2.1 (m, 6H), 1.96 (m,
1H, H-3b), 1.8 (m, 1H, H-3a), 1.68 (m, 4H), 1.35 (m, 2H, H-17), 1.2-1.5 (m, 81-1),
0.99-1.1 (m, 2H), 0.90 (m, 15H, 7 lines), 0.84-0.9 (m, 1H), 0.79 (m, 6H, 3 lines), 0.77
(m, 1H, H-7b), 0.68 (dt, 1H, J = 8.6, 5.4, H-7a).
Formation of Bis-( Menthoxycarbonyl )- Constanolactone B from Constanolactone B
Per-acetate (1 0) and Ozonolysis to form Dimethyl-menthoxycarbonyl-malate (21).
Treatment of constanolactone B diacetate (10, 5 mg) with 0.4 ml of 10% NaOH and 1.6 ml
Me0H for 18.5 hr at rt was followed by acidification to pH 3 (pH paper) and extraction
with EtOAc. The reduced EtOAc- soluble product was redissolved in Me0H (0.5 ml) and
treated with excess ethereal CH2N2 for 1 mM. Excess reagent was removed under a stream
of N2 and applied as a band in Et20 to a TLC plate and developed in 100% EtOAc. The
major product, Rf = 0.07-0.17, was removed and extracted with EtOAc. A portion of the107
product (1% by volume) was treated with equal volumes (3 drops) of pyridine,
1,1,1,3,3,3-hexamethyldisilazane and chlorotrimethylsilane for 20 min. Excess solvent
and reagents were removed in vacuo , the products dissolved in hexane, and analyzed by
GC-MS (120 °C to 220 °C, 10 min, 18.05 min retention) obs. mtz 405 (1), 384 (8), 383
(27), 293 (9), 257 (57), 243 (10), 203 (6), 167 (47), 129 (25), 103 (13), 73 (100).
Hydrogenation of this TMS ether derivative with H2/Pd on CaCO3 in Me0H for 30 min
followed by re-trimethylsilyation as detailed above, gave a derivative with clearer MS
cleavage patterns: (120 °C-220 °C, 10 min, 19.80 min retention) obs. nitz 446 (2), 408
(1), 397(19),385(8), 345 (28), 307 (8), 295 (14), 289 (14), 255 (50), 229 (17), 215
(19), 191(14),129(96), 73 (100). One third of the remainder of the triol methyl ester was
treated with 50µl toluene, 10 Al pyridine and 50 Al of (-) menthoxycarbonylchloride for 30
min at it Tic purification of the resulting derivative (10% EtOAc/hex) was followed by
ozonolysis for 2 min at -20 °C followed by 10 min at rt. Excess 03 was removed under a
stream of N2 and the product treated overnight with 0.3 nil of peracetic acid at 50 °C.
Again, reagents were removed under a stream of N2, methylated with CH2N2 as above for
1 min, solvents removed under N2, dissolved in hexane and analyzed by GC versus
standards: (170 °C) obs. 14.869 min retention (standard S-malate = 14.893 min, R-malate
= 15.011 min). The constanolactone B-derived malatederivative did not show a detectable
peak at the R-malate retention time, and is therefore, essentially "100%"S.
Ozonolysis of Bis-( Menthoxycarbonyl )- Constanolactone A (2 01 to form Dimethyl-
menthoxycarbonyl-malate (21). The bis- (menthoxycarbonyl) derivative of constanolactone
A (2 0, 3.4 mg, 4.9 Innol) was added to 1.0 mL CHCL3, the solution cooled to -11 °C
(ethylene glycol and solid CO2), and 03 was bubbled through the solution (2 min.). The
reaction flask was removed from the bath and allowed to reach rt (10 min.) and then
evaporated under vacuum. Conc. acetic acid (1.0 mL) and 30% H202 (250 pL) were
added and the flask sealed in a 48 °C water bath overnight (17.5 h). The products were108
dried under N2, dissolved in Me0H (1.0 mL), and treated with CH2N2/Et0H (1.0 mL, 2
min., 23 °C). The product was evaporated under vacuum, dissolved in Et20, and isolated
by prep-TLC (10% (v/v) EtOAc in hexanes) to yield 21 (0.5 mg, 1.5 pmol, 30%
recovery). Oil: 1I-1 NMR: (300 MHz, CDC13) 6 5.40 (dd, 1H, J = 6.7, 5.7), 4.57 (td, 1H,
J = 11.0, 4.4), 3.778* (s, 3H), 3.722* (s, 3H), 2.92 (m, 3 lines, 2H), 1.98-2.1 (m, 2H),
1.68 (bd, 2H, J = 12), 1.39-1.53 (m, 2H), 1.0-1.13 (m, 2H), 0.92 (m, 4 lines, 6H),
0.83-0.9 (m, 1H), 0.81 (d, 3H, J= 6.9); GC-EIMS (70 eV) m/z 206 (18), 138 (78), 123
(42), 113 (33), 95 (68), 81 (100), 71 (28), 56 (42), 44 (60), 41 (22). * data is reported to
three decimal points in order to clearly differentiate 2 0 and 21.
Formation of Authentic Dimethyl-menthoxycarbonyl-S-malate (2 1).L-malate
(39.8 mg, 0.294 mmol, 99%) in 400 AL of Me0H was treated with an excess of
CH2N2/Et20 (3 min) in a 10 mL recovery flask and dried under N2 The methylated L-
malate (48.4 mg, 0.29 mmol) was dissolved in a toluene/pyridine mixture (4:1, 250 ilL),
an excess of (-)-menthoxycarbonyl chloride (1 9, 600 'IL of a 1.0 mM solution in toluene)
was added, the flask was purged with N2, sealed, and stirred overnight (24 h, 23 °C). The
product was dissolved in 1% (v/v) EtOAc in hexanes and fractionated over a small silica
flash column. The fraction eluting in 3% (v/v) EtOAc in hexanes was evaporated to yield
21 (61.5 mg, 0.179 mmol, 60.9% yield): IR (neat) 2956, 2933, 1747, 1292, 1264, 1218,
1197, 1173, 1038, 956 cm-1;1H NMR (300 MHz, CDC13) 6 5.40 (dd, 111, J = 6.7, 5.7),
4.57 (td, 1H, J = 11.0, 4.4), 3.778* (s, 3H), 3.722* (s, 3H), 2.92 (m, 3 lines, 2H),
1.98-2.1 (m, 2H), 1.68 (bd, 2H, J= 12), 1.39-1.53 (m, 2H), 1.0-1.13 (m, 2H), 0.92 (m,
4 lines, 6H), 0.83-0.9 (m, 1H), 0.81 (d, 3H, J= 6.9); GC-EIMS (70 eV) naz 207 (4),
138 (100), 123 (40), 113 (29), 95 (78), 81 (74), 55 (31). * data is reported to three
decimal points in order to clearly differentiate 2 0 and 21.
Formation of Authentic Dimethyl-menthoxycarbonyl-R-malate (21). D-malate
(40.3 mg, 0.30 mmol, 99%) in 1.0 mL of Me0H was treated with an excess of109
CH2N2/Et20 (3 min) in a 10 mL recovery flask and dried under N2 The methylated L-
malate was dissolved in a toluene/pyridine mixture (4:1, 250 ilL), an excess of (-)-
menthoxycarbonyl chloride (19, 600 pL of a 1.0 mM solution in toluene) was added, the
flask was purged with N2, sealed, and stirred overnight (24 h, 23 °C). The productwas
dissolved in 1% (v/v) EtOAc in hexanes and fractionated over a small silica flash column.
Components eluting in both 1% and 3% (v/v) EtOAc in hexanes were discarded. The
following fraction eluting with 100% EtOAc was evaporated to yield 21 (106.2mg, 0.30
mmol, 100% yield): IR (neat) 2957, 2933, 1747, 1439, 1371, 1292, 1265, 1219, 1198,
1174, 1039, 956 cm-1; 1H NMR (300 MHz, CDC13) 6 5.39 (dd, 1H, J= 6.6, 5.6), 4.54
(td, 1H, J = 10.9, 4.4), 3.792* (s, 3H), 3.720* (s, 3H), 2.93 (m, 3 lines, 21-1), 2.1 (bd,
1H, J = 11.8), 1.94 (pd, 11-1, J = 7.0, 2.6), 1.69 (bd, 2H, J= 11.4), 1.38-1.5 (m, 2H),
1.10 (q, 1H, J = 11.7), 0.97-1.11 (m, 1H), 0.91 (m, 3 lines, 6H), 0.83-0.9 (m, 1H),
0.79 (d, 3H, J = 6.8); 13C NMR (75 MHz, CDC13) 6 169.17, 169.06, 153.75, 79.296,
70.88, 52.55, 51.99, 46.76, 40.39, 35.80, 33.90,31.26, 25.93,23.22, 21.78,20.49,
16.13; GC -EIMS (70 eV) m/z 207 (3), 138 (100),123 (44), 113(29), 95 (74),81 (68),
55 (27). * data is reported to three decimal points in order to clearly differentiate 2 0 and
21.
Formation of Bis-( p- Bromobenzoyl)- Constanolactone A (2 3) and 12-Acetoxy-9-
(p-Bromobenzoy1)-Constanolactone A (2 4).To 7.7 mg of 7 (0.023 mmol), 102 mg of 4-
bromobenzoyl chloride (98%, 0.466 mmol) and a catalytic amount of 4-
dimethylaminopyridine were added in dry CH2C12/triethylamine (3:1, 10 mL). The
solution was purged with N2 and stirred at rt (23 °C) for 22 h. The solvents were
evaporated under vacuum and the products dissolved in hexanes and applied to a small
silica flash column. The fractions eluting with 20 and 50% (v/v) EtOAc in hexaneswere
evaporated under vacuum and further purified by NP-HPLC (dual 10-pm Alltech Versapak
Si columns; 300 x 4.1 mm; 30% (v/v) EtOAc in hexanes; UV detection at 254 nm; flow110
rate 2.0 mUmin)to give 1.2 mg pure bis-(p-bromobenzoate) constanolactone A (2 3, 0.002
mmol) and 0.7 mg 12- acetoxy- 9- (p- bromobenzoyl)- constanolactone A (2 4) (0.0013
mmol, 5.4% yield).
Bis-( p- Bromobenzoyl)- Constanolactone A (2 3).Oil: IR (neat) 2955, 2928, 1719,
1590, 1398, 1267, 1237 cm-1; UV (MeOH) Xmax 246 nm (log c 4.54); CD (MeOH)
+1.4, -1.7 (Xmax 252, 238 nm); 1H NMR: (300 MHz, CDC13) 6 7.91 (2 broad lines, 4H,
OCOBzBr), 7.59 (4 broad lines, 4H, OCOBzBr), 5.99 (ddd, 1H, J= 15.7, 6.1, 0.9, H-
11), 5.86 (ddd, 1H, J = 15.7, 5.6, 0.7, H-10), 5.54 (q, 1H, J = 6.1-6.3, H-12), 5.49
(dtt, 1H, 10.8. 7.2, 3.3, H-15), 5.36 (dtt, 111, 10.8, 7.1, 3.3, H-14), 5.17 (dd, 1H, J=
7.7, 5.8, H-9), 3.87 (ddd, 1H, 10.4, 7.0, 3.1, H-5), 2.50 (dt, 1H, J= 17.7, 6.1, H-2b),
2.43 (ddd, 1H, J = 17.7, 8.7, 7.0, H-2a), 2.02 (bt, 2H, 7.4, H-13), 2.0 (m, 2H, H-16),
1.6-1.9 (m, 4H, H-3 and H-4), 1.2-1.3 (m, 8H, H-8 and H-17 to H-19), 1.11 (m, 1H, H-
6), 0.86 (t, 3H, J = 6.7, H-20), 0.80 (dt, 1H, J = 8.8, 5.3, H-7b), 0.70 (dt, 1H, J= 8.6,
5.4, I-1-7a).
12- Acetoxy- 9- (p- Bromobenzoyl)- Constanolactone A (2 4). Oil: IR (neat) 2955,
2926, 1736, 1725, 1519, 1268, 1237 cm-1; UV (MeOH) Xmax 246 nm (log e 4.47); CD
(EtOH) De -7.3 ( ?max 244.5 nm); 1H NMR: (300 MHz, CDC13) 6 7.92 (dt, 2H, J= 8.6,
2.1, OCOBzBr), 7.59 (dt, 214, J = 8.6, 2.1, OCOBzBr), 5.88 (bdd, 1H, J= 16.0, 5.8,
H-11), 5.78 (bdd, 1H, J = 16.0, 5.3, H-10), 5.48 (bdt, 1H, J = 10.9, 7, H-15), 5.30 (m,
11-1, H-14), 5.30 (m, 1H, H-12), 5.17 (dd, 1H, J= 7.7, 5.3, H-9), 3.85 (m, 1H, H-5),
2.57 (bdt, 111, J = 18, 6.8, H-2b), 2.45 (ddd, 1H, J = 18, 8.6, 6.8, II-2a), 2.39 (m, 2H,
H-13), 2.07 (s, 3H, -OAc), 1.99 (m, 2H, H-16), 1.95 (m, 114, H-3b), 1.95 (m, 114, H-
4b), 1.84 (m, 1H, H-3a), 1.65 (m, 11-1, H-4a), 1.25-1.35 (m, 8H, H-8 and H-17 to H-
19), 1.12 (ddd, 1H, J = 11.4, 9.6, 5.1, H-6), 0.87 (t, 3H, J = 6.9, H-20), 0.81 (dt, 1H, J
= 8.8, 5.3, H-7b), 0.68 (dt, 1H, J = 8.5, 5.4, 14-7a); CIMS (CH4, positive ion) nitz111
M+H1+ 561 (8), [M+H Ac01-1]+ 501 (17), [M+H - (BrC6H4CO2H)]+ 361 (35), [M+H
(BrC6H4CO2H) Ac011]+ 301 (100), [BrC6H4CO2H + 1-1]+ 201 (11).
Formation of 9-( p- Bromobenzoyl)- Constanolactone A (2 5).Constanolactone A
(7) (2.5 mg, 7.9 pmol) was dissolved in dry CH2CL2/triethylamine (5:1, 12 mL) and small
portions of 4-bromobenzoyl chloride (98%) (typically 3 to 10 mg) were added regularly
over a period of 5 days while the reaction was stirred at rt (23 °C). The solvents were
evaporated under vacuum and the products were dissolved in hexanes and applied to a
small silica flash column. The fraction eluting with 100% Et20 was evaporated in vacuo
and further purified by NP-HPLC (10-pm Phenomenex Maxsil Si column; 500 x 10.0 mm;
50% (v/v) EtOAc in hexanes; UV detection at 254 nm; flow rate at 8.0 mUmin) to give ca.
0.5 mg pure 9-p-bromobenzoyl-constanolactone A (2 5, 1.0 pmol, ca. 13% yield). Oil: IR
(neat) 3400, 2956, 2926, 1716, 1589, 1268, 1241 cm-1; UV (MeOH) Amax 245 nm (log e
4.34); CD (EtOH) De -4.6 (Amax 242.0 nm); 11-1 NMR: (300 MHz, CDC13) b 7.92 (bd,
2H, J = 8.6, OCOBzBr), 7.59 (bd, 2H, J = 8.6, OCOBzBr), 5.95 (bdd, 111, J = 15.7,
5.7, H-11), 5.83 (bdd, 1H, J= 15.7, 6.4, H-10), 5.55 (bdt, 1H, J= 10.9, 7.4, H-15),
5.38 (bdt, 1H, J = 10.9, 7.2, H-14), 5.07 (dd, 1H, J = 8.3, 6.2, H-9), 4.20 (bq, 1H, J =
6.1, H-12), 3.78 (m, 1H, H-5), 2.57 (m, 1H, H-2b), 2.45 (m, 1H, H-2a), 2.33 (m, 2H,
J= 6, H-13), 1.99 (m, 214, H-16), 1.95 (m, 111, H-3b), 1.95 (m, 1H, H-4b), 1.84 (m,
1H, H-3a), 1.65 (m, 1H, H-4a), 1.25-1.35 (m, 81-1, 11-8 and H-17 to H-19), 1.09 (m,
1H, H-6), 0.87 (t, 3H, J = 6.9, H-20), 0.9 (m, 1H, H-7b), 0.69 (dt, 1H, J = 8.5, 5.3, H-
7a); CIMS (CH4, positive ion) Fritz 1M+Hr 519 (5), [M+H H2Or 501 (11), 347 (27),
[M +H (BrC6H4CO2H)[± 319 (92), [M+H (BrC6H4CO2H) H20]+ 301 (100), 282
(11), [BrC6H4CO2H + HT 201 (97), 163 (43).
Constanolactone C Per-acetate (2 8). Oil: [a]) 0 (c 0.62, Me0H); IR (neat) 3446,
2960, 2931, 2859, 1737, 1733, 1662, 1646, 1372, 1235, 1037, 1023 cm-1; 111 (400
MHz, CDC13) and 13C NMR (100 MHz, CDC13) data in Table 111.4; 111 NMR (400 MHz,112
C6D6) 6 6.13 (ddd, 1H, J = 15.3, 5.9, 1.3, H-11), 5.92 (ddd, 1H, J = 15.3, 5.0, 1.0, H-
10), 5.58 (m, 2H), 5.5 (m, 1H), 5.43 (m, 2H), 4.99 (dd, 1H, J= 8.7, 5.0, H-9), 2.86
(m, 3H, H-5 and H-16), 2.62 (dt, 1H, J = 14.6, 6.5, H-13b), 2.52 (dt, 1H, J = 14.6,
6.4, H-13a), 2.04 (m, 2H, 11-2), 1.96 (m, 1H), 1.80 (s, 3H, OAc), 1.76 (s, 31-1, OAc),
1.32 (m, 1H), 1.27 (m, 1H), 1.17 (m, 1H), 1.01 (m, 1H), 0.92 (t, 3H, J= 7.5, H-20),
0.89 (m, 1H), 0.61 (m, 2H), 0.20 (dd, 1H, J = 8.3, 1.4, H-7a); GC-EIMS (70 eV) m/z
[M + H2O] 436 (1), [M+H Ac0Hr 359 (1), 309 (10), [M 2(AcOH)]+ 298 (12), 267
(11), 231 (28), 207 (63), [M 2(AcOH) C81113]+ 189 (100), 171 (40), 129 (44), 99
(55), 91 (61); CIMS (CH4, positive ion)[M+H]+ m/z 419 (10), [M+H Ac0H]+ 359 (35),
[M+H 2(AcOH)]+ 299 (100); HR CIMS (CH4, positive ion), obs [M+H]+ 419.2433,
calc for C24H3506 419.2433.
Constanolactone D Per-acetate (2 9). Oil: [a]p -4.7° (c 0.26, CHC13), [a]p +0.2°
(c 0.88, Me0H); IR (neat) 2960, 2931, 1737, 1372, 1237, 1037, 1021, 969 cm-1; 1H
(400 MHz, CDC13) and 13C NMR (100 MHz, CDC13) data in Table 111.4; 1H NMR (400
MHz, C6D6) 6 5.85 (m, 2H, H-10 and H-11), 5.5 (m, 2H), 5.4 (m, 211), 4.99 (dd, 1H, J
= 7, 5, 11-9), 2.93 (m, 1H, H-5), 2.80 (t, 2H, J= 7, 11-16), 2.50 (dt, 1H, J= 15, 7, H-
13b), 2.35 (dt, 1H, J = 15, 7, H-13a), 2.0 (m, 41-1), 1.87 (s, 31-1, OAc), 1.72 (s, 3H,
OAc), 1.3 (m, 1H), 1.25 (m, 111), 1.05 (m, 411), 0.92 (t, 3H, J = 7.5, 11-20), 0.9 (m,
1H), 0.28 (dt, 1H, J = 8.5, 5.0, H-7b), 0.20 (dt, 1H, J = 8.5, 5.0, H-7a); GC-EIMS (70
eV)[M + H201+ m/z 436 (1), [M+H Ac01-1]+ 359 (1), 341 (3), 309 (8), [M 2(AcOH)]+
298 (15), 281 (9), 267 (9), 231 (24), 207 (93), [M 2(AcOH)C81-113]+ 189 (90), 171
(41), 129 (43), 117 (47), 109 (52), 107 (53), 99 (69), 91 (68), 81 (100); FAB-MS
(glycerol, positive ion) m/z 461 (2), [M+1-1]+ 419 (2), [M+H Ac0H]+ 359 (1), [M
2(AcOH)]+ 299 (2), 185 (40), 93 (90), 79 (76), 67 (100), 55 (75); FABMS (glycerol,
positive ion), obs 419.2434, caic for C24H3506 419.2434 [M+Hr.
Formation of Bis-(p-Bromobenzoy1)-Constanolactone B (31) and Bis-(p-113
Bromobenzoyl)- Constanolactone D (3 0).A 85:15 mixture of 8 and 2 6 (11.2 mg, cri. 33
mmol) was treated with 103 mg 4-bromobenzoyl chloride (98%, 0.460 mmol) anda
catalytic amount of 4-dimethylaminopyridine in dry CH202/triethylamine (5:1, 12 mL).
The solution was stirred under N2 at rt for 22 h. The solvents were evaporated under
vacuum and the products partitioned (4x) between Et20 and dil. NaHCO3 (pH at. 10 by
paper). The dried Et20 extract was triturated with hexanes and purified by preparative TLC
(1:1, Et20/Bz). The major UV-active band was removed and eluted with EtOAc, the
solvent evaporated in vacuo and further purified by NP-HPLC (Versapack Si, 2 x 300 mm
x 4.1 mm, 30% Et0Acthexanes, 2.0 mL /min) to yield 8.6 mg of bis-(p-bromobenzoyl)-
constanolactone B (31, 12.3 ktmol, 44% yield) and 1.5 mg bis-(p-bromobenzoyl)-
constanolactone D (3 0, 2.2 gmol, 44% yield). Pure bis-(p-bromobenzoyl)-
constanolactone B (3 1) was an oil: IR (neat) 2955, 2928, 1720, 1590, 1397, 1267, 1236
cm-1; UV (MeOH)Amax 246 nm (log c 4.58); CD (MeOH) Ac +6.3 (Amax 250 nm); 1H
NMR: (300 MHz, CDC13) 6 7.92 (3 broad lines, 4H, OCOBzBr), 7.59 (4 broad lines,
4H, OCOBzBr), 5.91 (m, 2H, J= 15.7, 6.1, 0.9, H-11), 5.53 (m, 1H, H-12), 5.50 (dt,
1H, H-15), 5.35 (dt, 1H, H-14), 5.07 (dd, 1H, J = 8.4, 2.5, H-9), 3.90 (ddd, 1H, H-5),
2.4-2.6 (m, 4H, H-2 and H-13), 2.0 (q, 2H, H-16), 1.6-1.9 (m, 4H, H-3 and H-4), 1.37
(td, 11-1, H-8), 1.2-1.3 (m, 711, 1-1-6 and 1-1-17 to H-19), 0.86 (t, 314, J= 7.0, H-20), 0.78
(dt, 1H, J = 8.8, 5.3, H-7b), 0.68 (dt, 11-1, J = 8.6, 5.4, H-7a).
Bis- (p- bromobenzoyl)- Constanolactone D (3 0).Formed as described above
during formation of derivative 31. Pure derivative 3 0 was an oil: IR (neat) 3450, 2959,
2931, 1719, 1590, 1484, 1398, 1267, 1238, 1102, 1012, 969, 757 cm-1; UV (MeOH)
Amax 246 nm (log c 4.55); CD (MeOH) Ac +6.7 (Amax 272 nm); 1H NMR (300 MHz,
CDC13) 6 7.92 (3 broad lines, 4H, OCOBzBr), 7.59 (4 broad lines, 4H, OCOBzBr),
5.89 (m, 2H, H-10 and H-11), 5.55 (m, 1H, H-12), 5.5 (dt, 1H, H-15), 5.35 (dt, 1H,
H-14), 5.30 (m, 1H, H-18), 5.25 (dtt, 1H, J= 10.7, 7.0, H-17), 5.07 (bdd, 1H, J= 8.4,114
2.5, H-9), 3.89 (ddd, 1H, H-5), 2.77 (bt, 2H, J = 6.9, H-16), 2.4-2.6 (m, 4H, H-2 and
H-13), 2.02 (m, 2H, H-19), 1.6-1.9 (m, 4H, H-3 and 1-1-4), 1.35 (m, 11-1, H-8), 1.23 (m,
1H, H-6), 0.94 (t, 31-1, J = 7.5, H-20), 0.79 (dt, 1H, J = 8.7, 5.4, 5.4, H-7b), 0.68 (dt,
1H, J = 8.9, 5.4, 5.3, H-7a); 13C NMR (75 MHz, 13C DEPT 135°, CDC13) 6 132.18
(CH, C18), 131.69 (CH)2, 131.62 (CH)2, 131.15 (CH)2, 131.09 (CH)2, 130.48 (CH),
129.51 (CH), 126.45 (CH, C17), 123.32 (CH), 122.80 (CH), 81.29 (CH, C5), 76.49
(CH, C9), 73.78 (CH, C12), 32.30 (CH2, C13), 29.42 (CH2, C2), 27.83 (CH2, C4),
25.56 (CH2, C16), 21.60 (CH, C6), 20.46 (CH2, C19), 19.72 (CH, C8), 18.25 (CH2,
C3), 14.14 (CH3, C20), 6.98 (CH, C7); FABMS (3-nitrobenzyl alcohol, negative ion)
[M-H + 3 -NBA]- miz 851/853/855 (1:2:1), 778/780/782 (2:2:1), 744/746/ 748 (0.5:1:0.5),
713/715/717 (0.5:1:0.5), 325.2 (2), 311.1 (1), 198.9/201 (100:93), 79/81 (69:64).
Isolation of Me0H solvolysis products (3 2 and 3 3). Frozen C. simplex, collected
May 5, 1992, (250 g dry weight) was repetitively extracted (3X) with warm CHC13/Me0H
(2:1) to yield 2.26 g of dark green oil. The extract was subjected to silica gel vacuum
chromatography, using a stepwise gradient from 0 to 100% (v/v) EtOAc in hexanes.
Fractions eluting with 20 to 30% (v/v) EtOAc in hexanes were determined by TLC to be of
similar composition, and were pooled. This combined fraction was further purified by
silica gel flash chromatography, using a stepwise gradient from 1.5 to 50% (v/v)
Isopropanol (IPA) in hexanes, Me0H flush. The fractions eluting with IPA concentrations
greater than 20% were subjected to preparative NP-HPLC (10-pm Phenomenex Maxsil Si
column; 500 x 10 mm; 20% (v/v) IPA in H2O; Differential refractometer detection; flow
rate at 3.0 mL/min) followed by an analytical HPLC separation (dual 10-pm Alltech
Versapak Si columns; 300 x 4.1 mm; 15% (v/v) IPA in hexanes; Differential refractometer
detection; flow rate 4.0 mL/min) to yield two minor epimeric compounds (3 2 0.5 mg,
0.02% and 3 3 1.1 mg, 0.05%).
9-0-Methyl Constanolactone A (3 2). Oil:l+7.3° (c 0.21, Me0H); IR (neat)115
3421, 2955, 2925, 1733, 1724, 1718, 1242, 1080, 1047, 1034, 973 cm-1; 1H (300 MHz,
CDC13) and 13C NMR (75 MHz, CDC13) data in Table 111.5; GC -EIMS (70 eV) m/z [M
Me0H H201+ 300 (0.7), [M C8H15]+ 239 (22), [M H2O C8H 15]+ 221 (4), 1M
C8H15 MeOffr 207 (99), [ M C8H15 Me0H H20]+ 189 (24), 161 (24), 113 (100),
109 (64), 99 (64); FABMS (sulfolane, negative ion), obsd 349.2379 calc for C21H3304
349.2379 [M-H
9-0-Methyl Constanolactone B (3 3). Oil: IR (neat) 3421, 2958, 2927, 2857,
1728, 1724, 1287, 1275, 1080, 1074 cm-1; 1H NMR (300 MHz, CDC13) data in Table
111.5; GC -EIMS (70 eV)[M Ac011]+ m/z 332 ( 2), IM Me0H Ac0141+ 300 (4), 1M
C8H,51, 281 (5), 249 (4), 239 (24), [M AcOH C81415]+ 221 (32), [M C8H15 Me0H
Ac0H]207 (27),205 (29),M C81415 Me0H Ac0H1+ 189 (16), 183 (15), 161
(12), 155(19), 127(19), 113(100), 109 (27), 99 (24).
Isolation of Constanolactones E (3 4) and F (3 5). As above, 3 4 and 3 5, were re-
isolated as natural products for further investigation. Frozen C. simplex (790 g dry
weight) was repetitively extracted (3X, as above). The extract was subjected to silica gel
vacuum chromatography, using a stepwise gradient from 10 to 100% (v/v) EtOAc in
hexanes. The fraction eluting with 50% (v/v) EtOAc in hexanes (60.3 mg) was subjected
to NP-HPLC (10-pm Phenomenex Maxsil Si column; 500 x 10 mm; 20% (v/v)
isopropanol in hexanes; Differential refractometer detection; flow rate at 6.0 mlJmin). A
second NP-HPLC (dual 10-pm Alltech Versapak Si columns; 300 x 4.1 mm; 10% (v/v)
EtOAc in hexanes; Differential refractometer detection; flow rate 3.0 mUmin) was
necessary to separate constanolactone F (3 4 9.0 mg) from G (3 5 3.2 mg).
Constanolactone E (3 4). Oil: [a]r) +33° (c 0.22, Me0H); IR (neat) 3427, 2956,
2927, 1732, 1244, 1048, 1038, 966 cm-1; 1H (300 MHz, CDC13) and 13C NMR (75
MHz, CDC13) data in Table 111.6; CIMS (CH4, positive ion) [M+Hr m/z 337 (14), [M +H
H20]+ 319 (100), [M+H 2(H20)]+ 301 (96), 197 (46), 179 (66), 161 (40), 151 (18),116
123 (18), 111 (14); HR CIMS (CH4, positive ion), obs [M+H]+ 337.2377, calc for
C20F13304 337.2375, obs [M+H H20]+ 319.2273, calc for C20H3103 319.2273.
Constanolactone F (3 5). Oil: IR (neat) 3422, 2956, 2925, 1731, 1243, 1080,
1044, 1038, 963 cm-1; 1H (300 MHz, CDC13) and 13C NMR (75 MHz, CDC13) data in
Table IH.6; CIMS (CH4, positive ion) [M+H H2O] + m/z 319 (96), [M+H 2(H20)]+ 301
(100), 254 (14), IM+HC81-1151+ 225 (7), 197 (26), 179 (78), 161 (40), 147 (31), 129
(27), 123 (62), 111 (20).
Isolation of Constanolactones E-G Per-acetate Derivatives (3 7-3 9).A silica gel
vacuum chromatographic fraction (459 mg, 50% (v/v) EtOAc in hexanes) from the same
collection of C. simplex which yielded 9 and 10 was subjected to a second silica gel
vacuum chromatography, using a stepwise gradient from 0 to 100% (v/v) EtOAc in
hexanes. The fraction eluting with 45% (v/v) EtOAc in hexanes (26.9 mg) was dissolved
in 0.5 mL pyridine and stirred with 0.5 mL Ac20 at rt overnight (27.5 h). Three new per-
acetate derivatives 3 7 (6.8 mg, 0.27%), 3 8 (3.2 mg, 0.13%), and 3 9 (0.5 mg, 0.02%)
were subsequently isolated by NP-HPLC (dual 10-pm Alltech Versapak Si columns; 300 x
4.1 mm; 35% (v/v) EtOAc in hexanes; Differential refractometer detection; flow rate 5.0
mUmin).
Constanolactone E Per-acetate (3 7). Oil: laiD -17.4° (c 0.41, Me0H); IR (neat)
3378, 2955, 2928, 2855, 1736, 1370, 1226, 1037, 963 cm-1; 1H (300 MHz, CDC13) and
13C NMR (75 MHz, CDC13) data in Table 111.6; 1H NMR (300 MHz, C6D6) 6 5.70 (dd,
1H, J = 14.8, 8.3, H-10), 5.62 (dd, 1H, J = 8.3, 6.9, H-11), 5.5 (dd, 1H, J= 10, 7, H-
15), 5.45 (m, 1H, H-12), 5.4 (m, 1H, H-14), 5.29 (dd, 1H, J = 14.8, 8.7, 11-9), 2.96
(ddd, 1H, J = 9.8, 7.1, 2.7, H-5), 2.45 (dt, 1H, J = 14.8, 7.8, H-13b), 2.33 (dt, 1H, J=
14.8, 5.8, H-13a), 2.02 (m, 214, H-16), 1.97 (m, 2H, H-2), 1.84 (s, 3H, OAc), 1.72 (s,
3H, OAc), 1.3 (m, 3H, H-8 and H-17), 1.25 (m, 4H, H-18 and H-19), 1.1 (m, 2H, H-3b
and H-4b), 0.94 (m, 2H, H-3a and H-4a), 0.88 (t, 3H, J = 6.7, H-20), 0.63 (m, 1H, H-117
6), 0.32 (m, 2H, H-7); 13C NMR (75 MHz, C6D6) 6 169.88, 169.37, 169.24, 139.32,
133.38, 124.11, 122.82, 81.49, 75.23, 73.85, 31.76, 29.56, 29.47, 28.60, 27.72,
27.62, 25.08, 22.94, 20.79, 19.34, 18.40, 10.47; GC-EIMS (70 eV) [M Ac011]+ m/z
360 (1.4), 318 (10), [M C81415]+ 309 (4), IM 2(AcOH)r 300 (18),281(14),267(15),
207 (33), [M 2(AcOH) C8H131+ 191 (30), 178 (56), 161 (19), 149(35),131(26),117
(37), 94 (100).
Constanolactone F Per-acetate (38). Oil: [a]r) +55° (c 0.19, Me0H); IR (neat)
3390, 2955, 2930, 2857, 1739, 1372, 1229, 1037, 958cm-1; 1H (300 MHz, CDC13) and
13C NMR (75 MHz, CDC13) data in Table 111.6; 1H NMR (300 MHz, C6D6) 6 5.62 (dd,
1H, J. 7.5, 5.5, H-11), 5.52 (m, 1H, H-15), 5.27 (dd, 1H, J= 12.6, 5.5, H-12), 5.49
(m, 2H, H-10 and H-14), 5.34 (dd, 1H, J= 15.2, 8.5, H-9), 3.01 (m, 1H, H-5), 2.40
(m, 2H, H-13), 2.00 (m, 2H, H-16), 1.97 (m, 2H, H-2), 1.79 (s, 3H, OAc), 1.70 (s,
3H, OAc), 1.3 (m, 3H, H-8 and H-17), 1.24 (m, 4H, H-18 and H-19), 1.10 (m, 2H, H-
3b and H-4b), 0.92 (m, 2H, H-3a and H-4a), 0.87 (t, 3H, J= 6.8, H-20), 0.66 (m, 1H,
H-6), 0.36 (dt, 1H, J= 8.4, 5.2, H-7b), 0.29 (dt, 1H, J= 8.8, 5.0, H-7a);13C NMR (75
MHz, DEPT (135°), C6D6) 6 138.18 (CH), 133.27 (CH), 125.39 (CH), 123.39 (CH),
81.02 (CH), 74.06 (CH), 73.68 (CH), 31.51 (CH2), 29.28 (CH2), 28.78 (CH2), 27.39
(CH2), 27.39 (CH2), 24.74 (CH), 20.40 (CH3), 20.40 (CH3), 18.79 (CH), 18.12 (CH2),
13.99 (CH3), 10.16 (CH2); CIMS (CH4, positive ion) [M+H]+ m/z 421 (13), [M+H
Ac0141+ 361 (38), 329 (13), 319 (15), [M+H 2(AcOH)]+ 301 (100), 283 (8); HR CIMS
(CH4, positive ion), obs [M+H]+ 421.2590, calc for C2 4H3 706421.2590.
Constanolactone G Per-acetate (3 9). Oil: IR (neat) 3433, 2958, 2918, 2850, 1736,
1712, 1650, 1646, 1366, 1225, 1039 cm-1; 1H NMR (300 MHz, CDC13) b 5.45 (m,
H-15), 5.40 (dd, 1H, J= 10.9, 7.4, H-18), 5.4 (m, 2H, H-9 and H-14), 5.25-5.45 (m,
2H, H-10 and H-11), 5.3 (m, 114, H-17), 5.02 (dt, 1H, J= 6.7, 5.9, H-12), 3.75 (ddd,
1H, J. 10.8, 7.4, 3.1, H-5), 2.75 (bt, 2H, J= 7.2, H-16), 2.57 (ddd, 1H, J= 17.8, 7.5,118
6.5, H-2b), 2.45 (ddd, 1H, J = 17.8, 8.6, 6.9, H-2a), 2.33 (bt, 2H, J = 6.9, H-13), 2.07
(s, 3H, -OAc), 2.06 (m, 2H, H-19), 2.05 (s, 3H, -OAc), 2.0 (m, 1H, H-4b), 1.95 (m,
1H, H-3b), 1.8 (m, 1H, H-3a), 1.7 (m, 1H, H-4a), 1.54 (m, 1H, H-8), 1.13 (m, 11-I, H-
6), 0.97 (t, 3H, J = 7.6, H-20), 0.76 (dt, 1H, J = 8.6, 5.2, H-7b), 0.69 (dt, 1H, J = 8.7,
5.2, H-7a); (400 MHz, C6D6) 6 5.63 (dd, 1H, J= 7.4, 5.8, H-11), 5.5 (m, 3H), 5.4 (m,
11), 5.36 (dd, 1H, J = 16.3, 6.9, H-9), 5.28 (dt, 1H, J = 6.9, 5.8, H-12), 3.00 (m, 1H,
H-5), 2.80 (m, 2H, J = 6.2, H-16), 2.4 (m, 2H, H-13), 2.0 (m, 6H, H-2, H-19, and H-
3), 1.78 (s, 3H, -OAc), 1.69 (s, 3H, -OAc), 1.2-1.37 (m, 1H, H-8), 1.06 (m, 1H, H-4b),
0.91 (t, 3H, J = 7.6, H-20), 0.9 (m, 1H, H4a), 0.66 (m, 1H, H-6), 0.37 (dt, 1H, J = 8.6,
5.2, H-7b), 0.29 (dt, 1H, J= 8.7, 5.2, H-7a); 13C NMR (100 MHz, C6D6) 6 169.71,
169.24, 168.64, 138.50, 132.31, 131.71, 124.15, 123.67, 81.20, 74.38, 73.82, 30.14,
29.50, 29.05, 27.60, 25.98, 25.04, 21.50, 20.88, 20.63, 19.04, 18.40, 14.41, 10.43;
FABMS (2:1 thioglycerol:glycerol, positive ion) [114+H1+ m/z 419.2 (34), IM+H
AcOHI+ 391.3 (22), 359.2 (14), 317.2 (20), IM+H 2(AcOH)j 299.2 (82), 281.1 (14),
215.1 (21), 207.1 (24), 149.1 (20), 121.1 (23), 109.1 (37), 95.1 (48), 81.1 (65), 69.1
(79), 55.1 (100); HR FABMS obs [M+H 2(AcOH)I+ at 299.2012, calc for C20H2702
299.2011.
Formation of the Acetonide of Methyl Constanolactone E (4 0).A catalytic amount
of p-toluenesulphonic acid was added to 1.1 mg of 34 (3.3 Amol) dissolved in 2, 2-
dimethoxypropane (0.5 mL). The solution was stirred at rt for 105 min. Triethylamine (50
pL) was then added to increase the pH prior to evaporation under vacuum. The products
were dissolved in hexanes and kept basic with the addition of triethylamine (10 mL) and
applied to a small silica flash column. The fraction eluting with 10% (v/v) EtOAc in
hexanes was further purified by NP-HPLC (10-jim Alltech Versapak, 2 x 300 mm x 4.1
mm; 25% (v/v) EtOAc in hexanes, 2.0 mUmin) to give ca. 1 mg pure methylated acetonide
product 4 0 (2.5 jimol, 75% yield) as an oil: IR (neat) 3485, 2986, 2955, 2931, 2859,119
1740, 1457, 1437, 1379, 1368, 1246, 1216, 1166, 1080, 1056, 1012, 967 cm-1; 114
NMR (400 MHz, CDC13) 6 5.54 (dd, 1H, J= 15.2, 8.2, H-10), 5.49 (m, 1H, H-15),
5.37 (dd, 1H, J= 15.2, 8.4, H-9), 5.35 (m, 1H, H-14), 4.48 (dd, 1H, J= 8.2, 6.2, H-
11), 4.10 (dt, 1H, J= 8.0, 6.2, H-12), 3.67 (s, 3H, OCH3), 3.06 (m, 1H, H-5), 2.35 (t,
2H, J= 7.3, H-2), 2.28 (dt, 1H, J= 14.6, 8.0, H-13b), 2.15 (dt, 1H, J= 14.6, 6.2, H-
13a), 2.04 (bq, 2H, J= 7.2, H-16), 1.77 (m, 214, H-3), 1.60 (m, 2H, H-4), 1.48 (s, 3H,
acetonide), 1.44 (m, 1H, H-8), 1.35 (m, 2H, H-17), 1.34 (s, 3H, acetonide), 1.3 (m, 4H,
H-18 and H-19), 1.00 (7 lines, 1H, H-6), 0.89 (t, 3H, J= 6.8, H-20), 0.70 (dt, 1H, H-
7b), 0.67 (dt, 1H, H-7a); GC-EIMS (70 eV) IM CH3_1+ m/z 393 (1.0), 1M H201+ 390
(1.5), 361 (2), [M CH3(CH3)2CO2]+ 334 (1.5), [M CH3 (CH3)2CO2 H20]+ 301
(4), 250 (7), 236 (7), 221 (9), 207 (15), 189 (23), 178 (19), 161 (23), 147 (27), 131 (55),
119 (25), 105 (28), 99 (100).
Formation of Acetonide of Methyl Constanolactone F (4 1).A catalytic amount of
p-toluenesulphonic acid was added to 4.2 mg of 35 were dissolved in 2, 2-
dimethoxypropane (0.5 mL). The solution was stirred at rt (23 °C) for 105 min.
Triethylamine (50 pL) was then added to increase the pH prior to evaporation under
vacuum. The products were dissolved in hexanes and kept basic with the addition of
triethylamine (10 pL) and fractionated over a small silica flash column. A fraction eluting
with 10%-100% (v/v) EtOAc in hexanes was further purified by NP-HPLC (10-pm Alltech
Versapak, 2 x 300 x 4.1 mm, 25% (v/v) EtOAc in hexanes, 2.0 mL/min) to give 2.0 mg of
pure methylated acetonide product 41 (5 pmol, 40% yield) as an oil: IR (neat) 3485, 2985,
2955, 2930, 2859, 1740, 1719, 1457, 1437, 1377, 1370, 1241, 1230, 1222, 1171, 1073,
1054, 1023, 967 cm-1; 1H NMR (400 MHz, CDC13) 6 5.55 (m, 1H, H-15), 5.49 (bdd,
1H, J= 15.3, 7.8, H-10), 5.4 (m, 1H, H-14), 5.35 (dd, 1H, J= 15.3, 8.5, H-9), 3.98 (t,
1H, J= 8.1, H-11), 3.70 (dt, 1H, J= 8.1, 5.7, H-12), 3.67 (s, 3H, OCH3), 3.03 (m,
1H, H-5), 2.35 (t, 2H, J= 7.3, H-2), 2.32 (m, 2H, H-13), 2.01 (bq, 1H, J= 6.9, H-16),120
1.77 (m, 2H, H-3), 1.60 (m, 2H, H-4), 1.403 (s, 3H, acetonide-CH3), 1.396 (s, 3H,
acetonide-CH3), 1.35 (m, 2H, H-17), 1.3 (m, 41-1, H-18 and H-19), 1.0 (7 lines, 1H, H-
6), 0.89 (t, 3H, J= 6.8, H-20), 0.71 (dt, 1H, J= 8.6, 5.2, H-7b), 0.65 (dt, 1H, J= 8.6,
5.2, H-7a); GC-EIMS (70 eV) [Mr m/z 408 (1), H201+ 390 (1), 361 (1), [M CH3
(CH3)2CO2]+ 334 (2), [M CH3 - (CH3)2CO2]+ 319 (2), [M CH3 (CH3)2CO2
H2O]+ 301 (4), 250 (9), 236 (8), 221 (10), 207 (15), 189 (27), 178 (38), 161 (26), 147
(29), 131 (58), 119 (30), 109 (46), 105 (29), 99 (100).
Formation of bis- (p- bromobenzoyl)- Constanolactone E (4 2) .Constanolactone E
(3 4, 9.9 mg, 29 pmol), 100.7 mg of 4-bromobenzoyl chloride (98%, 0.45 mmol), and a
catalytic amount of 4-dimethylaminopyridine were dissolved in dry CH2CL2/triethylamine
(5:1, 12.0 mL). The solution was purged with N2 and stirred at rt (23 °C) for 18 h. The
solvents were evaporated under vacuum and the products were dissolved in hexanes and
fractionated over a small silica gel flash column. The fractions eluting with Et20 were
further purified by NP-HPLC (10-pm Phenomenex Maxsil Si column, 500 x 10.0 mm,
30% (v/v) EtOAc in hexanes, UV detection at 254 nm, flow rate 8.0 mL/min) to give 10.8
mg of the pure bis-(p-bromobenzoate) 4 2 (15 pmol, 53% yield) as an oil: UV (EtOH) Amax
246 nm (log E 4.56); CD (EtOH) AE +9.1 (Amax 252.5 nm); 1H NMR (300 MHz, CDC13)
6 7.89 (bd, 21-1, J= 8.5, 1.7, O2CC6H4Br), 7.82 (bd, 2H, J= 8.5, 1.7, O2CC6H4Br),
7.59 (bd, 2H, J= 8.5, 1.7, O2CC6H4Br), 7.55 (bd, 2H, J= 8.5, 1.7, O2CC6H4Br),
5.71 (dd, 1H, J= 15.0, 8.0, H=10), 5.63 (dd, 1H, J= 8.0, 3.7, H-11), 5.50 (dd, 1H, J
= 15.0, 8.4, H-9), 5.40 (m, 2H, 11-2 and H-15), 5.35 (m, 1H, H-14), 3.77(ddd, 1H, J=
10.4, 7.7, 3.0, H-5), 2.56 (dt, 1H, J= 17.6, 6.7, H-2b), 2.5 (m, 2H, H-13), 2.45 (ddd,
1H, J= 17.6, 8.6, 6.8, H-2a), 2.0 (m, 3H, H-4b and H-16), 1.9 (m, 1H, H-3b), 1.8 (m,
1H, H-3a), 1.6 (m, 2H, H-4a and H-8), 1.35 (m, 21-1, H-17), 1.3 (m, 41-1, H-18 and H-
19), 1.09 (7 lines, 1H, H-6), 0.85 (t, 3H, J= 6.7, H-20), 039 (dt, 1H, J= 8.6, 5.2, H-
7b), 0.71 (dt, 11-1, J= 8.6, 5.2, H-7a); 11-1 NMR (300 MHz, C6D6) 6 7.91 (d, 2H, J=121
8.4, O2CC6H4Br), 7.83 (d, 2H, J = 8.2, O2CC6H4Br), 7.29 (d, 2H, J = 8.2,
02CC6H4Br), 7.16 (d, 2H, J= 8.4, O2CC6H4Br), 5.97 (dd, 1H, J= 8.0, 4.5, H-11),
5.85 (dd, 1H, J= 15.0, 8.3, H-10), 5.76 (dt, 1H, J= 7.6, 4.5, H-12), 5.53 (m, 2H, H-
14 and H-15), 5.45 (dd, 1H, J= 15.0, 8.8, H-9), 3.02 (m, 1H, 1-1-5), 2.65 (dt, 1H, J=
14.0, 7.4, H-13b), 2.53 (m, 111, H-13a), 2.06 (bq, 2H, J= 6.9, H-16), 2.00 (bq, 2H, J
= 6.8, H-2), 1.42 (m, 1H, H-8), 1.32 (m, 2H, H-17), 1.25 (m, 4H, H-18 andH-19),
1.12 (m, 2H, H-3b and H-4b), 0.97 (m, 2H, H-3a and H-4a), 0.91 (t, 3H, J = 6.8, H-
20), 0.67 (m, 1H, H-6), 0.39 (m, 2H, H-7); CIMS (CH4, positive ion) IM1+ nilz 700 (3),
623 (2), [M+H BrC6H4CO21-1]+ 501 (15), IM+H 2(BrC6H4CO2H)1+ 301 (72), [M+H
2(BrC6H4CO2H) H201+ 283 (8), 229 (8), [BrC6H4CO2H+H]+ 201 (82), 183 (15), 157
(19), 123 (100).
Formation of bis- (p- Bromobenzoyl)- Constanolactone F (4 3) .Constanolactone F
(3 5) (1.4 mg, 0.0042 mmol),23.8 mg of 4-bromobenzoyl chloride (98%, 0.106 mmol),
and a catalytic amount of 4-dimethylaminopyridine were dissolved in dry
CH2CL2/triethylamine (5:1, 6.0 mL). The solution was purged with N2 and stirred at rt (23
°C) for 17 h. The solvents were evaporated under vacuum and the products were dissolved
in hexanes and fractionated over a small silica flash column. The fractions eluting with 36
to 80% Et20 in hexanes were further purified by NP-HPLC (10-pm Alltech Versapak, 2 x
300 x 4.1 mm, 30% (v/v) EtOAc in hexanes; 254 nm detection, 2.0 mL/min) to give ca.
0.5 mg pure bis-(p-bromobenzoate) product 4 3 as an oil: UV (EtOH) Amax 246 nm (log E
4.29); CD (EtOH) AE +5.4, -11.8 (Amax 255, 240 nm); 1f1 NMR (400 MHz, CDC13) 6
7.81 (bd, 4H, J= 8.4, O2CC6H4Br), 7.51 (bd, 4H, J= 8.4, 1.4, O2CC6H4Br), 5.62
(dd, 1H, J= 15, 7, H-10), 5.56 (bd, 1H, J= 7, H-11), 5.5 (m, 2H, H-12 and H-15), 5.4
(m, 1H, H-9), 5.35 (m, 1H, H-14), 3.73 (m, 1H, H-5), 2.5 (m, 3H, H-2b and H-13),
2.4 (m, 1H, H-2a), 1.99 (m, 114, H-4b), 1.95 (m, 2H, H-16), 1.8-2.0 (m, 2H, H-3),
1.66 (m, 1H, H-4a), 1.54 (m, 11-1, H-8), 1.3 (m, 6H, H-17 to H-19), 1.12 (m, 1H, H-6),122
0.81 (t, 3H, J=6.8, H-20), 0.76 (m, 1H- H-7b), 0.67 (m, 1H, H-7a); CIMS (CH4,
positive ion) m/z [M]+ 700 (0.5), 623 (0.5), 1M+H BrC6H4CO2Hr 501 (9), [M+H
2(BrC6H4CO2H)]+ 301 (48), [M+H 2(BrC6H4CO2H) H2O] 283 (6), 229 (9),
[BrC6H4CO2H+H]+ 201 (92), 183 (16), 157 (22), 123 (100), 105 (19).
General Biosynthetic Methods. C. simplex (1 Kg, wet weight) was obtained from
exposed low intertidal rocks at Seal Rock, Oregon on 30 August 1989. Voucher specimens
of this alga are deposited at the College of Pharmacy, Oregon State University. The alga
was frozen on site using dry ice and then stored at -70 °C prior to extraction. Arachidonic
acid (AA, 99%) was purchased from Sigma. EtOH from Midwest Grain Products Co.
Oxygen-1802 from Cambridge Isotope Laboratories: MS analysis of this gas mixture
showed it to be of random speciation (23.6 % 1602, 48.4 %160180,28 % 1802),
although originally sold as "Oxygen-t802;18095--m." 50 %." other compounds and solvents
were of the highest purity commercially available.
Enzyme Extraction and Preparation. C. simplex (980 g frozen) was repeatedly
extracted with 500 mL fractions of acetone -CO2 (s) until acetone extract was nearly
colorless (slightly yellow). Solvent was removed from tissue by filtration using a 10-20
sintered glass funnel. The final residue was then dried under N2.143 The dry acetone
powder (176 g) was divided into six portions and stored under N2 at -70 °C. Portions of
acetone powder (1.00 g) were then used in all incubations except for the1 802 labeling
experiment (see below). Each of these was then dissolved in 125 mL Erlenmeyer flasks
with 75 mL of 0.1 M K2HPO4 buffer, pH 7.4. Boiling of the enzyme preparation was
accomplished by heating with occasional stirring (98-100 °C, 10 min). At the end of this
time the enzyme preparation had changed from pink to green. All flasks were allowed to
reach the desired temperatures and monitored periodically throughout each incubation.
Acetone Powder Incubations. Arachidonic acid was dissolved in EtOH to a final
concentration of 0.1 mg 1.11-1. Treatments of "AA + AP", "AA + boiled AP", and "AA +123
pH 7.4 buffer alone" each received 2.0 mg of AA in 20 ill EtOH at 20 °C. "AA + AP"
treatments were then performed in duplicate at 25 °C using 0.0, 1.0, 5.0, and 10.0 mg of
AA respectively. "AA + AP" treatments were performed at 9 °C using 0.0 and 5.0 mg of
AA. A final "AA + AP" treatment was performed in duplicate at 1 °C using 5.0 mg of AA.
All incubations were allowed to run 20 min with continuous agitation.
Enzyme Product Extraction. Following the incubation period, enzyme preparations
were adjusted to pH 4 with 10% HC1. Lipids were extracted four times with 60-80 mL
portions of CHC13. The combined extracts were evaporated in vacuo and the recovered
lipids, stored in Et20 at -20 °C.
Analysis of Enzyme Products. TLC of the acetone extract and enzyme incubation
treatments was performed on silica gel 60 F254 using (10% (v/v) Me0H in CHC13). The
TLC was developed then sprayed with a solution of 50% H2SO4. Blue char reactions
characteristic of oxylipins were produced upon heating. Enzyme products were analyzed
by normal phase HPLC (10-pm Alltech Versapak, 300 x 4.1 mm, 85% (v/v) EtOAc in
hexanes; 4.0 mL/min) using a Waters M-6000 pump, U6K injector and R 401 differential
refractometer. NP-HPLC.Enzyme products were quantified by area under the curve
measurements coupled with actual recovered product masses.
Molecular Oxygen Incorporation Study. Incubation was conducted using "Oxygen-
1802; 180,50 %"in a closed system containing 10 g of C. simplex acetone powder stirring
in 100 mL of 0.1 M phosphate (K2HPO4/HC1) buffer (pH 7.4) at 21.5 °C. The buffer
medium and head space (ca. 25 mL) were repeatedly gas-stripped with N2 alternating with
water aspirated vacuum. The system was then charged three times with the 160/180 gas
mixture and then 10 mg of 90% pure AA dissolved in 100 Al of ethanol was added. After
20 minutes at 21.5 °C the reaction was immediately extracted four times with CHC13 (125
mL) and evaporated in vacuo. TLC analysis (10% (v/v) Me0H in CHC13) of the oil
suggested the presence of several oxidized AA metabolites. The crude extract was124
methylated (CH2N2/Et20) to yield 3.32 mg of a colorless oil. The oil was dissolved in 2
drops dry pyridine to which 2 drops 1,1,1,3,3,3-hexamethyldisilazane and 2 drops
trimethylchlorosilane were then added. The mixture was mixed (vortex) and allowed to
stand at room temperature for 20 minutes, the reagents evaporated in vacuo, and the
samples dissolved in hexanes to a concentration of 100-500 ng/juL (dependent upon
complexity of mixture). The material was vortex agitated, centrifuged, and the surface
hexanes drawn off (decanted) with a pipet to a clean tube prior to GC-MS analysis.
Analysis of 180-labeled Constanolactones and Derivatives. Following extraction
and methylation of the products (as above) the oxylipins were analyzed by GC -ELMS of
their corresponding bis-trimethylsilyl (TMSi) ethers (4 6 and 4 7). Incorporation of labeled
02 was observed by analysis of isotopic abundance patterns in key MS fragments in
labeled and non-labeled products. Significant incorporation of one 180 was achieved as
evidenced by an enhancement of the ion at m/z 371 [M CH3(CH.,)4CH=CHCH2 + 2]+
(28±1% incorp.), corresponding to a-cleavage to the C-12 TMSi ether (Figure 111.36).
However, the 180-label substitution was not clearly identifiable by the fragmentation
pattern. Therefore, catalytic hydrogenation (1-12, 5% PtC12) of 180-labeled and unlabeled
control incubation products afforded constanolactone derivatives which were re-silated (as
above) to form a mixture of 10,11,14,15-tetrahydrogenated TMSi ethers (4 8 and 4 9) .
Incorporation of 180-label into crucial fragments were calculated by first
establishing the isotopic contribution of unlabeled product (i.e. [ion] ++ 1, lionl++ 2,
[ion] ++ 3, etc. as a percentage of the I ionr ), adjusting these figures to a percentage of the
lionr abundance in the labeled fragment, and subtracting this contribution from the total
abundance of each corresponding ion in the labeled fragment. The remaining 180-label
contribution was then divided by the total ion abundance of the fragment and reported as an
average percent incorporation for each pair of constanolactone derivatives.
Methyl -9,12-Bis-(CH313Si-Constanolactones (4 6 and 4 7).GC-EIMS (70 eV),125
peak 1: GC-retention 27.9-29.4 min., IM C81-1151+ / [M C8H15 +/ IM C8H15 +
21+/ [M C8H15 + 3] +/ [M C8H15 + 4] +m/z 369/370/371/372/373
(59.7/18.8/7.42/1.64/0.31), 279/381 (96.0/7.25), 243/245 (11.2/1.57), 189 (12.2), 129
(17.7), 73 (100), 55 (14.5); peak 2: GC-retention 30.2-31.9 min., [M C8H151+ / [M
C81-115 +/ IM C81-115 + 21+/ [M C81-115 + 3]
+/ [M C8I-115 + 4] +m/z
369/370/371/372/373 (63.4/19.6/7.69/1.72/0.49), 279/381 (77.1/5.58), 243/245
(13.0/1.78), 189 (11.8), 129 (18.1), 73 (100), 55 (15.2).
180-labelled Methyl -9,12-Bis-(CH313Si-Constanolactones (4 6 and 4 7).GC-
EIMS (70 eV), peak 1: GC-retention 28.2-29.2 min.,[MC8I-115]+ / [M C81 -115 + 1]+ /
IM C8H15 + 21+/ [M C8H15 + 3] ±/ [M C8H15 + 4] +m/z 369/370/371/372/373
(40.9/13.8/20.2/6.39/2.33), 279/381 (69.1/28.7), 243/245 (10.4/4.68), 189 (11.0), 129
(18.3), 73 (100), 55 (16.6); peak 2: GC-retention 29.8-30.6 min., [M C8H15r / [M
C81-115 + C8F115 + 2r/ [M C8I-115 + 3]
+/ [M C8H15 + 4] +m/z
369/370/371/372/373 (40.2/13.4/20.3/6.31/1.98), 279/381 (50.0/21.1), 243/245
(12.8/4.7), 189 (9.0), 129 (33.0), 73 (100), 55 (14.8).
Methyl -10,11,14,15-tetrahydro-9,12-Bis-(CH313Si-Constanolactones (4 8 and
4 9). GC-EIMS (70 eV), peak 1: GC-retention 32.3 min., IM C8H17r / [M C8H17 +
11' / [M C8H17 + 2]+ / [M C81-117 + 3]+ m/z 371/372/373/374 (10.5/4.05/<1/<1), 342
(3.1), 314/316 (5.07/1.51), 281/283 (28.4/3.64), [M C14H31180Si]+ / [M
C14H3118OSi + 1]+ / [M C14H31180Si + 2]+ / [M C141-131180Si + 3]+ 241/242/243/244
(100/16.6/6.66/<1), ICH3(CH2)7COSi(CH3)31+ / [CH3(CH9)7COSi(CH3)3 + 11+ /
ICH3(CH2)7COSi(CH3)3 + 2r / [CH3(CH2)7COSi(CH3)3 + 3-1+ 215/216/217/218
(15.2/6.66/3.83/<1), 191 (10.3), 185 (20.3), 129/131 (54.7/16.1), 73 (84.6), 55 (23.6);
peak 2: GC-retention 33.5 min., [M C8I-117]+ / [M C81-117 + 1 f/[m_c8H17+ 2]+ / IM
C8H17 +m/z 371/372/373/374 (10.2/3.30/<1/<1), 342 (2.79), 314/316 (13.5/1.43),
281/283 (31.1/4.53), [M C14H31180Si]+ / [M C14H31180Si +irm_ci4H3,180si126
2]+ / C14H3118OSi + 3r241/242/243/244 (91.6/21.1/7.661<1),
ICH3(CH2)7COSi(CH3)31+ / ICH3(CH2)7COSi(CH3)3 +11+ / [CH3(CH2)7COSi(CH3)3 +
21+ / [CH3(CH2)7COSi(CH3)3 + 3r 215/216/217/218 (15.5/4.96/2.89/0.97), 191 (15.5),
185 (18.3), 129/131 (61.7/13.1), 73 (100), 55 (20.2).
180-Labelled Methyl -10,11,14,15-tetrahydro-9,12-Bis-(CH313Si-Constanolactones
(48and4 9). GC-EIMS (70 eV), peak 1: GC-retention 32.4 min., [M C81-117]+ / [M
C8H17 + 1] + / [M C81-117 + 21+ / [M C8H17 + 3]+ mtz 371/372/373/374
(7.66/3.37/3.32/1.79), 281/283 (24.3/8.4), [M C14H31180Si]+ I I-M-Ci4H31180Si +
in /[M C14H31180Si + 2]+ / C14H3118OSi + 31+ 241/242/243/244
(86.3/18.0/546/<1), ICH3(CH2)7COSi(CH3)31+ / ICH3(CF12)7COSi(CI-13)3 + 11+ /
[CH3(CH2)7COSi(CH3)3 + 21+ / [CH3(CH2)7COSi(CH3)3 + 31+ 215/216/217/218
(14.6/7.16/2.35/1.43), 191 (10.1), 185 (21.1), 129/131 (89.5/13.7), 73 (100), 55 (18.5);
peak 2: GC-retention 33.5 min., [M C81-1171+ / [M C8H17 + 11+ / 1M C8H17 + 21+ /1M
C8H17 + 31+ m/z 371/372/373/374 (4.69/2.31/2.91/2.27), 342 (4.6), 314/316
(14.2/5.37), 281/283 (28.4/11.57), [M C14H31180Si]+ / [M C14H31180Si + 1]+ / [M
4H31180Si + 2]+ / [M C14H3118OSi + 3]+ 241/242/243/244 (100/22.4/8.2/2.53),
[CH3(CH2)7COSi(CH3)31+ / [CH3(CH2)7COSi(CH3)3 + 11+ / [CH3(CH2)7COSi(CH3)3 +
21+ / [CH3(CH2)7COSi(CH3)3 + 31+ 215/216/217/218 (12.5/9.10/8.37/1.03), 191 (18.0),
185 (21.1), 129/131 (51.7/17.5), 73 (94.5), 55 (21.8).127
CHAPTER IV.
NAKIENONES A-C AND NAKITRIOL, NEW CYTOTOXIC C11 METABOLITES
FROM AN OKINAWAN CYANOBACTERIAL (SYNECHOCYSTIS SP.)
OVERGROWTH OF CORAL
Abstract
Nakienones A-C and nakitriol, a series of reactive cytotoxic metabolites, were
isolated from dead and necrotic branches of stony coral (Acropora sp.) which were
completely covered with a gray-black mat of cyanobacteria (Synechocystis sp.). Their
structures were determined spectroscopically by interpretation of 2D-NMR experiments,
including HMBC and NOESY, and by comparison with model compounds.128
Introduction
Marine algal overgrowths have recently been established as contributing factors
leading to the destruction of hard-coral communities.144 Dramatic phase shifts in
Caribbean reef species composition have been observed over the past twenty to thirty
years. A combination of human and natural disturbances have resulted in severe disruption
of the density and diversity of coral reef communities. Overfishing, pollution, disease, and
tropical storms have together contributed to destabilize herbivore population density,
resulting in large-scale algal blooms and massive destruction of hard-corals. Little is
known about how specific chemical-ecological interactions between algae, herbivores, and
predatory species may influence the dynamics of disrupted or damaged reef populations.
As part of our ongoing survey of marine algae for biomedical potential, I
discovered at a depth of -1 to -2 m several large (diameter 3-4 m), nearly concentric, zones
where blackened mats of Synechocystis sp. were completely overgrowing and apparently
smothering an otherwise heathy-appearing staghorn coral reef (Acropora sp.) in the waters
off Yonaine at Nakijin Village, Okinawa. While I am unable to prove that this overgrowth
caused the death of the subtending coral, I strongly suspect this to be the case due to the
observed growth pattern of the cyanobacteria. From this microalgal-coral assemblage, I
have isolated four new cytotoxic Cli metabolites which may be involved in the chemical
ecology of this interaction.
Only cursory data concerning the chemistry of Synechocystis spp. is available.
However, at least two species of Synechocystis contain small molecules (640 to 1250
daltons) which potently act to induce settling of planktonic red abalone larvae (Haliotis
rufescens).145Further, these metabolites were demonstrated to trigger metamorphosis in
these larvae, much as gamma-aminobutyric acid (GABA). While these compounds have
not been fully characterized, they may be important to the ecology of both organisms.129
Results and Discussion
Matted algal material on completely denuded coral (1 L, 1.091 kg dry material) was
preserved in 2-propanol and stored at -20 °C until extracted with CH2C12/Me0H (2:1).
The extract was partitioned into two fractions, a non-polar CH2C12 fraction (2.70 g, dark
oil), and a polar aqueous-alcohol (sec-butanol) fraction (1.294 g, oil). Two-dimensional
TLC analysis of the extracts suggested the presence of several UV-active secondary
metabolites in both the lipid and aqueous fractions. Both fractions were subjected to size-
exclusion chromatography (Sephadex LH-20, 25 x 340 mm column, 50% (v/v) EtOAc in
Me0H and further purified by silica gel flash chromatography with a gradient from hexanes
to EtOAc to Me0H). Final purification by repetitive NP-HPLC (50 and 80% EtOAc in
hexanes) provided nakienone A (1, 21.1 mg, 0.53%), the hydroquinone nakitriol (2, 5.9
mg, 0.15%), and a mixture of several other UV active compounds which were
subsequently acetylated (Ac20/Pyr) and purified by NP-HPLC (25% EtOAc in hexanes) to
yield nakienone B (3) as the peracetate derivative (4, 1.0 mg, 0.012%) (Figure IV.1).
Additionally, an unusual rearrangement of triene 1 to a reduced diene hemiacetal 5, was
observed while obtaining initial NMR spectra of 1.
Analysis of 1 by 13C NMR and HRCIMS (195.1021; -0.01 mmu; CH4) provided a
molecular formula for IM+Hl+ of C11H1503. Examination of the IR (u = 3650-3100,
1683 cm-1), UV (Xmax 234 nm; log E 4.7; EtOH), and NMR data (Tables IV.1 and IV.2)
revealed the presence of two primary hydroxyl groups, a 1,1-disubstituted diene, and an
a, 13- unsaturated cyclopentenone moiety. With the aid of COSY (Figure IV.2 and Table
IV.3) and HETCOR spectra, two distinct spin systems could be assembled (A and B;
Figure IV.3). In fragment A, the H8 proton was allylicly coupled to the H11 protons of a
primary alcohol methylene, allowing the construction of a conjugated terminal diene.130
OR OR OH
10
1 R H
6 R = OAc
10
3 R = H
4 R = OAc
OR
H3C
HO
2
OH
5
Figure IV.1 Structures of Nakienones A-C (1,3,5), Nakitriol (2), and Per-acetate
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Figure IV.2 COSY Spectrum of Nakienone A (1).Table
#C
1
2
IV.1 1H NMR Data for
Nakienone A (1)
Nakienones.a
Nakitriol (2) Nakienone B per-acetate (4) (5)
4.37 bd 5.0
4.24 bt 5.0 (-OH)
6.49 d 2.9
7.71 bm (-OH)
6.66 dd 2.8, 1.3
5.64 ddd 8.8, 5.0, 2.8
5.62 bs
3.11 m (-OH)
32.81 m 6.65 dd 8.5, 2.9 a) 2.14 m a) 2.60 dt 18.8,5.0
b) 2.38 bm b) 2.78 dt 18.8,5.2
42.40 m 6.72 d 8.5 a) 2.51 ddd 16.9, 11.8, 4.7 2.52 m
b) 2.70 dt 16.9, 5.2, 5.0
5
7.71 bm (-OH)
6
7
86.35 bd 11.0, 1 6.43 d 11.0 6.34 bd 10.9 5.60 t 7.7
96.12 dt 16.9, 10.4 6.27 dt 16.9, 10.2 6.25 bddd 16.3, 10.9, 9.1 a) 2.37 m
b) 2.49 m
10a) 5.04 ddd 10.4, 1.5,1 a) 5.03 dd 10.2, 2.0 a) 5.20 dd 9.1, 1.5 1.03 t 7.4
b) 5.24 ddd 16.9, 1.5,1 b) 5.26 dd 16.9, 2.0 b) 5.34 dd 16.3, 1.5
114.10 bd 5.0 4.31 bs 4.68 m a) 3.92 bd 11.6
3.99 bt 5.0 (-OH) b) 4.32 bd 11.6
2.12 s (- OCOCH3)
2.04 s (- OCOCH3)
a) All spectra recorded on Bruker AC-300 or AM-400 spectrophotometers; data presented as 5, multiplicity, J in Hz. Data for 1, 2 , and 4were recorded in
acetone-d6 (spectra referenced to the center line of acetone-d6 methyl pentet at 2.04 ppm). Data for 5 was obtained in CDC13 (spectra referenced to TMSat 0.0
ppm). Assignments based on 1H-1H COSY and 1H-13C XHCORR spectra.133
9
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Figure IV.3 Partial Structures for Nakienone A (1) from COSY Spectrum.
Fragment B also contained a primary alcohol (H1), allylicly coupled to a methylene (H3)
through a quaternary carbon. 1H-13C HMBC spectra placed fragment B in the a ,13-
unsaturated pentenone ring and facilitated the attachment of both spin-systems, defining the
structure of nakienone A as 1 (Figure IV.1).
Table IV.2 13C NMR Data for Nakienones.a
#C Nakienone A Nakitriol (2)Nakienone B ( 5 )
per-acetate (4)
1 61.10 118.07 146.94 91.00
2 176.94 150.87 67.97 167.30
3 27.81 116.28 28.81 25.90
4 34.92 117.59 35.40 35.29
5 207.85 148.46 196.10 204.75
6 137.46 126.97 132.69 137.49
7 136.95 141.80 137.89 122.28
8 129.46 129.87 133.02 135.85
9 134.63 135.24 132.21 23.58
10 118.15 117.87 120.72 14.24
11 65.03 67.12 67.01 66.04
(-000CH3)
170.24 / 20.98
170.22 / 20.88
a) All spectra recorded on Bruker AC-300 or AM-400 spectrophotometers; data presented as 6,
multiplicity. Data for 1, 2 , and 4 were recorded in acetone-d6 (spectra referenced to the center line of
acetone-d6 methyl heptet at 29.8 ppm). Data for 5 was obtained in CDC13 (spectra referenced to the
center line of CDC13 at 77.0 ppm). Assignments based on 1H-111 COSY and II-1-13C X1-1CORR spectra.134
The C7-C8 olefinic geometry was assigned as E by comparison of the Cl 1
primary hydroxy-methylene 13C NMR shift (6 65.03 ppm, acetone-d6; 65.82 ppm,
CDC13) with both E (range: 65.6-66.3 ppm) and Z (range: 59.2-60.3 ppm) 1,1-
disubstituted olefinic and dienoic model compounds (Figures IV.4 and IV.5).146-152
The E configuration was confirmed by a NOESY correlation observed between the Cl
acetate methyl singlet and H lOb in the peracetate (Ac20/Pyr) derivative (6).
Table IV.3 1H-1H and Long-Range 1H-13C Correlations for Nakienone A (1).
Proton #
H-1
(OH-1)
11-3
H-4
H-8
H-9
H-10 (a)
(b)
H-11
(OH-11)
1H-1H COSY 1H-13C HMBC (10 Hz)
(OH-1), H-3
H-1
H-1, H-4
H-3
H-9, H-10a, H-10b, H-11
H-8, H-10a, H-10b
H-8, H-9, H-10b, H-11
H-8, H-9, H-10a, H-11
(OH-1)
H-11
C-2, C-3, C-6 or -7
C-2, C-4, C-6 or -7
C-2, C-3, C-5
C-6 OR -7, C-9, C-10, C-11
C-6 OR -7
C-8, C-9
C-8, C-9
C-6 OR -7, C-8
Table IV.4 1H-1H and Long-Range 1H-13C Correlations for Nakitriol (2).
Proton #
H-1
H-3
H-4
11-8
1-1-9
H-10 (a)
(b)
H-11
1H-1H COSY 1H-13C HMBC (5 Hz)
H-3
H-1, H-4
H-3
H-9, H-11
H-8, H-10a, H-10b
14-9, H-10b, H-11
H-9, H-10a, H-11
H-8, H-10a, H-10b
C-2, C-5, C-7
C-2, C-4, C-6
C-2, C-5, C-6, C-7
C-6
C-7, C-8
C-8
C-8, C-9
C-6, C-7, C-8135
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Figure IV.4 Z-Geometry Model Compounds Used to Deduce C7-C8 Olefin
Geometry in Nakienone Series.136
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Figure IV.5 E- Geometry Model Compounds Used to Deduce C7-C8 Olefin
Geometry in Nakienone Series.137
Compound 2, UV ('max 228, 302 nm; log E 3.6, 4.3; Me0H), yielded a
molecular formula of C11H1203 by HRCIMS (192.0787; 0.3 mmu; CH4). While the
1H and 13C NMR data for 2 were analogous to that of 1 in the 1,1-disubstituted diene
spin-system, the IR spectrum for 2, unlike 1, did not show a carbonyl stretch. Like 1,
two partial structures were defined for structure 2 by1H-1Hcorrelations from COSY
spectra (A and B; Figure IV.6). An exchangeable 1H NMR resonance (6 7.71 bm 2H)
and pair of 13C' s (6 150.87 and 148.46) suggested the presence of a hydroquinone
moiety. Juxtaposition of the two spin-systems was accomplished by HMBC (Table
IV.4). Specifically, correlations from C7 to H1 and from C6 to H8 and H11 defined
the structure of metabolite 2, trivially named nakitriol. Similarly, an E configuration
was assigned for the C7-C8 olefin from the 13C NMR chemical shift of the C11
methylene (6 67.12 ppm).
Per-acetate derivative 4, [a ]2D5= +123° (c = 0.11, Me0H), yielded a molecular
formula of C15H1905 for IM+Hr by HRCIMS (279.1233; +0.1 mmu). Its 13C NMR
spectrum differed from that of 1 in the conspicuous absence of the cyclopentenone
carbonyl resonance (6 207. 85 ppm), which was replaced by a cyclohexenone carbonyl
10
A
4
B
Figure IV.6 Partial Structures for Nakitriol (2) from COSY Spectrum.138
Table IV.5 1H-1H and Long-Range 111-13C Correlations for Nakienone B Diacetate
(4).
Proton #
H-1
H-2
H-3 (a)
(b)
H-4 (a)
(b)
H-8
H-9
H-10 (a)
(b)
H-11
(OCOCH3)
(OCOCH3)'
1H-1H COSY 1H-13C HMBC (7 Hz)
H-2, H-3b
H-1, H-3a, H-3b
H-2, H-3b, H-4a, H-4b
H-2, H-3a, H-4a, H-4b
H-3a, H-3b, H-4b
11-3a, H-3b, H-4a
H-9, H-10b, H-11
H-8, H-10a, H-10b
H-9, H-10b
11-8, H-9, H-10a
H-8, H -i0a, H-10b
C-3, C-5, C-6
C-1, (OCOCH3) or (OCOCH3)'
C-4
C-1, C-2, C-4, C-5
C-2, C-3, C-5
C-2, C-3, C-5, C-7
C-7, C-10, C-11
C-8
C-6, C-7, (OCOCH3) or
(OCOCH3)'
(OCOCH3)'
(OCOCH3)
resonance at a shift of 196.10 ppm (Table IV.2). HMBC correlations from C6 to H11
and from C7 to H4a and H4b connected the 1,1-disubstituted diene to C6 of a
cyclohexenone ring, thus establishing the structure of nakienone B per-acetate as 4
(Figure IV.7 and Table IV.5). An E geometry of the C7-C8 olefin was assigned by the
C11 13C chemical shift (6 67.01 ppm), as previously described for 1 and 2, using
peracetylated model compounds E (range: 68.8-69.1 ppm) and Z (range: 61.3-61.9
ppm) (Figures IV.5 and IV.6).152-155 Coincidentally, examination of numerous model
compounds uncovered what appears to be a discrepency in the assignment of olefinic
geometry of a spatane diterpenoid derivative from the brown alga Spatoglossum howleii
(see endnote).
Rearrangement of the triene 1 to 5 (also found in the organic extract) was
observed while obtaining the initial NMR spectra of 1 in CDC13. Compound 5
possessed a UV absorbance for a dienone (Xma. 262 nm; log E 4.2; Me0H), was shown0N4-47.01 IN COCO
H-0
H-1 H-9
H-2
H-10. H-10.
H2-11
H-4H-4 H_3b
Ac0- Ae0-
I
.K1. I
44
Oa
eo Edo
0100
10
4
0Ae
*V0%4
a0 et.100
CZ>
c011 CII=t1.1193
4.1
6.5 6.0 5.5 5.0 4.5 4.0
PPM
Figure IV.7 HMBC Spectrum of Nakienone B per-acetate (4).
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to have the same molecular formula as 1 by HRCIMS ( C11H1503; [M+H] +; 95.1022;
+0.1 mmu; CH4). However, the NMR spectra of 5 was notably different from that of
1 (Tables 1 and 2). Specifically, the chemical shift of the Cl carbon now resonated at
91.00 ppm, suggestive of an hemiacetal moiety, and the olefinic methylene signal in 1
(6 118.15 ppm) was replaced by a methyl signal at 8 14.24 (1H 6 1.03). As with
compounds 1, 2, and 4, a 3-bond coupling from C6 to H8 as well as 3iti0c couplings
from Cl to H1 la and H1 lb established structure of 5 as a reduced diene hemiacetal
(Table IV.6). The rearrangement of reactive 1, presumably by an acid catalyzed
mechanism (Figure IV.8), suggests a potential artifactual origin for 5 as obtained from
the crude lipid extract.
H
HOH2C 1/4CHOH CH2OH CH2OH
OH
1
H+
5
Figure IV.8 Proposed Acid-Catalyzed Rearrangement of Nakienone A (1) to
Compound 5.141
Table IV.6 1H-1H and Long-Range 1H-13C Correlations for 5.
Proton # 11-1-1H COSY 1H-13C HMBC (10 Hz)
H-1 (OH-1), H-1 1a, H-1 1b C-6, C-11
(OH-1) H-1
H-3 (a) H-3b, H-4 C-2, C-4, C-5, C-6
(b) H-3a, H-4 C-2, C-4, C-6
H-4 H-3a, H-3b C-2, C-3, C-5
H-8 H-9a, H-9b C-9, C-10
H-9 (a) H-8, H-9b, H-10 C-7, C-8, C-10
(b) H-8, H-9a, H-10 C-7, C-8, C-10
H-10 H-9a, H-9b C-8, C-9
H-11 (a) H-1, H-11b C-1, C-7, C-8
(b) H-1, H-9b, H-11 C-1, C-7, C-8
Both 1 and the rearrangement product 5 are structurally similar to the cytotoxins
didemnenones A-D (7 -10, Figure IV.9), isolated from Didemnum and Trididemnum
spp. Both of these ascidians have been reported to harbor unicellular algal
symbionts.146,156 Additionally, the antimicrobial bromophenolic compound
aplysinadiene (1 1, Figure IV.9), isolated from the marine sponge Aplysina aerophoba,
is remarkably similar in structure to nakienone B (2) and nakitriol (3).157 The
occurrence of these and other related metabolites158 suggests that symbiotic
cyanobacteria may be involved in the production of these compounds in marine
invertebrates. To date, three microalgae have been cultured from the original algal
infected coral tipS.156
Nakienone A (1) was determined to be cytotoxic to both KB (human epidermoid
carcinoma) and HCT 116 (colonic carcinoma) cell lines, with LD50's of ca. 5 and 20
pg/ml, respectively. Additionally, 2 was shown to be wealdy and nonselectively
cytotoxic to DNA repair defective cell lines EM9 (topoisomerase I sensitive Chinese142
didemnenone A (7)
R1 = H, R2 = OH
didemnenone B (8)
R1 = 01-1, Ri = H
didemnenone C (9)
OH OH
didemnenone D (10)
OH
aplysinadiene (11)
Figure IV.9 Didemnenones A-D (7-1 0) and Aplysnadiene (11).143
hamster ovary line), XRS-6 (topoisomerase II sensitive), UV20 (DNA cross-linking
agent sensitive), and BR1 (DNA repair competent) cell lines, LD50's ca. 20 pg/mL.
Cytotoxic properties associated with this entire class of chemistry may be due, at least in
part, to the presence of activated a,13-unsaturated ketone moieties, acting as Michael
acceptors for 1,4- or 1,6-additions.
Experimental
General Methods. UV spectra were recorded on a Hewlett Packard 8452A
diode array spectrophotometer and IR spectra were recorded on a Nicolet 510 FT-IR
spectrometer. Low resolution mass spectra were obtained on either a Varian MAT CH7
spectrometer or by GC-MS using a Hewlett Packard 5890 Series II gas chromatograph
and a 5971 mass selective detector. HRMS were obtained on a Kratos MS 50 TC.
HPLC was performed using a M-6000 pump, U6K injector, and either a R401
differential refractometer or a lambda-Max 4801c spectrophotometer. NMR data were
obtained on either Bruker AC 300 or Bruker AM 400 spectrometers. TLC-grade (10-40
jam) silica gel was used for vacuum chromatography and Kieselgel 60 silica (40-63 iim)
was used for flash chromatography .
Nakienone A (1). FTIR vf21; cm-1: 3367, 2925, 1687, 1683, 1435, 1286,
1154, 1114, 1056, 994, 915; UV Xr:nm: 234 (log e = 4.7). CIMS (CH4, positive
ion) 1M+141+ /viz 195 (30), 1M+H H201+ 177 (100), [M+H 2(H20)]+ 159 (54), 149
(15); HR CIMS (CH4, positive ion) [M+Hr at 195.1021 talc for C14141503
195.1021.
Nakienone A Diacetate Derivative (6). GC-EIMS (70 eV) [M Ac0H]+ m/z 278
(3), 236 (5), 218 (2), 194 (2), 176 (100), 161 (45), 147 (42), 133 (53), 115 (16), 105
(32), 91 (41), 77 (15), 65 (6), 55 (7);144
Nalcitriol (2). FTIR vnift cm-1: 3309. 1496, 1490, 1447, 1199, 787; UV
XlmV1Inm: 228, 302 (log E = 4.3, 3.6); CIMS (CH4, positive ion) [M+H] + m/z. 193
(22), IM+H H2O] + 175 (100); HR CIMS (CH4, positive ion) IM+Hr at 192.0787
calc for C 11H1203 192.0786.
Nakienone B Diacetate Derivative 4. FTIR Vmfilamx Ct11-1: 1739, 1738, 1684, 1374,
1230, 1045, 1022, 995, 911; [a1+123° (c 0.11, Me0H); GC-EIMS (70 eV) [M
Ac0Hr m/z 218 (27), 176 (100), 158 (60), 157 (65), 147 (62), 129 (28), 115 (15), 91
(38), 57 (19); CIMS (CH4, positive ion) [M+H]
+m/z 279 (4), [M+H Ac0H] + 219
(12), 1114+H(AcOH)2_1+ 259 (100); HR CIMS (CH4, positive ion) [M+H]+ at
279.1233 calc for C151{1905 279.1232.
Compound 5. FTIR vmmamx cm-1: 3368, 2967, 2930, 2872, 1702, 1693, 1437,
1401, 1141, 1101, 1080, 1038, 987, 963; UV Ammf Hnm: 262 (log E = 4.2); CIMS
(CH4, positive ion) IM+Hr m/z 195 (86), [M+H H2O]+ 177 (100), 149 (37); HR
CIMS (CH4, positive ion) IM+Hr at 195.1022 calc for Ci iH1503 195.1021.145
Endnote
The Z geometry of the C13-C15 olefin in the spatane tetraol (1 2) and its per-
acetate derivative (13) (Figure V.10) were assigned solely upon negative data from nOe
experiments.I59 Specifically, the lack of H15 nOe enhancement when the C14
methylene was irradiated was used as the basis for the assignment. The 13C chemical
shift of the C14 methylene (6 68.4 ppm) falls significantly outside the range observed
for acetylated primary vinylic alcohols on Z olefins (6 61.3-61.9ppm): 52-155
However, this chemical shift fits perfectly within the range for E geometry models
(range: 68.8-69.1 ppm) (Figures IV.5 and IV.6).152-155 I therefore suggest the true
structure of this derivative and the corresponding natural product from which it was
prepared to be 14 and 15, respectively.
OR H CH3 z.-
OR
OR
OH
CH3
OR
12 R = H
13 R = Ac
14 R =
15 R = Ac
Figure IV.10 Original (12 and 13) and revised (14 and 15) structures of
Spatoglossum howleii compounds.146
CHAPTER V.
BIOLOGICALLY ACTIVE NEW COMPOUNDS FROM LYNGBYA MAJUSCULA
Abstract
A survey of marine algae for their biomedical potential has led to the discovery
of a chemically rich strain of cyanobacteria with diverse biological properties.
Bioassay-guided fractionation of the organic extract of a Curacao Lyngbya majuscula
organic extract led to the isolation of an extremely potent brine shrimp toxin with
antiproliferative activity. The structure of this new thiazoline ring-containing lipid,
curacin A, was deduced from spectroscopic information. NOe data and 1H NMR
coupling constants were used to deduce the geometry of three olefins and relative
stereochemistry of a cyclopropyl ring. The complete relative and absolute configuration
of curacin A was determined by comparison of products obtained from chemical
degradation of the natural product with the same substances prepared by synthesis.
Curacin A was shown to have a 2R, 13R, 19R, 21S absolute configuration. Curacin A
is an antimitotic agent (IC50 values in 3 cell lines ranging from 7 to 200 nM) that inhibits
microtubule assembly and the binding of colchicine to tubulin. A mixed polyketide-
amino acid (cysteine) biogenesis, analogous to ceramide biosynthesis, is hypothesized.
In addition to curacin A, a potent new ichthyotoxic depsipeptide (antillatoxin), a new
malyngamide derivative, and an unusual molluscicidal compound have been isolated
from this alga.147
Introduction
Cyanobacteria (blue-green algae) are recognized as a rich source of unusual
toxins160 and biologically active lead compounds.21 Cyanobacterial hepatotoxins
represent a worldwide health problem due to algal bloom contamination of water
supplies.161 Microcystins, a large group of cyclic heptapeptides, have been isolated
from numerous Microcystis, Anabaena, Oscillatoria, and Nostoc species.16°
Nodularins are cyclic pentapeptides which until recently were known only from various
Nodularia spp.162 '163The nodularins and microcystins act as potent hepatotoxins by
inhibiting protein phosphatases 1 and 2.164 Microcystin-LR (1, Figure V.1), the most
common microcystin peptide, displays an LD50 of 50 jug/kg inmice.165 Motuporin (2)
is a new nodularin derivative which was recently been isolated from the sponge
Theonella swinhoei.166 This discovery suggests the possibility that 2 may ultimately be
derived from symbiotic cyanobacteria or other microorganisms associated with this
marine invertebrate. Recently, Microcystis aeruginosa has been shown to
simultaneously produce a series of depsipeptides called aeruginopepsins (ie.
aeruginopepsin 917S-A, 3), which appear to enhance the toxic effects of
microcystins.167 Another potent hepatotoxin, cylindrospermopsin (4), has been
isolated from an Australian Cylindrospermopsis raciborskii (Woloszynska) culture
which was obtained following an outbreak of hepatoenteritis on Palm Island in northern
Queensland.168 Two small neurotoxic compounds, anatoxin-a (5, Figure V.2) and
anatoxin-a(s) (6) have been characterized from several Anabaena spp.
169-171Numerous
animal poisonings have been correlated to Anabaena blooms.
Lyngbya mujuscula, a cyanobacterium responsible for an inflammatory
condition known as "swimmer's itch," has been demonstrated to produce a diversity of
biologically active compounds.172 Both lyngbyatoxin A (7) and debromoaplysiatoxin148
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Figure V.2 Structures of Neuotoxic and Cytotoxic Compounds From Cyanobacteria.150
(8) (Figure V.2), pro-inflammatory cytotoxins which are now used as biochemical
tools, were first isolated from Hawaiian collections of this organism.173'174
Westiellamide (9, Figure V.3), a cytotoxic cyclic peptide has recently been
isolated from Westiellopsis prolifica (Stigonemataceae).175 The porphyrin-containing
Tolypothrix nodosa compound tolyporphrin (1 0) potentiates the antimitotic activity of
vinca alkaloids.176 Tolypothrix, Scytonema, and Cylindrospennum species have been
shown to contain cytostatic antimitotic metabolites called sytophycins.177-18° Spurred
by selective antitumor activity in vitro, one of the scytophycins, tolytoxin (1 1) is
currently under investigation as a potential new anticancer agent.21'181
Borophycin (12), a boron-containing cytotoxin, has recently been isolated from
a marine strain of Nostoc linckia (Roth).182 While 12 was potently cytotoxic to two
human tumor cell lines in vitro (LoVo: MIC 0.066 pg/mL; KB: MIC 3.3 pg/mL), it
showed no tumor selectivity.
Our survey of marine algae for biomedical potential (Chapter 2) has resulted in
the identification of several structurally diverse cytotoxic substances from microalgal
sources. Hormothamnin A (1 3), isolated from a northern Puerto Rican collection of
Honnothamnion enteromorphoides Grunow, was found to be potently antimicrobial to
Bacillus subtilus and cytotoxic to several cancer cell lines (Figure V.4).183 Caribbean
collections of the cryptophyte Chysophaeum taylori, which were tentatively
misidentified as H. enteromorphoides, were found to contain two closely related
cytotoxic styrylchromones, hormothamnione A (1 4) and 6-
desmethoxyhormothamnione A (15).184,185Compound 14 was shown to possess
pronounced cytotoxic activity toward both lymphocytic and promyelocytic leukemia cell
lines. Additionally, 15 has recently been selected for in vivo antitumor evaluation at the
National Cancer Institute.HO
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Figure V.3 Structures of Westiellamide (1 0), Tolytoxin (1 1), and Borophycin (12).L-HYPRO L-HSER 1
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Figure V.4 Biologically Active Metabolites From Microalgae Screening Efforts at the
OSU College of Pharmacy.153
Extracts of Lyngbya majuscula collected from shallow mangrove branches in
Puerto Rico were found to be antimicrobial toward pathogenic bacteria in vitro. The
most active antibacterial substance in the extract was found to be elemental sulphur;
however, the mildly cytotoxic compound malyngamide D (1 6) was also isolated (Figure
1.1.4).186
As with cyanobacteria and the cryptophyte Chysophaeum taylori the examination
of other microalgae has provided valuable lead compounds for anticancer research.
Cultures of the cryptophyte Poteriochromonas malhamensis were found to contain
compounds which have been shown to inhibit the cancer-linked enzyme protein tyrosine
kinase (PTK) in vitro. An unusual chlorinated enol sulfate derivative, malhamensilipin
A (17, Figure V.5), was subsequently isolated and demonstrated to possess PTK
activity (pp60' PTK, IC50 = 35pm).187
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Figure V.5 Structure of Malhamensilipin A (17).
Results and Discussion
24
My anticancer drug discovery efforts have focussed on a Caribbean collection of
the cyanobacterium Lyngbya majuscula which was strongly cytotoxic against a monkey
Vero cell line (ATCC CCL81) (work initiated by Dr. Lerwick). Subsequent evaluation
in the National Cancer Institute 60-cell line assay uncovered a potent antiproliferative
and cytotoxic activity showing some selectivity for colon, renal and breast cancer-
derived cell lines (Figure V.6). The NCI 60-cell line assay was not available for100
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Figure V.6 NCI 60-Cell Line Tumor Growth Inhibition Dose Response Curves for
Curacin A (18).
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evaluating our fractionation, however the extract was also highly toxic to brine shrimp
(LC50 = 25 ng/mL, Figure V.7a).98 Using the brine shrimp assay to guide
fractionation, a unique metabolite curacin A (18, Figures V.7b and V.8), isolated as 8-
10% of the crude extract, was found to be responsible for the potent brine shrimp
toxicity (LC50 = 3 ng/mL, Figure V.7) and mammalian cell antiproliferative activity
(IC50 = 6.8 ng/mL in the Chinese hamster Aux B1 cell line).
188
Isopropanol preserved L. majuscula was extracted with CHC13/Me0H (2:1).
Gradient vacuum chromatography of the crude extract (543 mg portion) gave 18
contaminated by free fatty acids. After confirming (1H NMR, GC-MS, brine shrimp
toxicity) that the bioactive component was unreactive to CH2N2, this fraction was
methylated and further purified by HPLC to yield 44.2 mg of 18 showing [GOD = +86°
(c = 0.64, CHCL3). High resolution FAB MS (positive ion, 3-nitrobenzyl alcohol) gave
a major [M+H r ion at m/z 374.2520 analyzing for C23H36NOS (0.3 mamu dev.). The
formula C23H35NOS suggested that curacin A possessed seven degrees of unsaturation,
five of which were due to double bonds and two due to rings.
Data from 1H-Ifl COSY and 1H-13C HETCOR were used to generate three
partial structures (a-c) for 1 8. Partial structure a contained a monosubstituted terminal
olefin adjacent to a methylene group (Figures V.9 and V.10). Neighboring this
methylene was a deshielded methine which was shown by HMBC to bear an OMe
group (Figure V.11). Sequential 1H-1H correlations placed two consecutive methylene
groups contiguous to this deshielded methine, the latter of which was adjacent to a
quaternary carbon, concluding partial structure a.Partial structure b possessed a
terminal methylene group bearing a heteroatom which was adjacent to a methine carbon
also bearing a heteroatom. This latter resonance coupled to an olefin proton at b 5.69,
which was in turn coupled by 10.7 Hz to its olefmic partner. Two methylene groups120
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Figure V.7a Dose-Response Curves for L. Majuscula Crude. Extract and Pure Curacin
A in Brine Shrimp Lethality Assay.
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Figure V.8 Antiproliferative and Cytotoxic Activities of Brine Shrimp Toxic L majuscula Fractions.16
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1H (boldface) and 13C (italics) NMR Data Assignments for Curacin A (18). Coupling
Constants for 18 (300 MHz, C6D6): Jia_ib = 10.7 Hz, Jla-2 = 10.0 Hz, 72_3 = 8.7 Hz, J2_4 = 1.1 Hz,
J3_4 = 10.7 Hz, 74_5 = 7.1 Hz, J64 = 7.0 Hz, J7_8 = 15.0 Hz, J8_9 = 10.8 Hz, J9.17 = 1.0 Hz, J19-20a
8.2 Hz, J20a-20b = 4.2 Hz, J2001-21 = 8.2 Hz, J21-22 = 6.2 hz.
Figure V.9 Partial Structures Used to Deduce Structure of Curacin A (18).159
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Figure V.11 1H-13C HMBC Spectrum of Curacin A (18) in C61)6.
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spanned between this olefin and a conjugated diene = 242 nm). The first of these
two latter olefins was disubstituted and trans while the second was trisubstituted and
possessed methyl and alkyl substituents at its distal position. The geometry of this latter
olefin was shown to be E by virtue of the high field 13C NMR chemical shift of the
methyl group (6 16.56) and observing nOe between the C-17 methyl group (6 1.74) and
H-8 (6 6.28) in CDC13. Partial structure c was readily formulated by spin coupling
information as a cis- disubstituted cyclopropyl ring with methyl and quaternary carbon
substituents (Figures V.9 and V.10).
HMBC data were used to connect these three partial structures as well as
confirm the above structural assignments (Figure V.11). Critically, the protons alpha to
the two heteroatoms in partial structure b were both correlated to the quaternary carbon
of partial structure c. Similarly, partial structures a and b were readily connected by
observing long range coupling between the olefinic proton at 6 6.02 (H-9) and
methylene carbon at 6 35.77 (C11). Placement of sulfur at Cl and nitrogen at C2 was
based on comparisons of 13C NMR chemical shifts with model compounds,189'19°
hence defining a thiazoline ring, and yielding the overall planar structure of curacin A
(18).
Curacin A was examined in the NCI cell line screen and its differential
cytotoxicity pattern was evaluated by the COMPARE algorithm.191 As this study
indicated that 18 was an antitubulin agent,192 it was subsequently evaluated for its
effect on tubulin polymerization. Curacin A was found to inhibit the polymerization of
purified tubulin induced either by glutamate or microtubule-associated protein dependent
microtubule assembly.193 Figure V.12 presents a study of the latter reaction condition,
comparing curacin A to podophyllotoxin, a well-studied inhibitor of the reaction.1940.3
to°
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Each 0.25 mL reaction mixture contained 1.5 mg/mL tubulin (15 iiM), 0.5 mg/mL heat-
treated microtubule- associted proteins (prepared as in ref. 10) 0.2 mM GTP, 0.2 mM MgC12, 1% (v/v)
dimethylsulfoxide (the drug solvent), 0.1 M 4-morpholineethane sulfonate (Mes) (pH 6.9 with NaOH),
and drug as follows: curve 1 (dots), none; curves 2-4 (solid), 2 ptM, 4 1.114, and 6 i.tM of curacin A,
respectively; curves 5-7 (dashes), 211M, 411M, and 6 iiM of podophyllotoxin, respectively. Baselines
were established with the cuvette contents held at 0' C; at to the reaction was initiated by a 75 sec
temperature jump to 3T C (absorbance measured at 350 nm).
Figure V.12 Inhibition of Microtubule Assembly by Curacin A and Podophyllotoxin.163
The two drugs were highly similar in their inhibitory effects, inhibiting the extent of
assembly about 50% when present at a concentration of 4 MM and nearly completely at 6
MM.
Cytotoxic agents that inhibit tubulin polymerization routinely cause the
accumulation of cells arrested in mitosis at cytotoxic drugconcentrations.I94'195 This is
also the case with curacin A. We compared it with colchicine in two cell lines (Table
V.1). The number of mitotic cells increased with both drugs as the cell number
decreased and was maximal at 1 MM, the highest concentration examined.
Furthermore, flow cytometric analysis of Chinese hamster cells treated with 18 (100
ng/mL) clearly demonstrated that the drug causes cells to accumulate in the G2/M phase
of the cell cycle; G2/M arrest was also observed with vincristine (300 ng/mL) while
hydroxyurea, a ribonucleotide reductase inhibitor (100 ng/ml) produced a distinctly
different profile (Figure V.13).
Most inhibitors of tubulin polymerization appear to interact at one of two
independent drug binding domains on tubulin and inhibit the binding of either colchicine
or vinblastine, but not both. We examined curacin A for suchinhibitory activity,
comparing it to podophyllotoxin, a known inhibitor of colchicine binding,I94 and to
maytansine, a known inhibitor of vinblastine binding195 (Table V.1). The data
demonstrate that 18 belongs to the colchicine class of inhibitors, as it inhibits the
binding of radiolabeled colchicine, but not radiolabeled vinblastine, to tubulin.
Since the relative stereochemistry of the cis-disubstituted cyclopropyl ring was
established, eight diastereomeric curacins were possible. It was hoped that constraints
on intermolecular distances from nOe difference (NOEDS) and NOESY spectra,
together with an estimation of chromophore orientation from circular dichroic (CD)
analysis, might provide enough evidence from which to construct an argument for the45
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Aux B1 cells were incubated with the indicated drugs for 30 hours in alpha-MEM supplemented
with 10% heat-inactivated fetal calf serum. Cells were harvested, washed in phosphate-buffered saline
(PBS), fixed in absolute ethanol at -20 °C, and stored overnight at 4 °C. After washing twice in PBS,
cells were resuspended in PBS containing 30 KU/mL RNase and 5 pg/mL propidium iodide and
incubated at 37 °C for 30 minutes. Samples were then placed on ice. Cell cycle analysis was perfored
using a Becton Dickinson FACStar Plus flow cytometer.
Figure V.13 Flow Cytometric Analysis of Chinese Hamster Cells Treated With a)
Ethanol Control, b) Curacin A (1 8, 100 ng/mL), c) Vincristine (300 ng/mL), or d)
Hydroxyurea (100 ng/mL).165
Table V.1 Effects of Curacin A (18) on Growth of Leukemia Cells and Ligand Binding
to Tubulin.
drug
L1210 leukemia cellsaBurkitt lymphoma cellsaligand binding (% inhibition)
ICso
(M)
Mitotic cellsb
(%)
ICso
(M)
Mitotic cellsb
(%)
colchicinecvinblastined
Curacin A (18)
Colchicine (3 6)
Podophyllotoxin
Maytansine (3 4)
9 x 10-9
4 x 10-9
46
41
2 x 10-7
1 x 10-8
51
67
76
94
0
4.6
7.5
90
a) Cells were grown for 15 hr (L1210 murine leukemia cells) or 24 hr (CA46 human Burkitt
lymphoma cells) in RPMI-1640 medium supplemented with 16% fetal bovine serum and 0.03% L-
glutamine at 37 °C in 5% CO2 atmosphere.
b) Mitotic cells are defined as those with condensed chromosomes. Drug concentration was 1.0
L1210 cells were harvested, fixed, and stained with Giemsa. The mitotic index of control cells was 2-
3 % for both cell lines.
c) The binding of 13H]- colchicine to tubulin was measured by the DEAE-cellulose filter technique.
Each 0.1 mL reaction mixture contained 0.1 mg/mL (1.0 1.1M) tubulin, 2.0 AM [3H] -colchicine
(DuPont), potential inhibitor at 10 1.1M (curacin A, podophyllotoxin) or 50 1.1M (maytansine), 1.0 M
monosodium glutamate (pH 6.6 with HCL), 1 mM MgCl2, 1 mM GTP, 0.1 M glucose 1-phosphate,
0.5 mg/mL bovine serum albumin, and 5% (v/v) DMSO. Incubation was for 30 min at 37 °C. In the
control reaction mixture, 0.20 mol of colchicine was bound per mol tubulin.
d) The binding of [31-1]-vinblastine to tubulin was measured by centrifugal gel filtration. Each 0.32 mL
reaction mixture contained 0.5 mg/mL (5.0 pM) tubulin, 10 uM [3H]-vinblastine (Amersham),
potential inhibitor at 100 MM, 0.1 M Mes (pH 6.9 with NaOH), 0.5 mM MgCl2, and 1% (v/v)
DMSO. Incubation was for 10 min at 22 °C. Triplicate 100 1,IL aliquots were placed on syringe-
columns containing G-50 (superfine) equilibrated with a solution containing 0.1 M Mes (pH 6.9) and
0.5 mM MgC12. In the control reaction mixture 0.21 mol of vinblastine was bound per mol of
tubulin.
stereochemistry of curacin A. Unfortunately, the CD spectrum of curacin A (1 8) was
uninterpretable due to its highly complex nature (Figure V.14a). Hydrogenated
derivatives were prepared to simplify the olefinic couplings observed by CD analysis.
Small quantities (less than 1 mg) of partially hydrogenated derivatives were produced by
catalytic hydrogenation of 18 with trace amounts of Pd (5%) on carbon. Subsequently,
the CD spectrum of pure 15, 16-dihydrocuracin A (19) was essentially166
Table V.2 Activity of Curacin A (18) and 15,16-Dihydrocuracin A (1 9) in Inhibition of
Tubulin Polymerization, Inhibition of Colchicine Binding to Tubulin, and the NCI 60-
Cell Line Panel.
Compound Tubulin Colchicine MG MID (60-cellSelectivity in
Inhibition Binding line panel, NCI)c TGId
(E. Hamel)(E. Hamel)
Curacin A (18)1.4 ± 0.2 itA458/95/94a-7.62/-5.17/-4.195 colon (103)
2 ovarian (103)
2 breast (103)
15,16-diH2- 1.3 + 0.1 IJM68193196b-7.79/-5.40/-4.432 NSCL (103)
Curacin A (1 9) 4 colon (103)
3 CNS (103)
1 ovarian (103)
a) Three numbers represent % inhibition of colchicine binding at 2 ktM, 5 501.1M
of the indicated compound.
b) Three numbers represent % inhibition of colchicine binding at 1 iuM, 2.5 1,tM, 5.0
of the indicated compound.
c) The three values given are the "means of all 60-cell lines" for the G150/TGI/LD50
intercepts, respectively. (GI = growth inhibition).
d) The number in parenthesis represents approximate fold greater of the indicated cell
lines to the effects of the indicated compound. (TGI = total growth inhibition).
indistinguishable from that of natural 18 (Figure V.14b). No direct answers to the
question of curacin A stereochemistry were provided by CD spectrum of 19. However,
this result suggests that, in regard to chromophoric disposition, both curacin A and
dihydrocuracin A adopt similar solution conformations, a critical point in establishing
the nature of structure-activity relationships. Further, tubulin inhibition studies,
colchicine binding experiments, and NCI 60 cell line antiproliferative data confiinied
that this new derivative 19 is nearly identical in activity and potency with natural curacin
A (Table V.2).20
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Figure V.14 CD Spectra of Curacin A (1 8, Above) and 15,16-Dihydrocuracin A (1 9,
Below).168
The absolute configuration of curacin A (1 8) remained unassigned. Crucial to
developing a more complete appreciation for the nature of the interaction between
curacin A and its biomolecular target, and as an essential precondition for efforts aimed
at its synthesis, I undertook a degradative approach (collaboration with Dr. James
White, OSU Chem. Dept.) to define its relative and absolute stereochemistry.
The strategy for determination of the C13 stereochemistry in 18 hinged upon
ozonolysis of the C9-C10 olefin to produce a methyl ketone. However, when curacin A
was subjected to ozonolysis directly, I was unable to recover a fragment deriving from
the C9-C17 region. Suspecting that the C15-C16 olefin was responsible for this
undesired reactivity, curacin A was partially hydrogenated with Wilkinson's catalyst to
yield a mixture of 15,16-dihydrocuracin A (19, Figure V.15) and 3,4,15,16-
tetrahydrocuracin A (2 0) by GC-MS analysis. This mixture was ozonized and the
ozonide was reduced with excess dimethyl sulfide to yield, following chromatography,
5-methoxyoctan-2-one (21). The latter was fully characterized by 'H and 13C NMR and
GC-MS, and showed [a],2,3 +14.2° (c 0.22, CDC13). Elucidation of the R configuration
of this fragment was achieved through comparison with (+)-2 1 obtained by
enantiospecific synthesis.
Allylation of 4-pentynal (2 2), prepared by Swern oxidation of the
corresponding alcohol, with the allylboronate 2 3 derived from (R,R)-(+)-diisopropyl
tartrate'96 gave (5R)-1-octyn-7-en-5-ol (2 4, Figure V.15). After conversion of 2 4 to its
methyl ether 2 5, the latter was treated with dicyclopentadienylzirconium dichloride in
the presence of trimethylaluminum and then with iodine, to yield the E-iodooctadiene
2 6.197 Selective hydrogenation of the vinylic olefin of 2 6 was accomplished with
Wilkinson's catalyst and the resultant alkene was ozonized to afford, after reductive
workup, (5R)-methoxyoctan-2-one (21), 1035 +10.0° (c 0.50, CDC13). This0
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Figure V.15 Convergent Formation of Methylketone 21 From Total Synthesis and
From Chemical Degradation of Curacin A (18).
I
substance was identical by comparison of 1H and 13C NMR and GC-MS with the
material obtained by degradation of curacin A (Figure V.16).
The strategy for determining the configuration of the C2, C19, and C21
stereocenters in curacin A originally envisioned oxidative cleavage of the C3-C4 olefin
and recovery of a methylcyclopropyl- and carboxyl-substituted thiazoline that would be
compared with synthetic substances of known chirality. However, ozonolysis of
curacin A (-78 °C, CHC13, 2 min), followed by oxidative workup (H202, 45 °C, 16 hr)
and then reaction with excess CH2N2 in Et20, gave after flash chromatography and
HPLC, methyl sulfonate derivative 2 7, [alp -17.1° (c 0.12, Me0H) (22% overall-014e
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Figure V.16 1H NMR Spectrum of Methylketone 21 in CDC13.171
yield). The sulfonate 2 7 (Figure V.17), of molecular constitution C101-117NO6S ,
displayed IR stretching absorptions for ester (1738 cm-1), amide (1637 cm-1) and
sulfonate (1353, 1170 cm-1) functionalities. The methylcyclopropyl and H2-1H-2
NH spin systems were readily evident in the 1H NMR spectrum of 2 7, as were two
ester methyl groups at 6 3.88 and b 3.82. By HMBC, we were able to connect the latter
signal to a 6 169.2 carbonyl which in turn showed 3-bond coupling to the Cl methylene
protons, thereby providing assignment of the two methyl groups.196 Combination of
these two partial structures through the remaining elements of the molecular formula,
"CO", completed the structure determination of this degradation product (2 7) .
This assignment was confirmed and the absolute configuration of 2 7 was
established by an asymmetric synthesis from cis crotyl alcohol (2 8, Figure V.17). The
latter, prepared by hydrogenation of 2-butyn-l-ol over Lindlar's catalyst, was
cyclopropanated with diethylzinc and diiodomethane in the presence of the n-butylboron
complex of (S,S)-(-)-N,N,NI,N'-tetramethyltartaramide (2 9) to give 3 0 in >95% ee.198
Oxidation of 3 0, first with perruthenate199 and then with sodium chlorite,200,201 afforded
(1R,2S)-2-methylcyclopropanecarboxylic acid (3 1) which was coupled with (R)-(-)-
cystine dimethyl ester dihydrochloride using DCC and HOBT.202 The resulting
disulfide 3 2 was ozonized and the crude product was treated with diazomethane to
furnish 2 7, 10; -21.4° (c 0.21, Me0H), identical by comparison of 1H (Figure V.18)
and 13C NMR and GC-MS with the corresponding substance obtained by degradation of
curacin A. A stereoisomer of 2 7 derived from (1S,2R)-2-methylcyclopropane-
carboxylic acid, prepared with the tartaramide complex antipodal to 2 9, was
distinguishable by 1H NMR,13C NMR and GC-MS from the sulfonate derived from
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These results fully define the absolute configuration of curacin A (1 8) .It is
noteworthy that 18 possesses R configuration at the a-amino center (C2), a fact
consistent with the thiazoline portion of the molecule being derived from L-cysteine.
From chemical and biochemical perspectives, the alkylated thiazoline clearly
represents the structurally unique portion of curacin A. In this respect, it bears some
relationship to the potent cytotoxins patellazoles A-C (patellazole C (3 3) , Figure V.19)
from the tunicate Lissoclinum patella.203 Similar to curacin A, these latter metabolites
possess a four carbon branch, three membered ring, and a long polyketide chain
substituents on a thiazole ring. The relationship of heterocyclic ring to diene
chromophore in curacin A is similar to that seen in the patellazoles as well as two other
antimitotic agents, maytansine (3 4) and rhizoxin (3 5) . However, these latter two
metabolites inhibit the binding of vinblastine, but not colchicine (3 6),to tubulin.202 In
fact, the interaction of curacin A (18) with the colchicine binding domain of tubulin is
remarkable, considering the lack of apparent structural similarity between the two
molecules (Figure V.20).
Biosynthetically, curacin A may derive from two polyketides joined together
through a decarboxylated cysteine residue (Figure V.21). The C3-C16 portion of 18
may be formed by condensation of a partially reduced and dehydrated polyketide chain
with a cysteine derived unit (Figures V.21 and V.22), a sequence analogous to
sphingolipid biosynthesis (Figure V.23). Alternatively, carbons 3 through 16 may arise
from a cysteine starter unit initiated polyketide chain formation (not shown). The origin
of the Cl'-05' cyclopropane containing unit is less clear. This five carbon unit may
derive from mevalonic acid, a polyketide, or an amino acid precursor (Figure V.22).
While curacin A (18) was the major secondary natural product in this Lyngbya
sp., other unusual compounds were apparent in the extract by TLC. Subsequently,175
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Figure V.19 Cytotoxic Agents With Similar Structural Features to Curacin A (1 8).176
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Figure V.20 Comparison of 3-Dimensional Energy Minimized (Chem 3D Plus)
Structures of Curacin A (1 8) and Colchicine (3 6) .0
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I evaluated crude L. majuscula extracts and purified ichthyotoxic compounds using a
goldfish (Carassius auratus) toxicity assay. Both lethality (LD50's) and sedation as
measured by a loss of ability to swim against a manually induced current (EC50' s) were
evaluated. The crude L. majuscula extract was potently ichthyotoxic (LC100 < 25
pg/mL). I was surprised to find that pure 18 showed essentially no fish toxicity.
However, on several separate occasions, goldfish tested with 18 showed signs of
pathogenic infection and died within a week following exposure.
Bioassay-guided fractionation of the extract (silica gel, Sephadex LH 20, and
reversed-phase ODS silica) led to the isolation of a new ichthyotoxic metabolite, 3 7,
and a previously described compound, 7-methoxytetradec-4(E)-enoic acid (3 8, Figure
V.24).204 The structure of 3 7 was determined by a combination of 1- and 2-D NMR
(Dr. Orjala). The absolute stereochemistry of the cyclohexenone moiety was deduced
by a combination of NOESY and circular dichroic (CD) spectroscopy. Compound 3 7
is the newest in a series of related Lyngbya metabolites known as malyngamides A-
G 186,204-209 andwas therefore named malyngamide H. Malyngamide H (3 7) is
structurally similar to deacetoxystylocheilamide (3 9), isolated from the sea hare
Stylocheilus longicauda.21° However the structure of 3 7 represents a new carbon
skeleton and lacks the characteristic vinylic chloride associated with other
malyngamides previously identified from L. majuscula. Remarkably, malyngamide H
(3 7) is moderately ichthyotoxic (LC50 = 5 pg/mL, EC50 = 2 tig/mL, Figure V.25), yet
is inactive in the brine shrimp assay. Malyngamide A, found in Hawaiian collections of
L. majuscula, has been reported to act as an antifeedant.211 This class of chemistry may
play an ecological role as herbivore deterrents.
The relatively moderate potency and low yield of 3 7 (0.32% of crude extract)
could not fully explain the ichthyotoxicity of the crude extract. Careful examination of14'
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Figure V.24 Structures of Malyngamide H (3 7), 7-Methoxytetradec-4(E)-enoic Acid
(3 8), and Deacetoxystylocheilamide (3 9).
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Figure V.25 Ichthyotoxic Effects of Malyngamide H (3 7).
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chromatographic fractions prepared during isolation of 3 7 were consistent with a loss of
activity during separation which suggested that a minor component in these fractions
was responsible for a considerable portion of this extract's toxicity. Due to the
extremely low concentration of this toxic substance it was impossible to follow its
isolation with conventional TLC analysis. Therefore, I utilized a bioassay-guided
isolation protocol, evaluating the ichthyotoxic potential of all chromatographic fractions.
Figure V.26 shows the chromatographic separation used to isolate a fish-toxic minor
compound which we have given the name antillatoxin (4 0, Figure V.27). Antillatoxin
(4 0) is a rapidly acting and extremely potent ichthyotoxin (Figure V.28). Its toxicity
may be vertebrate specific as it does not effect either brine shrimp or the mollusc
Biomphalaria glarnbrata.
I evaluated L. majuscula fractions for molluscicidal activity and detected the
presence of a snail toxic metabolite which we subsequently isolated. The structure of
the molluscicidal agent, barbarmide A (41, Figure V.27), was deduced
spectroscopically (Dr. Orjala). Like 4 0, the toxic effects of 41 appear to function rather
selectively. Barbarmide (41) is not toxic to brine shrimp or fish.
Investigation of the cyanobacterium L. majuscula has led to the isolation of a
remarkable number of biologically active natural products. These potent toxins may
play an important ecological role in the survival of this species. Implementation of
multiple screening techniques in the chemical evaluation of this organism was a crucial
factor leading to these discoveries. Great potential for the further discovery of unique
marine derived lead compounds appears limited only by our understanding of the
complex relationships between ecology and biologically active chemistry.183
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Figure V.28 Ichthyotoxic Effects of Antillatoxin (40).
Experimental
General Methods. UV spectra were recorded on a Hewlett Packard 8452A diode
array spectrophotometer and IR spectra were recorded on a Nicolet 510 FT-IR
spectrometer. CD measurements were obtained on a Jasco 41A spectropolarimeter.
Low resolution mass spectra were obtained on either a Varian MAT CH7 spectrometer
or by GC-MS using a Hewlett Packard 5890 Series II gas chromatograph and a 5971
mass selective detector. HRMS were obtained on a Kratos MS 50 TC. H PLC was
performed using a M-6000 pump, U6K injector, and either a R401 differential
refractometer or a lambda-Max 480 lc spectrophotometer. NMR data were obtained on
either Bruker AC 300 or Bruker AM 400 spectrometers. 1H NMR spectra were
acquired with tetramethylsilane (TMS) as an internal chemical shift reference. 13C
spectra referenced to the center line of CDC13 at 77.0 ppm or C6D6 at 128.0 ppm. 13C186
assignments are based on 1H-' 3C HETCOR, DEPT multiplicity data, and comparison
with previously identified derivatives. TLC-grade (10-40 pm) silica gel was used for
vacuum chromatography and Kieselgel 60 silica (40-63 pm) was used for flash
chromatography.Aluminum-backed thin-layer chromatography sheets were used for
TLC, and all solvents were distilled prior to use.
Isolation of Curacin A (18). One liter of Lyngbya majuscula was collected from
CARMABI beach, Curacao, Netherlands Antilles, -0.3 m, 13 December 1991 and
preserved in isopropyl alcohol. Compound 18 is named to reflect this site of collection.
The collection was repetitively extracted with CHC13/Me0H (2:1, v/v) and a 543 mg
batch of the extract was separated by successive tiers of silica gel vacuum
chromatography. Fatty acid contaminants were separated by treatment with
N2CH2/Et20 and HPLC (5% EtOAc in hexanes, 2 x 30 cm Versapack Silica 10p,
collected elution volume 57-66 ml) to isolate curacin A (18, 44.2 mg, 8.1%).
Curacin A .(1 8). FTIR v21,', cm-1: 2928, 1618, 1439,1381, 1097, 1074, 1054,
964; [c]P +86° (c 0.64, CHC13); UV 1211P nm: 242 (log E = 4.60); CD (CH3CN):
AC = -9.7, +16.4 (Amax = 257, 229.5 nm); GC ELMS 70 eV m/z (rel. int.): 373 [Mr
(3), 358 [M CH3I+ (7), 342 [M- (8), 332 (12), 300 (7), 288 (5), 274 (11),
180 [M Ci3H21o]+ (100) 166 (8), 140 (12), 119 (13), 105 (16), 91 (22), 79 (25); HR
FABMS (positive ion, 3-nitrobenzyl alcohol) m/z obs.+ }11+ 374.2520
(C23H36NOS, 0.3 mmu dev.).
Partial Hydrogenation of Curacin A (18) with Pd on carbon to produce 15, 16-
dihydrocuracin A (19). Compound 18 (14.39 mg, 38.6 pmol) was dissolved in
absolute EtOH (0.50 mL) and 0.2 mg of Pd on activated carbon (5%, 0.094 prnol) was
added. A balloon filled with H2 was attached. After stirring for 3 h, the reaction was
passed through a Celite® plug (1 cm) which was subsequently flushed with hexanes.187
The solution was reduced in vacuo. Final purification by RP-HPLC (5-11 Partisil ODS
C18 Silica column, 250 x 5.0 mm, 95% (v/v) Me0H in H2O, UV detection at 254 nm;
flow rate at 0.8 mL/min) provided 15, 16-dihydrocuracin A (1 9) as a colorless oil (0.21
mg, 0.56 pmol, 1.5% yield) and unreacted 1 8.
15.16-dihydrocuracin A (1 9). FTIR cm-1: 2929, 1617, 1449, 1439, 1380,
1093, 1074, 1053, 962; [a]° +60° (c 0.22, CHC13); UV X,1%,4,rnm: 241 (log E =
4.57); UV 4,110 nm: 242 (log E = 4.53); CD (CH3CN): AE = -7.24, +13.1 (Xmax =
257, 229 nm); 1H NMR (C6D6, 400 MI-lz) 6 6.41 (dd, 1H, J = 15.0, 10.8, H-8), 6.05
(bd, 1H, J = 10.8, 1-2, H-9), 5.70 (dd, 1H, J = 10.7, 9.0, H-3), 5.60 (dt, 1H, J =
15.0, 6.2, H-7), 5.46 (dt, 1H, J = 11.1, 6.3, H-4), 5.11 (bq, 1H, J8-9, H-2),
3.22 (s, 3H, -OMe), 3.10 (dd, 1H, J = 10.7, 8.4, H-lb), 3.1 (m, 11-1, H-13), 2.80
(dd, 1H, J = 10.7, 9.8, H-la), 2.2 (m, 2H, H-11), 2.1 (m, 4H, H-5 and H-6), 1.74
(bs, 3H, H-17), 1.6-1.72 (m, 5H, H-12, H-15, and H-19), 1.41 (m, 2H, H-15), 1.23
(d, 3H, J = 6.1, H-22), 1.2 (m, 1H, H-20b), 0.95-1.04 (m, 1H, H-21), 0.76 (td, 1H,
J = 8.1, 4.3, H-20a); 13C NMR (C6D6, 100 MHz) 6 168.61(C18), 136.62 (C10),
131.31 (2C, C3 and C7), 130.88(C4),127.72(C8),125.42(C9),80.20(C13),74.35
(C2),56.18 ( -OMe), 39.95 (C1),35.98(C14),35.80(C11),33.13(C6),32.21(C12),
28.15(C5), 20.12 (C19), 18.79 (C15),16.64 (C17),15.97 (C21),14.49(C16),
14.23 (C20), 12.32 (C22); GC EIMS 70 eV m/z (rd. int.): 375 [M]+ (6), 360 Uvl
CH31+ (8), 344 [M OCH31+ (6), 302 (3), 288 (12), 274 (11), 180 [M C13H2301+
(100) 166 (22), 140 (15), 107 (14), 93 (21), 79 (26), 67 [C5H7I+ (12), 55 [C4H71+
(13); HR EIMS m/z obs. IM1+ 375.2594 (C23H37NOS, -0.17 mmu dev.).
Selective Hydrogenation of Curacin A (1 8) with Tris-(triphenylphosphine)-
rhodium (I) chloride, [(C6H5)3E13RhC1, "Wilkinson's catalyst" and Ozonolysis to form
methyoxy ketone derivative (21). Curacin A (18, 49.0 mg, 131 ktmol) was dissolved188
in absolute EtOH (0.50 mL), placed in a 4-dram vial, and a solution consisting of 11.3
mg of [(C6H5)3P13RhC1, 99.99%, 12.2 pmol) in 0.50 ml dried CH2C12 was added.
The mixture was diluted with an additional 2.5 ml CH2C12 and a balloon filled with H2
was attached. After stirring for 7 h, the Wilkinson's catalyst was removed by eluting
the reaction mixture through a silica plug (1 cm, TLC-grade) with 20 ml EtOH, then
through a second plug with 20 ml Et20. GC-MS analysis of the recovered material
showed it to consist primarily of 3,4,15,16-tetrahydrocuracin A (2 0). The product (55
mg) was reduced in vacuo, redissolved in 25% (v/v) Me0H in CH2C12 (ca. 4 ml), and
cooled to -78 °C (acetone/CO2 [s]). Ozone was bubbled through the solution (45 min,
0.2 L/min), at which time the solution was allowed to warm to 23 °C. Dimethyl sulfide
(130 pL) was added to the ozonide mixture. The vial was stoppered and allowed to
stand at RT overnight. After 18 hours, the solvent was carefully evaporated in vacuo
(volatile product) and redissolved in pentane. The solution was subjected to silica gel
flash chromatography using a stepwise gradient from 0 to 100% (v/v) Et20 in pentane.
The fraction eluting with 25% Et20 in pentane was purified by HPLC (dual 10-pm
Alltech Versapak Si columns; 300 x 4.1 mm; 10% (v/v) EtOAc in hexanes; UV
detection at 254 nm; flow rate 2.5 mL/min) to give methyoxy ketone derivative (21) as a
colorless oil (4.0 mg, 25.3 innol, 19.3 % overall yield).
3,4,15,16-tetrahydrocuracin A (2 0). GC ELMS 70 eV m/z (rel. int.): 377 [M]+
(31), 362 [M CH3]+ (41), 346 [M OCH3]+ (29), 334 [M C3H7]+ (12), 302 (12),
290 [M C5H1 10]+ (33), 276 [IV C6H1 30]+ (67), 262 [M C7H1 501+ (14), 234 (20),
222 (12), 208 (33), 194 (28), 180 [M C13H230]+ (40), 176 (50), 166 (35), 154
[C8H12SN]+ (56), 140 [C71110SN]+ (100), 113 (17), 107 (27), 105 (31), 99 [C5H7S1+
(21), 93 (45), 91 (40), 87 [C5H110]+ (52), 81 (39), 79 (51), 67 [C5H7]+ (26), 55
[C4H7 1+ (36);189
5-methoxyoctane-2-one (2 1).FTIR van, cm-1: 2958, 2932, 2886, 2874, 1717,
1457, 1361, 1205, 1164, 1129, 1092; NIP +14.2° (c0.22, CDC13); 1H NMR
(CDC13, 400 MHz) 6 3.30 (s, 3H, -OCH3), 3.16 (ddd, 1H, J = 6, 5, 5, H-5), 2.50
(m, 2H, H-3), 2.15 (s, 3H, H-1), 1.79-1.87 (m, 1H), 1.67 (6-lines, 1H), 1.50 (m,
1H), 1.30-1.41 (m, 3H), 0.92 (t, 3H, J = 7.0, H-1); 13C NMR (CDC13, 100 MHz) 6
208.92 (C-2), 79.75 (C-5), 56.39 (OCH3), 39.28, 35.59, 29.94, 27.33, 18.52, 14.21
(C-8); GC EIMS 70 eV ink, (rel. int.): 143 IM CH3r (6), 126 (2), 115 (100), 100
(13), 87 (39), 83 (38), 72 (28), 71 (18), 55 (35).
Formation of Dimethyl Sulfonate Derivative 2 7. Curacin A (18, 13.0 mg, 34.9
ttmol) was placed in a 4-dram glass vial, dissolved in 1.5 mL CHC13, and cooled to -77
°C (acetone/CO2 [s]). Ozone was bubbled through the solution (2 min), at which time
the solution was allowed to warm to 23 °C and reduced in vacuo. The ozonide was
dissolved in AcOH (1.0 mL, glacial) to which H202 (0.3 mL, 30%) was added. The
vial then was stoppered and placed in a sand bath at 45 °C. After 16 hours, the solvent
was evaporated under N2 at 45 °C, dissolved in Me0H (0.25 mL) and allowed to react
with an excess of N2CH2/Et20 (2 min.). The solution was then dried in vacuo,
subjected to silica gel flash chromatography using a stepwise gradient from 10 to 100%
(v/v) EtOAc in hexanes. The fractions eluting with 50 to 80% EtOAc in hexanes were
combined and further purified by NP-HPLC (10-1.1 Phenomenex Maxsil Si column; 500
x 10.0 mm; 40% (v/v) EtOAc in hexanes; differential refractometer detection; flow rate
at 6.0 mL/min) to give 2.1 mg pure derivative 2 7 (7.53 jumol, 21.6% yield). FTIR vmaX
cm-1: 3340, 1738, 1637, 1536, 1353, 1275, 1182, 1170, 996, 833; [45 -17.1° (c
0.12, Me0H); 1H NMR (CDC13, 300 MHz) 6 6.62 (bd, 1H, J6, N-H), 4.90 (dt,
1H, J = 7.3, 4.8, 4.7, H-2), 3.88 (s, 3H, -S03CH3), 3.82 (s, 3H, -CO2CH3), 3.79
(d, 21-1, J = 4.8, H-1), 1.55 (m, 1H, H-2'), 1.26 (m, 1H, H-4'), 1.16 (d, 3H, J =190
6.1, H-5'), 0.95 (m, 2H, H-3'); 13C NMR (CDC13, 75 MHz) 6 171.80, 169.16,
56.04, 53.23, 50.12 (C-1), 48.81, 20.29 (C-2'), 15.68 (C-4'), 13.00 (C-3'), 11.97
(C-5'); GC EIMS 70 eV m/z (rel. int.): 279 IMI+ (7), 264 [M CH3]+ (1), 248 IM
OCH3_1+ (1), 220 [M -CO2CH3 r (18), 198 (43), 196 FM C5H701+ (9), 184 [M
SO3CH3]+ (4), 164 (9), 138 (36), 83 [C5H701+ (100), 55 (29); HR ELMS m/z obs.
[M]+ 279.0775 (C10H17NO6S, -0.15 mmu dev.).191
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APPENDIX
NEW SPHINGOLIPIDS FROM THE OREGON MARINE SPONGE HALICHONDRIA
PA NICEA
Abstract
A novel sphingolipid containing an iso-fatty acid, (4E, 8E )-N-13'-methyl-
tetradecanoy1-1-0-13-D-galactopyranosy1-4-sphingadiene, was isolated from the Oregon
marine sponge Halichondria panicea and its structure determined using a combination of
spectroscopic and chemical degradation techniques. A second galactosyl-ceramide which
contained an unusually long chain fatty acid amide component was also isolated from H.
panicea.206
Introduction
Sponges have long been recognized to be a rich source of structurally novel lipids
including unique sterols, fatty acids, phospholipids, and triglycerides." The major point
of structural novelty in sponge sterols is the incorporation of additional carbon atoms as
branches on the side chain. Further, the unique fatty acids, either in free form or as present
in phospholipids and triglycerides, not only incorporate additional branch carbons, but
many are of unusual length with unique patterns of unsaturation. These findings suggest
that fundamental differences may exist between sponge membranes and those of all other
animals. While the presence of sphingolipids in sponges was first suggested from TLC
evidence over twenty years ago,4'5 structural proof for the existence of cerebrosides in
sponges was not provided until the mid-seventies.6 Recently, Halichondria japonica has
been shown to contain galactosylceramides with branches in the sphingosine base portion.7
Results and Discussion
As part of our continuing evaluation of the chemistry of Pacific Northwest marine
organisms,8 the lipid extract of the marine sponge Halichondria panicea Pallas
(Homorrhaphidae, Demospongiae) was found to possess several interesting acid-charring
compounds by TLC and appeared to warrant further investigation. Herein we report our
isolation and structure elucidation of a novel galactopyranosyl-((31-1")-ceramide from this
temperate water sponge which contains an iso-fatty acyl group.
The CHC13 -MeOH (2:1) extract of H. panicea was largely a complex mixture of
homologous glycolipids (21%). These were separated following acetylation of the crude
mixture (Ac20-pyridine) by repeated Si gel vacuum chromatographic separation and rp-
hplc. High field 1H-NMR analysis of the glycolipid mixture before acetylation showed
there to be no acetate groups of natural origin. In this fashion, the polar acid-charring207
compound (1) was first isolated as the optically active per-acetate derivative (2, Figure
A.1), and its molecular formula determined asC4 9H8 3013N1by negative ion hr-FABMS.
1 R=H
2R=COCH3 MeO
14
(4) R=H
(5)R=COCH3
Figure A.1 Structures of Halichondria panicea Sphingolipids.
Four spin systems were determined in 2 from analysis of the 1H-1H COSY (Table
A.1). The first 1H-1H spin system was that of a sugar moiety, assigned as the tetra-acetate
ester of a 13-galactopyranosyl residue from 3J nu values and a comparison to models.9,10
From observation of a correlation between the signals at 6 4.34 (m, H-2) and 6 5.72 (d, J
= 4.2, N-H) a second spin system was established as the C-3 acetate ester of a mono-
unsaturated sphingosine base unit.
A third spin system was assigned as a saturated ceramide acyl group. A 61-1 signal
in the methyl region, 6 0.86 (d, J = 6.6), was correlated to a methine resonance at 6 1.51
(m) and suggested that either the sphingosine base or the acyl chain contained a terminal
gem-dimethyl group.Overlap in the methylene region made placement of the gem-
dimethyl group and chain length determination impossible from 1H-NMR alone.208
Table A.1'H and 13C NMR Data for Derivative 2a.
C# 1H NMR 13C NMR
1(A)
(B)
Sphingosine Base
67.14 3.58 dd (10.4, 4.5)
3.94 dd (10.4, 4.2)
2 4.34 m 50.52
3 5.26 t (6.8) 73.76
4 5.4 m 124.92
5 5.80 dt (15.3,6.2) 136.25
6 2.1 m 32.44b
7 2.05 m 32.0313
8 5.39 m 128.98
9 5.41 m 131.28
10 1.96 q (6.6) 32.63
11 1.3 m 29.2-.9c
12 1.26 m 29.2-.9c
13 1.26 in 29.2-.9c
14 1.26 m 29.2-.9c
15 1.26 in 29.2-.9c
16 1.26 m 29.2-.9c
17 1.25 in 29.2-.9c
18 0.88 t (6.5) 14.12
Sugar
1' 4.44 d (7.8) 101.03
2' 5.15 dd (10.4,7.8) 68.88
3' 5.00 dd (10.4,3.2) 70.76
4' 5.4 in 66.95
5' 3.90 t (6.6) 70.76
6' 4.13 dd (6.6) 61.24
Fatty Acid
N-H 5.72 d (4.2)
1" 172.68
2" 2.14 in 36.89
3" 1.62 m 25.72
4" 1.3 m 29.2-.9c
5" 1.26 in 29.2-.9c
6" 1.26 m 29.2-.9c
7" 1.26 in 29.2-.9c
8" 1.26 m 29.2-.9c
9" 1.26 m 29.2-.9c
10" 1.26 in 29.2-.9c
11" 1.26 in 29.2-.9c
12" 1.14 ci (6.8) 39.09
13" 1.51 in 27.99
14",15" 0.86 d (6.6) 6H 22.66 (2C)
Acetate Esters
2.17 s 21.12d170
2.06 s 20.83d170
2.05 s 20.67d170
2.05 s 20.67d170
1.99 s 20.65d170
a) All 1H NMR spectra recorded at 400 MHz and 13C NMR spectra at 100 MHz in CDC13 with 0.05%
TMS as internal chemical shift reference.
b-d) Values with the same superscript may be interchanged.209
However, the positional attachments of the sugar, sphingolipid base, and fatty acid amide
moieties were established from spectroscopic comparison with well characterized
galactopyranosyl-((31-1')-ceramide analogues.6'10'11
The length and branching pattern of the fatty acyl chain was determined by base
hydrolysis of derivative 2 (10% KOH in Et0H-H20), methylation (CH2N2 in Et20), and
lr-GCMS. Although, the lr-MS fragmentation pattern for this fatty acid methyl ester (3)
gave a 93% match with that of a standard sample of methyl n-pentadecanoic acid, the
presence of a gem-dimethyl group in 3 was confirmed by1H-NMR analysis which
established its structure as the methyl ester of 13-methyl-tetradecanoic acid (iso-
pentadecanoic acid).
The trans (E) configuration of the C-4 and C-8 double bonds in derivative 2 was
assigned by a combination of 1H coupling constants, 13C chemical shifts, and comparison
with known C-4, C-8 diene sphingolipids.
10-12The length of the sphingosine backbone
was deduced from consideration of the molecular composition of derivative 2 and 3, and
the partial structures described above, thus defining the structure of 1 as (4E, 8E )-N-13'-
methyl-tetradecanoy1-1-0-15-D-galactopyranosyl-4-sphingadiene.
Further study of H. panicea's polar lipids resulted in the partial isolation of a
number of sphingolipid constituents including compound 4 (Figure A.1). These isolation
efforts were complicated by the occurrence of a number of structural homologs within each
structure class of sphingolipid. Comparison of1H-NMR, 13C-NMR, 1H-1H COSY,1H-
1 3CHETCOR, as well as lr-FABMS established compound 4, isolated as its per-acetate
derivative 5, as a structural analogue of derivative 2 differing in the absence of a gem-
dimethyl grouping, C-8 olefin, and the length of the fatty acid amide and sphingolipid base
chains (Table A.1). The principal methyl ester (82%) of the fatty acyl chain obtained from
5 upon base hydrolysis and methylation was shown to be methyl-docosanoate by lr-GCMS
(m/z 354 [Mr). Correspondingly, the sphingolipid backbone chain length was deduced210
from hr-MS, yielding the structure of 4 as (4E )-N-docosanoy1-1-0-13-D-galactopyranosy1-
4-hexadecasphinganine. The fatty acid amide chain lengths of several structurally related
minor impurities in this preparation of derivative 5 were determined from lr-GCMS of their
corresponding methyl ester derivatives (5 b, eicosanoate, 10%; 5 c, tetracosenoate, 6%; 5 d,
tricosanoate, 1.7%; see experimental).
Djerassi and coworkers have suggested that the unusual branched and elongated
fatty acyl chains found in sponge phospholipids may be the result of necessary adaptations
to impart fluidity deep within the membrane bilayer, and may have evolved in conjunction
with the "fluidizing" methylated sterols found in these marine animals.13 If these unusual
sterol and phospholipid structural modifications are important to functional characteristics
of sponge membranes, it is conceivable that other membrane components, including the
sphingolipids, may have evolved similar methylation and chain elongation patterns. This
study of the novel sphingolipid chemistry of H. panicea, which contains these unusual
methylation and chain length modifications, supports this hypothesis. Compound 1 is, to
our knowledge, the first reported ceramide to contain an iso-fatty acid at C-2.
Experimental
Spectroscopic Data. Ir spectra were recorded on a Beckman Acculab 7
spectrophotometer. Optical rotation(s) was measured on a Perkin Elmer Model 141
polarimeter using a 10-cm microcell. NMR spectra were obtained at 400 MHz for 1H and
100 MHz for 13C on a Brucker AM 400-NMR spectrometer, and all shifts are reported
relative to an internal TMS standard. Low resolution gas chromatography-electron impact
mass spectra (Ir GC-EIMS) of methylated fatty acid fragments were obtained on a Finnigan
4023 spectrometer, and low and high resolution mass measurements (hr-MS) of acetylated
glycosphingolipids were obtained on a Kratos MS 50 TC. I-Iplc employed a Waters M-211
6000 pump, U6K injector, R 401 differential refractometer, and TLC used Merck
aluminum-backed TLC sheets (Si gel 60 F254) with 50% H2SO4 as a spray indicator. All
solvents were distilled from glass prior to use.
Sponge Material. Halichondria panicea (collection SH 15V1187-1: voucher
available from WHG) was collected from exposed low intertidal rock surfaces (-1.0 to -0.5
m) at Strawberry Hill on the Oregon coast in July 1987. The sponge material was
immediately frozen at the site in CO2 (s) and stored at -20°.
Extraction and Isolation of Glycosphingolipids. The sponge (1 gallon) was broken
into small pieces and extracted with 2 L of CHC13 -MeOH (2:1) to produce 10.9 g of a dark
green-brown oil. Vacuum chromatography of this extract over normal phase Si gel and
eluting with mixtures of EtOAc in isooctane gave 10 fractions. TLC showed that fractions
5 and 6 contained a nearly equal distribution of extremely polar non-uv active acid-charring
substances. These fractions were combined (2.3 g) and acetylated over an 18-h period at
room temperature in 6 ml of Ac20-pyridine (1:1). The reaction was terminated with the
addition of ice and then H2O and extracted (4X) with Et20. The combined Et20 layers
were sequentially washed with 5% HCI (3X), saturated NaHCO3 (3X), distilled H2O
(2X), and then dried over MgSO4. Following filtration the solvents were removed in
vacuo to yield 2.0 g of oil. The oil was then subjected to additional vacuum
chromatography over Si gel and eluted with mixtures of EtOAc in isooctane to give 9
fractions (1'-9'). Fractions 3' and 4' were shown by TLC to contain nearly all of the
acetylated material. RP-hplc (10 mm X 25 cm LiChrosorb 7 iLt C-18 column, 5% H2O in
Me0H ) of fraction 3' (0.652 g) resulted in the separation of 15 structurally related per-
acetate derivatives including derivative 2 (44.8 mg). RP-hplc (conditions as above) of
fraction 4' (0.652 g) resulted in the isolation of a similar, if not identical, set of related
derivatives including derivative 5 (23.8 mg).212
Preparation of Fatty Acid Derivatives. The fatty acyl components of the
glycosphingolipids were obtained by reaction of the per-acetylated glycosphingolipid
derivatives with 10% KOH in Et0H-H20 (4:1), reflux for 20-h. The hydrolysate was
adjusted to pH 4 with 5% HC1 and partitioned between CHC13 and H2O (3X) after removal
of the EtOH in vacuo. The organic extract was then washed repeatedly with distilled H2O
to remove any salts. The fatty acids were methylated (1-2 ml CH2N2 in Et20, 1-h) and
purified by hplc (4.1 mm X 30 cm Versapack® Si 101.1 column, 2% EtOAc in isooctane) or
analyzed directly by lr-GCMS.
Derivative 2. Oil, it (CC14) 3100, 3004, 2390, 1720, 1661, 1346, 1225, 1070
cm-1; [a ID-11.7° (c=1.56, CHC13); lr-FABMS (3-nitrobenzyl alcohol, neg. ion) m/z [M +
3 -NBA]- 1046.6 (52), 939.6 (38), IM-Hr 892.6 (11), 850.6 (47), 808.6 (12.5), 746.5
(5), 500.4 (11), 472.4 (5), 240.2 (2.5), 153.1 (100); hr-FABMS m/z ( neg. ion) IM + 3-
NBA + H r 1047.6352 (C56H91016N2) 1.6 mmu dev.; deduced molecular formula of
derivative 2: C49H83013N1 ; 1H and 13C-NMR see Table 1.
Derivative 3: (Fatty Acid Methyl Ester of Derivative 2) Oil, Ir GC-EIMS m/z
[M]+256(55),IM-CH31+ 241 (2),225(13), [M-CH(CH3)21+ 213 (39),199 (16),185
(11),171(11), 157 (17), 143 (44),129(21), 97 (30), 87 (62), 83 (33),74 (100),69 (40);
1H-NMR (400 MHz, CDC13) 6 3.68 (3H, s, -OCH3), 2.31 (211, t, J =7.5, C-2"), 1.65
(2H, m, C-3"), 1.55 (1H, m, C-13"), 1.26 (16H, s, H-4" to H-11"), 1.18 (2H, m, C-
12"), 0.86 (6H, d, J = 6.6, C-14" and C-15").
Derivative 5. Oil, it ( CC14) 3100, 2960, 2930, 1750, 1680, 1225, 1070 cm-1; lr-
FABMS (3-NBA, neg. ion) m/z [M + 3-NBAJ- 1119 (69), 1012 (62), [M-Hr 965 (22),
923 (86), 53 (38), 380 (100); 1H-NMR (400 MHz, CDC13) 6 5.75 (1H, dt, J =15.6, 6.6,
H-5),5.7 (1H, d, J=10, N-H), 5.4 (1H, m, H-4'), 5.4 (1H, m, H-4),5.28 (1H, t, J
=7.0,H-3), 5.15 (1H, dd, J=10.6, 8.0, H-2'),5.00 (111, dd, J=10.6,3.2, H-3'), 4.44
(1H, d, J=7.9, H-1'), 4.35 (11-1, m, H-2), 4.14(1H, d, J =6.6, H-6'),3.93 (1H, dd, J213
=10.0, 3.7, H-1a), 3.92 (1H, t, J=6.6, H-5'), 3.58 (1H, dd, J=10.0, 4.2, H-lb), 2.17
(3H, s, -OAc), 2.15 (2H, m, H-2"), 2.06 (311, s, OAc), 2.05 (3H, s, -OAc), 2.04 (3H,
s, -OAc), 2.04 (2H, m, H-6), 1.99 (3H, s, -OAc), 1.6 (2H, m, H-3"), 1.35 (2H, m, H-
7), 1.3 (2H, m, H-4"), 1.26 (32H, m, H-5" to H-21"), 1.26 (18H, m, H-8 to H-16),
0.88 (6H, t, J=6.6, H-16 and H-22"); "C-NMR (100 MHz, CDC13) 6 172.70 (C-1"),
170.32 (-000CH3), 170.19 (- OCOCH3), 169.92 (-000CH3), 170.0 (- OCOCH3),
169.59 (- OCOCH3), 137.07 (C-5), 124.67 (C-4), 100.95 (C-1'), 73.75 (C-3), 70.80 (C-
5'), 70.72 (C-3'), 68.85 (C-2'), 67.07 (C-1), 66.91 (C-4'), 61.18 (C-6'), 50.50 (C-2),
39.05, 36.80 (C-2"), 36.60, 34.39, 31.90, 30.02, 29.93, 29.69, 29.54, 29.49, 29.40,
29.32, 28.97, 27.95, 27.40, 27.10, 25.09, 22.66, 21.08 (-000CH3), 20.80 (-
OCOCH3), 20.61 (2C, OCOCH3), 19.20 (-000CH3), 14.14 (C-16), 14.12 (C-22").
Derivative 5a: (Major Fatty Acid Methyl Ester of Derivative 5), (82%), oil, lr
GC FINS m/z 354 (87) [M]+ for CH3(CH2), 2OC°2CH3, 323 (9), 311 (19), 297 (3), 283
(1), 269 (4), 255 (10), 241 (3), 227 (1.5), 213 (3), 199 (12), 185 (6), 171 (2), 157 (4),
143 (37), 129 (12), 115 (3), 101 (7), 97 (11), 87 (75), 74 (100), 55 (21), 43 (31);
Derivatives 5b-d: (Minor Fatty Acid Methyl Esters of Derivative 5) b. (10%) lr
GC-EIMS m/z 340 (93) [M]+ for CH3(CH2)CO2CH3, 309 (10), 297 (21), 283 (2), 255
(5), 241 (9), 199 (9), 185 (6), 157 (3), 143 (34), 129 (11), 111 (5), 97 (12), 87 (76), 74
(100), 69 (16), 55 (21), 43 (29); c. methyl tetracosenoate (6%) 1r GC-EIMS m/z 380 (9)
IMI+ for CH3(CH2).CH=CH(CH2)20nC°2CH3 (n<20),348 (100),306 (12),264(14),
250(8), 236(6), 222(5), 208(5), 194(4), 180(4), 166(5), 152 (9),138 (8),125(13),
111(22), 97(42), 87(29), 83(43), 74(39), 69(47), 55(53), 43 (27); d. (1.7%) lr GC-
EIMS m/z 368 (100) [M]+ for CH3(CH2)21CO2CH3, 337 (3), 325 (19), 311 (2), 283 (3),
269 (7), 255 (2), 241 (2), 227 (2), 213 (2), 199 (9), 185 (6), 157 (3), 143 (37), 129 (12),
111 (6), 97 (13), 87 (78), 74 (98), 69 (18), 55 (22), 43 (36).214
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